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´´An experiment is a question which science poses to Nature and a measurement is the 
recording of Nature´s answer.´´ 
(Max Karl Ernst Ludwig Planck, 1858-1947) 
 
´´Zwar weiß ich viel, doch möchte ich alles wissen.´´ 
(Johann Wolfgang von Goethe, 1749-1832) 
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Of all neurodegenerative diseases, Alzheimer´s Disease is the most widespread 
dementia syndrome, exhibiting progressive memory loss and intellectual abilities. One of 
the pathological hallmarks of this disease is associated to the presence of abundant 
intracellular deposits of the Tau protein. Accumulation of these stable species is a multistep 
process that involves the formation of various transients. Understanding this key step may 
eventually enable to obstruct aggregation.  
Tau protein is an intrinsically disordered protein, abundant in neuronal axons where 
it promotes and stabilizes microtubule assembly. Chapter 1 discusses the physiological 
function and pathological consequences of this protein and sheds light on the current Tau-
based research implemented in therapeutic strategies. This chapter also reviews the 
identification of inhibitors of Tau aggregation as potential disease-modifying drugs; with 
a detailed discussion of two organic compounds we have recently screened, 
Phthalocyanine Tetrasulfonate and Phenothiazine Methylene Blue. The same chapter then 
introduces the Heat shock proteins and their role in Tau clearance.  
The chapters that follow report our research investigation of aggregation inhibitors 
and chaperonic partners of Tau where we used an integrated approach to detect possible 
assemblies of pathogenic conformational transitions. Chapter 2 represents the 
Phthalocyanine tetrasulfonate study and its inhibition of Tau filament formation by 
conformational modulation. Chapter 3 investigates the mechanistic basis of the 
phenothiazine-driven inhibition of Tau aggregation. Chapter 4, examines how the 
imbalance of Hsp70 family variants fosters Tau accumulation. As a final point, the 
significance of the biophysical techniques incorporated in the three published manuscripts 
are briefly discussed in the last part of Chapter 1. 
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Proteins are versatile macromolecules that constitute a network of structurally 
complex systems with crucial biological relevance in life. Through the course of evolution, 
mammalian cells have adapted machineries that synthesize linear chains of several amino 
acids and ensure the conformational integrity of folding polypeptides to their native state 
with defined three-dimensional structures. Typically, these cells regulate the expression of 
more than 10,000 different protein species, which makes them prone to acute and severe 
malfunctions. Yet, this highlights the fundamental role and medical relevance of proteins 
in biology. The remarkable features of protein folding define its functionality by the ability 
of retaining its proper conformation. However, many proteins or protein domains are 
functional despite their partially or fully unstructured conformations. Nevertheless, the 
outstanding characteristic of such disordered or misfolded proteins decodes in the 
generation of proteinaceous aggregates of highly defined structures with abundant cross-β 
structural motifs, termed amyloid. These amyloidogenic proteins are the basis of 
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1.1 Protein Folding, Misfolding, and Aggregation 
In nature, a protein folds to acquire a biologically-active native state defined by a 
precise three-dimensional structure. This complicated cascade is achieved either 
spontaneously or with enzymatic assistance from molecular chaperones.1,2 Yet, deeper 
understanding of this intricate network remains partially undisclosed. Nevertheless, 
intensive pioneering studies have investigated the nature of folding mechanisms and 
implicated transitional states with their kinetic, thermodynamic and structural 
information.3-5 Based on configurational entropy, the folding energy landscape of a protein 
has a funnel-shaped profile that represents the pathway by which folding or aggregation 
follows (Figure 1). An unfolded state of various conformations (1) adapts specific changes, 
and through intramolecular contacts, it populates folding intermediates (2) that further 
proceed to the de novo native state (3). Since the energy landscape surface and its 
ruggedness are unique to the primary sequence of the protein;6 potential domain 
interactions increase the propensity of misfolded conformations. If failed to reorganize, 
this partially folded state (4) is prone to aggregation since it favors a major kinetic trap 
during folding pathways. Driven by intermolecular contacts, the exposed hydrophobic 
residues then induce the association of protein molecules into oligomers (5) that further 
assemble into amorphous aggregates (6) or trigger the formation of highly ordered amyloid 
fibrils (7). Whether progressing through folding or aggregation, it is astonishing how the 
high degree of disorder of an unfolded state is reduced by selecting the more favorable 
enthalpy and the lowest entropy so the structure becomes more ordered, being native or 
fibrillar.  





Figure 1: The Energy Landscape of Protein Folding and Aggregation.  
a) The multitudinal conformations of an unfolded protein (1) populate folding intermediates (2) while 
funneling through the energy landscape towards a single de novo native state (3). Partially folded states (4) 
are kinetically trapped as oligomers (5), which further deposit as amorphous (6) and amyloid fibrillar (7) 
aggregates. Adapted from 6,7. 
 
Protein folding and unfolding are ultimate biological events that regulate cellular 
trafficking, secretions and immune response. Aberrations in these mechanisms impede cell 
regulations and initiate diseases that are often accompanied by the conversion of misfolded 
intermediates to aggregates. Despite the diversity in the pathogenesis of these diseases, the 
aggregation of a functional soluble protein into insoluble amyloid fibers with cross-β 
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structural motifs arises by common mechanisms and involves several species (Figure 2).4,8 
A native state is highly sensitive to destabilizing conditions (low pH, high temperature, 
mutation, presence of denaturant), thereby increasing the population of the misfolded 
state.9 If molecular chaperones and ubiquitin-proteasome machineries fail to refold or clear 
the partly folded species back to the normal state or to amorphous aggregates,10-12 then 
nucleation of ordered oligomers becomes kinetically favored. With an increased propensity 
to cross-β structures, the amyloidogenic precursors have the potential to progressively 
assemble through membrane embedded pores and lateral-aggregating protofibrils. This 
stream of aggregates is finally deposited in forms of mature amyloid fibers.  
 
 
Figure 2: The Cascade of Protein Folding and Aggregation. 
Destabilizing a healthy native state increases the population of the misfolded state. Refolding or degrading 
pathways along with external factors aim to re-establish proper folding, formation of amorphous aggregates 
or complete unfolding. The failure of these defensive mechanisms triggers the nucleation of ordered 
oligomers that assemble into amyloid pores, protofibrils and mature fibers. The whole assembly process 
provokes cell impairment and gained toxicity that defines this disease state. Modified from 4,6. 
1.2 Neurodegenerative Diseases 
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1.2 Neurodegenerative Diseases 
Dementia is a wide term for collective symptoms that include:  
1. severe deterioration of concentration and judgment, 
2. loss of memory and intellectual capacity, 
3. subsequent damage of brain neurons, 
4. progressive motor impairment.  
Until the end of the nineteenth century, diagnosis remained within a broad clinical concept. 
In 1907, Alois Alzheimer and Oskar Fischer associated the presence of abundant 
aggregates of neuritic amyloid plaques and neurofibrillary tangles (NFTs) in the cerebral 
cortex to dementia that was pathologically termed Alzheimer´s Disease (AD).13-15 In 1911, 
Alzheimer observed specific inclusions related to frontotemporal dementia,16 which was 
later referred to as Pick´s Disease (PiD) after Arnold Pick. A year later, Fritz Heinrich 
Lewy associated certain inclusions as features in Parkinson´s Disease (PD) and identified 
them as Lewy bodies.17,18 Over the years that followed, the notion of Neurodegenerative 
Diseases (ND) experienced substantial progress in brain study with attempts to uncover 
molecular and pathological bases. Soon after, this area of research has moved from 
descriptive phenomenology to mechanistic analysis.  
Clinical diagnosis of different neurodegenerative brain tissues revealed that the 
pathological markers (Figure 3) consisted primarily of aggregates related to specific 
proteins that can be cytoplasmic, nuclear or extracellular.19 These aggregates and their 
corresponding proteins were identified respectively as amyloid plaques of amyloid-Beta 
(Aβ),20 NFTs of Tau,21 Lewy bodies of alpha-synuclein (αS),22 neuronal inclusions of 
huntingtin,23 prion plaques of protease-resistant prion (PrP-res),24 and Bonina bodies of 
Superoxide dismutase-1 (SOD1).25 Today, it is widely recognized that the generation of 
1.2 Neurodegenerative Diseases 
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protein aggregates with rich β-sheet conformation and inclusion body formation is a 
common pathological process in numerous neurodegenerative diseases.26 Nevertheless, 
each disorder is associated to its own set of pathological features (Table 1). The most 
common neurodegenerative diseases are classified based on their clinical symptoms, the 
affected regions of the brain, their pathological hallmarks and the involved proteins.19,27,28  
AD remains the most widespread progressive dementia syndrome featuring 
neuronal degeneration along with the presence of extracellular Aβ and intracellular NFTs. 
Importantly, the cytoplasmic Lewy body, a pathological hallmark of PD, is linked to the 
degeneration of dopaminergic neurons and consequently to movement disorders, postural 
and autonomic instability. Impaired muscle coordination and motor activity are common 
symptoms of the inherited neurological Huntington´s disease (HD). The neuronal 
inclusions are nuclear deposits of Huntingtin protein with abnormal long polyglutamine 
stretches at the N-terminal region. Transmissible Spongiform encephalopathies (TSE) are 
diseases showing extracellular prion plaques as pathological markers. These syndromes are 
spread among different species; mostly featuring dementia, psychiatric breakdown and 
cortical spongiform degeneration. Amyotrophic Lateral Sclerosis (ALS) is a fatal disease 
characterized by the degeneration of motor neurons and atrophy. The major hallmarks of 
this disease are cytoplasmic Bonina bodies composed of SOD1. 
 




Figure 3: Pathological Hallmarks of Neurodegenerative Diseases. 
The neuropathological lesions of common neurodegenerative diseases: AD´s extracellular plaques and 
intracellular NFTs; the cytoplasmic Lewy bodies of PD, neuronal inclusions of HD, TSE´s extracellular prion 
plaques, and ALS cytoplasmic Bonina bodies. Adapted from 19. 
 
Extensive studies hypothesize that these insoluble deposits do not induce 
neurotoxicity but rather the soluble oligomeric intermediates formed during the 
aggregation process are the most toxic species.26,29,30 This strengthens the notion that 
diverse ND pathogeneses indeed arise from common mechanisms. 
Table 1: Classification of Neurodegenerative Diseases. 
NDs are classified based on their clinical symptoms, the affected regions of the brain, proteins involved and 
pathological hallmarks. Adapted from 19,27,28.  
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1.3 Intrinsically Disordered Proteins 
The discovery of intrinsically discorded proteins (IDPs) was accompanied by an 
evolutionary paradigm in the field of structural biology. Proteins that fail to adopt a defined 
three dimensional structure under physiological conditions are termed IDPs and are 
represented as dynamic conformational ensembles with the characteristic of a weakly 
funneled energy landscape.31 Nevertheless, a significant fraction of partially and 
completely disordered proteins are functionally active in eukaryotic cells32 and are 
involved in cellular processes such as signaling, transcription control, replication, and 
molecular recognition.33-35 IDPs are also prone to lose their physiological function and 
exhibit pathological features that appear in cancer, neurodegenerative diseases, 
cardiovascular diseases and others.36 
 
1.3.1 Structural Characteristics  
The prediction of the three-dimensional structures of globular proteins from their 
primary sequence is challenging, however, the analysis of its composition and relative 
occurrences of the amino acids has been established to identify intrinsically disordered 
domains.37 The sequence signature of an intrinsic disorder is reflected by a low content of 
bulky hydrophobic order-promoting residues (Asparagine, Cysteine, Histidine, Isoleucine, 
Leucine, Phenylalanine, Threonine, Tryptophan, Tyrosine, and Valine) and the abundant 
presence of polar and charged disorder-promoting (Arginine, Aspartic acid, Glutamic acid, 
Glutamine, Lysine, Methionine, Proline, and Serine) and neutral residues (Alanine and 
Glycine).38-40 Despite their highly unfolded states, IDPs have the tendency to form low 
content of local secondary structures. Due the lack of specific tertiary structure, IDPs are 
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commonly represented by ensembles of conformations with defined  and  backbone 
angles.37 However, IDPs are clearly distinguished from both, folded and completely 
unfolded proteins. IDPs do not behave like the denaturated states of folded proteins in terms 
of true random coils. Even at extreme pH, temperature and pressure, the propensity for 
local structures and hydrophobic clusters is to some extent retained.41 
 
1.3.2 Biological Function 
Accumulating evidence from genomic analysis of disordered proteins demonstrated 
the vital biological activity of IDPs despite the lack of a well-defined structure.33,42-44 These 
proteins maintain various biological processes and specific signaling interactions that are 
controlled by numerous posttranslational modifications and alternative splicing. This 
comprises transcriptional regulation of DNA binding, mRNA splicing, biogenesis of 
chromatin, and intricate organization of the cytoskeleton.45 Some IDPs undergo a disorder-
to-order transition upon binding to one or more partner proteins46,47 while others carry 
normal functions despite their disordered state. Based on functionality and binding modes, 
IDPs have been classified into different categories (Figure 4).33 Some IDPs that are 
functioning irrespective of any binding partner are termed Entropic chains. These include 
disordered regions or full proteins that incorporate entropic springs and spacers between 
two adjacent domains or flexible linkers that facilitate conformational modulations. Other 
IDPs function upon molecular recognition of their partners via transient or permanent 
binding. For instance, molecular chaperones exhibit transient activities through their 
disordered regions to assist RNA and protein folding. Alternatively, an IDP might display 
sites to accommodate the targeted protein for further posttranslational modifications. On 
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the other hand, IDPs with permanent bindings fall in three categories. Effectors inhibit or 
activate their partner proteins, assemblers favor formation of large complexes while 
scavengers target smaller ligands.  
 
 
Figure 4: Classification of Intrinsically Disordered Proteins. 
Based on their function, IDPs are classified into major categories. Entropic chains function irrespective of 
partner binding. Other IDPs bind their partners via transient (chaperones, displayed sites) or permanent 
recognition modes (effectors, assemblers, scavengers). Adapted from 33. 
 
Several proteins associated with human neurodegenerative diseases are intrinsically 
disordered. As mentioned before, each of the proteins Aβ, Tau, αS, huntingtin, PrP-res and 
SOD1 exists or coexists in the ND hallmarks amyloid plaques, NFTs, lewy bodies, 
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neuronal inclusions, prion plaques and bonina bodies, respectively. These proteins either 
contain intrinsically disordered regions or themselves are IDPs. The generation of these 
protein aggregates from a natively unfolded state to a rich β-sheet conformation proved the 
interconnection between intrinsic disorder and human neurodegenerative diseases. 
 
1.4 Tau Protein 
The isolation of a heat stable protein purified from porcine brain, identified as Tau, 
was an outstanding discovery in the field of neurobiology.48 Linked to the dimerization of 
α and β tubulin, Tau was the first to be reported as a microtubule-associated protein soon 
after its sequence was determined from murine cDNA.49 Tau protein has gained significant 
prominence as it is associated to a physiological function in the regulation of MT stability 
and a pathological hallmark in AD and other NDs.  
 
1.4.1 Localization, Function and Modifications 
MAPT is a single gene located on chromosome 17q2150 and contains 16 exons, 11 
of which are engaged for encoding Tau protein in the human brain (Figure 5). The 
alternative mRNA splicing of exons 2, 3, and 10 generates six different Tau isoforms 
ranging from 352 to 441 amino acids. These isoforms are distinguished by the absence or 
presence of one (I1) or two (I2) inserts at the N-terminal domain and a repeat region (R2) 
within a repeating-motifs domain.51 The constitutive splicing of the remaining exons 
encode for the motifs that are present among all isoforms (exons 1, 4, 5, and 7 for the N-
terminus and Proline-rich region P1; exons 9, 11 and 12 for P2 and repeat motifs R1, R3 
and R4; and exon 13 for R´ and the C-terminus). The 5 additional exons are not involved 
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in Tau expression. Exons 0 and 14 are both non-coding, exon 4a is associated only to the 
peripheral nervous system, whereas the transcription of exons 6 and 8 is prohibited in the 
human brain.52  
The composition of the six Tau isoforms have been categorized into two large 
domains: the projection domain and the microtubule-binding domain (Figure 5). The 
domain organization of Tau is based on the primary sequence of the longest human 
isoform, hTau40 (Figure 6). The projection domain combines two regions, a highly 
negatively charged region incorporating the abundant number of acidic residues of the N-
terminus and the inserts (I1, I2), followed by the first Proline-rich region (P1). As the name 
refers, the second domain accommodates the regions that have been identified for their 
binding to microtubules. These four motifs, termed Pseudo-repeats (R1, R2, R3, R4), are 
imperfect copies of a sequence of 18 amino acids scattered between inter repeating 
sequence of 13 or 14 amino acids. Together with the second Proline-rich region and the 
less conserved pseudo-repeat (R´), all these three regions define the interface upon which 
Tau binds to microtubules through a highly conserved tubulin-binding motif.49 The 
postnatal expression of exon 10 distinguishes the isoforms containing 3-repeats (3R) from 
4-repeats (4R) based on the existence of R2.51 During development, the various isoforms 
are differentially expressed, however, 3R and 4R isoforms are equally expressed in cerebral 
cortex of healthy adults.53 Notably, the R1 and R2 provoke the highest capacity to bind 
tubulin54 and this is in line with the fact that 4R adult Tau isoforms interact with 
microtubules more efficient.55,56 On the other hand, the projection domain interacts with 
cytoskeleton and plasma membrane proteins.57,58 Moreover, specific motifs were 
highlighted upon its binding to cations, heparin (KKXK), and proteins containing the SH3 
domain (PXXP).59  





Figure 5: MAPT Gene and the Six Human Tau Isoforms. 
MAPT consists of 16 exons in which the alternative mRNA splicing of E2, E3, and E10 generates the six 
human isoforms. The highlighted regions correspond to the domain organization present among the isoforms.  
(N or C = N or C terminus, I = insert, P = proline-rich regions, R = pseudo-repeat). Modified from 52,60. 
 
Sequencing studies showed high conservation of the microtubule-binding repeats 
across various species including mouse, rat, cow, monkey, goat and chicken.49,61 Tau is 
mainly expressed and located in the neuronal cells where it conceives its assembly with 
microtubules but also potentially associates with the plasma membrane62,63 after its 
phosphorylation in the cytosol.64 Tau expression has been reported to be higher in the grey 
matter of the neocortex than in the white matter.65 Importantly, non-neuronal Tau 
expression has been observed in muscle, liver, and kidney;66 as it has been confirmed in 
breast, prostate, gastric and pancreatic cancer lines.67-71 To date, the function of 
nonneuronal Tau remains unclear. 




Figure 6: Primary Sequence of the Human Tau Protein hTau40. 
The primary sequence of the longest Tau isoform contains two negatively charged inserts (I1, I2) two proline-
rich regions (P1, P2), four pseudo-repeat regions (R1, R2, R3, R4) and one repeat-like region (R´). The amino 
acids are color-coded based on their chemical properties.    
Tau phosphorylation is the most significant posttranslational modification (Figure 
7) with extensive studies focusing on serine/threonine72,73 and recently on tyrosine 
phosphorylation sites.74 Inside the cell, the distribution of Tau is influenced by 
phosphorylation. For instance, Tau with modified sites of the proline-rich region occurs in 
the somatodendritic compartment, but is translocated to the distal axonal region once these 
sites are dephosphorylated or as a consequence of additional phosphorylation at the C-
terminus.54,74 The regulation of Tau phosphorylation is crucial to its affinity for 
microtubules especially during early developing neurons, with evidence implicating higher 
phosphorylation levels in fetal Tau than adult Tau.75 hTau40 accommodates 85 putative 
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phosphorylation sites (45 serines, 35 threonines, 5 tyrosines)76 that are phosphorylated 
either by (a) proline-directed kinases (GSK3β, cdk5, MAPK, p38)77-79 or by (b) non-
proline directed kinases (PKA, PKC, MARK, CaMKII).80 The first group of kinases targets 
the 17 serine/proline (SP) and threonine/proline motifs (TP) whereas the other sites are 
phosphorylated by the kinases of the second group. Most importantly is the 
phosphorylation of the serine residues of the 4 KXGS motifs spread along the 4 repeat 
regions (S262, S293, S324, and S356).81 Additionally, S214 is upregulated during mitosis 
and is exclusively phosphorylated by PKA.82 On the other hand, certain residues such as 
T231 are termed prime epitopes meaning that their phosphorylation is only possible 
whenever the fourth succeeding residue is a phosphorylated serine or threonine, in this case 
S235.83 
Like most amyloid forming proteins, recombinant Tau is natively unfolded with a 
high fraction of basic and hydrophilic amino acids that resist compact folding and result in 
low content of secondary structure (Figure 7).84 Additionally, Tau is resilient to heat and 
acid treatment.85 Both, flexibility and lack of an ordered structure impede the high 
resolution analysis of IDPs by X-ray crystallography, thus leaving NMR spectroscopy as 
the only descriptive technique to access the conformations and dynamics of natively 
unfolded proteins. Indeed, the complete backbone resonance NMR assignment of the full-
length human Tau protein was achieved86 in a divide and conquer strategy.56,87,88 Tau was 
found to be highly dynamic in solution with a distinct domain character and an intricate 
network of transient long-range contacts.86 Further analysis of Tau fragments incorporating 
only 3R (K19) and 4R (K18) repeat domains unveiled short stretches that (1) adopt highly 
populated turn conformations in the monomeric form88, (2) fold into α-helical 
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conformations upon binding to lipid surfaces89 and (3) consist of β-strands in the course of 
filament formation.90,91  
 
Figure 7: Structural Polymorphism of Tau Protein. 
The prediction of disorder in the primary sequence of hTau40 is compared to experimental secondary 
structure propensities. The ensemble structural representation of hTau40 is color-coding the domain 
organization and overlaying 20 conformations. Tau undergoes numerous posttranslational modifications that 
involve a large number of sites as depicted in the graph. Disorder prediction was performed by the meta 
predictors DisProt92 and metaPrDOS.93 The transient secondary structures and ensembles were adapted from 
86. Posttranslational modifications were adapted from 74.   
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In eukaryotic cells, MTs constitute an indispensable component of the cytoskeleton 
with diverse functions ranging from regulation of cell shape and growth to intracellular 
machinery transport. MTs are highly dynamic cylindrical structures assembled by 
polymerized α- and β-tubulin heterodimers. The high expression of Tau protein in the 
neuronal axons is directly connected to its functions in machinery transport.94 The 
primarily role associated to Tau existence is its modulation to the stability and flexibility 
of axonal microtubules upon interaction with tubulin. Together with the microtubule-
associated protein 2 (MAP2), Tau shifts the reaction kinetics in favor of promoting MT 
assembly. Despite the fact that the structure of MT-bound Tau remains unrevealed, several 
scenarios suggested that the negatively charged MT surface tightly binds the positive 
proline rich region but repels away the negatively charged projection domain. Notably, the 
affinity of Tau to MT is highly regulated by phosphorylation, particularly at the KXGS 
motifs.95 However, as will be discussed later (Part 1.4.2), Tau hyperphosphorylation 
compromises this binding ability, triggers Tau aggregation and consequently MT 
disassembly. 
 
1.4.2 Tau Pathology in Neurodegenerative Diseases 
Tauopathies are group of neurodegenerative disorders associated to the presence of 
NFTs in the form of straight or paired helical filaments (PHFs) and are linked to the 
pathological aggregation of aberrantly phosphorylated Tau protein.96,97 The classification 
is based on (1) the domination of Tau deposition or its coexistence with amyloid plaques, 
(2) the relative isoform composition of Tau filaments,98 (3) cell type and (4) affected 
regions of the brain (Table 2).52 Tau-Aβ concurrence has been detected in Alzheimer´s 
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disease (AD), Down´s Syndrome (DS) and Dementia Pugilistica (DP). On the other hand, 
the predominance of Tau pathology occurs in other tauopathies that include Fronto-
Temporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17), Progressive 
Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Argyrophilic Grain 
Disease (AGD). Although the dominating existence of NFTs is intracellular, extracellular 
tangles (ghost tangles) have been observed in late stages of disease progression.     
 
Table 2: Classification of Tauopathies. 
The classification of Tauopathies is based on cell type, affected regions and the domination of Tau deposition 
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Of all Tauopathies, AD is the most widespread syndrome, exhibiting protein 
deposits that consist of extracellular amyloid plaques of Aβ and intracellular neurofibrillary 
tangles of Tau,101-103 both associated to the diagnostic hallmarks of the disorder (Figure 8). 
The amyloid precursor protein (APP) is an integral membrane protein with unclear 
functions but its proteolysis produces Aβ. The amyloid hypothesis states that upon 
mutations in the genes encoding APP and presenilin proteins, the cellular protective role 
of the enzyme α-secretase is replaced by the dominant behavior of β-secretase. APP is then 
cleaved and released as sAPPβ. The remaining fragment is processed by γ-secretase to 
yield Aβ peptide. Extracellular accumulation of Aβ40 or Aβ42 (40 or 42 residues) then drives 
hyperphosphorylation and aggregation of Tau.28,104 Reports have shown that despite this 
hypothesis, Tau deposits were detected in the brain before the formation of amyloid 
plaques.105,106 This suggests that the occurrence of Tau inclusions is age-dependent 
whereas clinical AD is attributed to the accumulation of Aβ.107 Moreover, the loss in 
mitochondrial function has been reported in late-onset sporadic AD.108 The precise 
character of these diagnostic hallmark lesions remains an open question, nevertheless, new 
discoveries continue to identify key structures on their intermediate pathways, kinetics and 
conceivable intervention.  





Figure 8: Neuronal Damage during Progression of Alzheimer´s Disease. 
Mutations in APP and Presenilin initiates the formation of β-secretase-mediated sAPPβ and γ-secretase-
mediated Aβ. This cascade triggers hyperphosphorylation of Tau and consequently its aggregation into NFTs. 
These events disrupt cellular functions following abnormal cell death. Adapted from National Institutes of 
Health and 109.  
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Despite the fact that phosphorylation is a major posttranslational modification for 
regulating MT assembly, hyperphosphorylation of Tau protein is regarded as an early event 
that precedes filament formation and impairs Tau ability to bind microtubules.110,111 
Antibodies directed against phosphorylation epitopes have shed light on these 
consequences. For instance, epitope 12E8 detects the hyperphosphorylation of S262/S356 
of pretangled Tau in AD brains and mouse models.112,113 A similar study using a triple 
transgenic mouse model of mutant APP, presenilin and the FTDP-17 mutation P301L 
suggests that phosphorylation of S214 precedes PHF formation.114 More importantly, the 
serine phosphorylation at the 4 KXGS motifs (S262, S293, S324, and S356) prevents the 
binding to microtubules115 however aggregation into PHFs does not proceed further on.116 
This suggests that the SP/TP sites of free Tau become more accessible to phosphorylation 
by the proline-directed kinases rather than promoting aggregation.117  As a consequence of 
destabilizing microtubule assembly, functions and localizations of other subcellular 
structures such as mitochondria and lysosomes could be altered.118,119 Noteworthy, 
Drosophila flies and mouse models have shown that hyperphosphorylated nonaggregated 
Tau can be itself toxic.95,120 
In addition to phosphorylation, other posttranslational modifications regulate the 
physiological functions of Tau or trigger the pathological pathways.74,121,122 This includes:  
1. O-glycosylation (attachment of oligosaccharide to asparagine, serine or threonine) 
2. Glycation (attachment of carbohydrates to lysine)  
3. Acetylation (attachment of an acetyl group to lysine) 
4. Prolyl-isomerization (conversion between cis and trans conformation) 
5. Nitration (attachment of nitrogen oxide to tyrosine) 
6. Polyamination (cross-linking between glutamine and lysine)  
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7. Deamidation (removal of amide group from asparagine and glutamine) 
8. Ubiquitination (binding to ubiquitin) 
9. Sumoylation (binding to SUMO1) 
10. Oxidation (formation of disulfide bond between two cysteines)  
11. Truncation (cleavage at aspartic and glutamic acids) 
 
From the above modifications, truncation of Tau protein has been extensively 
examined. Truncated species of Tau at three distinctive sites (D13, E391, D421) were 
detected in the form of PHFs in AD brains.123-125 Nevertheless, it is still debatable whether 
truncation occurs prior aggregation.126 Accumulating evidence has demonstrated that 
hyperphosphorylation precedes Tau truncation, and only after dephosphorylation, 
aggregation proceeds.127-129 On the other hand, Tau oxidation at the two native cysteines 
(C291, C322) and, consequently, the formation of a disulfide bond has a high impact on 
aggregation. This will be comprehensively discussed in Part 1.8.3. 
To date, no mutations in the Tau gene in chromosome 17 have been correlated to 
AD. However, gene sequencing revealed several mutation sites linked to FTDP-17.130 The 
identified mutants (K257T, G272V, N279K, ΔK280, P301L, P301S, S305N, V337M, 
G389R and R406W)131-135 mostly affect the repeat domain and reduce MT binding.97 
Notably, the point mutant P301L and deletion mutant ΔK280 particularly increase the in 
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1.4.3 Tau Aggregates 
Noninvasive tools such as positron emission tomography (PET) imaging with 
plaque-binding and tangle-binding tracers have been developed to diagnose tauopathies.136 
Electron micrographs of Tau filaments purified from infected human brains or assembled 
in vitro have implicated three types of morphologies. In AD brains, PHFs constitute more 
than 90% of NFTs and the remaining are straight filaments.137 Two ribbon-like strands 
assimilate together to form the helical structure of PHFs with diameters ranging between 8 
and 20 nm and periodicity of 80 nm.102,138 Although most tauopathies share this feature, 
some contain higher distributions of straight filaments139 while others exhibit twisted 
ribbon-like filaments with irregular periodicity.140 During late stages of AD, filaments 
further adopt average lengths of 300 to 600 nm.141,142 Despite the fact that the sequence of 
Tau has a relatively low secondary structure content and is disordered,143 the filaments 
contain a highly structured core with repeating cross β-sheets.144 Proteolysis studies have 
shown that the assembly is mediated by the MT-binding regions but varies among the 
relative abundance of isoforms.145  
It is definitely astonishing how a large number of peptides and proteins with no 
similarities in their primary sequences can self-assemble into amyloid fibrils of common 
structural features and physico-chemical properties.146,147 The conformational switch from 
natively unfolded to an ordered cross-β fibrillar structure is indeed a common pathway 
recognized in numerous human diseases.26,148,149 Extensive studies at atomic-resolution 
demonstrated the hierarchy and organization of these aggregates.150,151 Remarkably, the 
dominant arrangement of interbackbone hydrogen bonding is the driving force of the 
structural basis behind β-sheet self-assembly (Figure 9). In this respect, favored side-chain 
interactions generate protofilament structures that further re-arrange in filaments. This 
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highly structured core of the filaments comprises the repeating cross β-sheets that are 
perpendicular to the axis. Following a growth phase, mature fibrils adapt a morphology of 
defined diameter and periodicity. 
 
 
Figure 9: Hierarchical Assembly of Cross-β Amyloid Fiber. 
The self-assembly of a β-sheet to an amyloid fibril increases the structural complexity and polymorphism of 
the transient motifs. The atomic-resolution structure of a triplet fibril is reconstructed from MAS NMR and 
cryo-EM. Scale bar 50 nm. Adapted from 150.  
 
 
In the case of Tau, biochemical and microscopic investigations demonstrated that 
PHFs isolated from AD brains and assembled in vitro exhibit similar morphologies.152 Tau 
filaments are isolated after incubation of the non-phosphorylated recombinant monomer 
with polyanions such as RNA,98 fatty acids,153 glycosaminoglycans,154 and heparin.155 
These molecules were proposed to facilitate Tau nucleation either by inducing 
conformational changes modulated by electrostatic interactions with positively charged 
residues,154 or by exposing charged surfaces.156 
The course of Tau aggregation from a natively unfolded state to cross-β structure157 
affects a limited region of the repeat domain,158 while both amino- and carboxy-terminal 
halves form the so-called fuzzy coat of the filament.159 Protease digestion and solvent 
accessibility techniques implicated the repeats R2 and R3 in the formation of the PHF 
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core.160 In particular, the two hexapeptide sequences in the second (275VQIINK280) and 
third (306VQIVYK311) repeats are most deeply buried within the PHF core.90 The 
hydrophobicity and high β-sheet propensity of these motifs161 mediates the intermolecular 
interactions between the different monomers162 and enable self-aggregation.163 Moreover, 
mutagenesis highlighted the essential role of the second hexapeptide 306VQIVYK311 during 
filament assembly158 with the Y310A and K311D mutations leaving the monomer 
incompetent to fibrillize.164,165  
While progress continues to explore the diagnostic hallmark lesions of AD by 
deciphering key structures attributed to Tau inclusions, their intermediate pathways and 
modifications (hyperphosphorylation, proteolytic truncations); the source of toxicity 
remains an open debate. Recent progress in scientific research has implicated the soluble 
oligomers to be the most neurotoxic species rather than the insoluble aggregates.166-168 
These species are extremely transient and labile, imposing a challenge in detecting them. 
Nevertheless, accumulating efforts have been incorporated to design approaches and 
develop techniques that can monitor their formation and elucidate their structural 
properties. During the early stages of oligomeric formation, truncated forms of Tau are 
indeed composed of monomeric and dimeric subunits that are excessively 
phosphorylated.169 These oligomers exhibit rich β-sheet conformations and can occur in 
various 3R or 4R isoforms.170 Once their size exceeds 20 nm, fibrillar accumulation would 
follow.171 Granular-shaped oligomers isolated from AD brain tissues and in vitro 
preparation were found to be assembled of approximately 40 Tau monomeric units in 
protofibrils and could further build up filaments at effective concentrations.172 Oligomers 
of comparable morphologies were also detected in a Tau P301L transgenic mouse model 
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(JNPL3)173 as well as in cellular cultures.174 Upon interaction with Tau, chaperones have 
been reported to decrease the levels of granular oligomers.175 
With this in mind, the pathology behind Tau aggregation can be outlined through a 
cascade of intermediates where the monomer switches from a random-coiled to an 
extended conformation before adopting an ordered β-sheet structure (Figure 10).74,96,176 
The events of uncontrolled kinase-mediated phosphorylation, mutations, and abnormal 
modifications of Tau provoke its dissociation from MT assembly. This loss-of-function 
induces subsequent impairment of axonal transport, neuronal dysfunction and synaptic 
degeneration. Under those circumstances, the high levels of unbound Tau in the cytosol 
then accommodate an aggregation-prone conformation158 enriched with β-sheets. 
Consequently, Tau dimers assemble through side chain interactions.90 Accompanied by a 
toxic gain-of-function, this nucleation step enables oligomerization to proceed with 
possible membrane interactions.177 The elongation of oligomers to protofilaments is 
energetically-favored and arranges the intermediates into in-parallel, in register cross β-
sheet structures. Two protofibrils arrange furthermore to form bundles of PHFs that 
accumulate into NFT deposits.
156  




Figure 10: Proposed Cascade for the Pathological Aggregation of Tau. 
Uncontrolled phosphorylation, mutations, and modifications dissociate Tau from MT assembly. Unbound 
Tau then adapts aggregation-prone conformations enriched with β-sheets and in favor of dimeric formation. 
This toxic gain-of-function is the basis of a nucleation step through which oligomerization proceed, followed 
by elongation to protofilaments, and accumulation of PHFs bundles. Modified from 74,96,176.  







1.5 Tau-Based Therapeutic Strategies 
 
Current understanding of the molecular mechanisms and modifications of Tau-
mediated neurotoxicity has established potential targets for the intervention of AD and 
tauopathies. Tau-based therapeutic approaches aim to regulate phosphorylation, inhibit 
aggregation, disassemble existing aggregates or divert them into nontoxic forms. Based on 
their modes of action and disease-modifying potentials, these strategies are classified into 
six categories that include antiphosphorylation strategies, vaccination, Tau clearance, 
isoform control, microtubule stabilizing drugs, and anti-aggregation strategies (Figure 
11).117,178,179 
 





Figure 11: Tau-Based Therapeutic Strategies. 
The intervention of AD and tauopathies aim to regulate phosphorylation, inhibit aggregation, disassemble 
existing aggregates or divert them into nontoxic forms. These approaches include antiphosphorylation 
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1.5.1 Anti-phosphorylation Approaches 
As already mentioned in 1.4.2, hyperphosphorylation of Tau protein is considered 
a major posttranslational modification associated to MT disassembly, involved in 
neurotoxicity and featured in PHF formation. This rises the motivation to interfere with 
phosphorylation by inhibiting the proline-directed kinases (GSK3β, cdk5) and the non-
proline directed kinases (PKA, MARK); or alternatively by activating the phosphatases. 
MARK is the most abundant calcium/calmodulin-dependent protein kinase 
associated to KXGS phosphorylation, specifically at S262 and S356. FRET measurements 
on extracts of AD PHFs confirmed that the active kinase is within close distances to the 
S262/S356 sites.180 MARK-mediated phosphorylation of Tau enhanced the expression of 
the toxic phenotype in the retina of Drosophila fruit fly but was absent in the S262A/S356A 
mutants.181 MARK becomes functional after the activating kinase MARKK phosphorylates 
one of its threonines residing in the active site. Since MARK phosphorylation is important 
during early stages, it is obvious that targeting its activation is of high interest. Indeed, 
MARK becomes inactive upon MARKK protein-protein interaction with testis-specific 
protein kinase 1 (TESK1)182 or due to the inhibitory effects of hymenialdisine.183  
PKA is cAMP dependent kinase that mediates in vitro and in vivo phosphorylation 
of Tau at S262 and S356 but also extends it to S214.184,185 This has an impact on further 
phosphorylation sites mediated by GSK3β. PKI is an inhibitor that has been proposed to 
displace PKA after binding to its catalytic subunit.186 By this mechanism, the gene 
expression of the cAMP response element is prevented. 
P35 is a neuronal-specific activator of cdk5 kinase. Calpain cleaves proteolytically 
the membrane-bound domain of p35 to generate p25 which itself binds cdk5 and increases 
the abnormal phosphorylation.187 Although targeting cdk5 seems to be a suitable strategy, 
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studies on neuronal cell cultures and p35 knock-out mice reported an increased activity of 
GSK3β upon inhibition of cdk5.188,189 Whether preventing p25-cdk5 complex association 
or blocking p25 generation by targeting calpain, a suitable approach should take into 
account the deactivation of both kinases. Indeed, the purine compound roscovitine 
interfered with p25-cdk5 formation and diminished Tau phosphorylation in p25 transgenic 
mice.187 On the other hand, preliminary results of calpain inhibitors screened in AD models 
were encouraging but with limited penetration to the blood brain barrier (BBB).190 
GSK3β is one of the two GSK isoforms that are engaged in glucose metabolism, 
cell proliferation and apoptosis. GSK3β activity is inhibited or triggered by the 
phosphorylation of S9 and Y216, respectively.191 GSK3β phosphorylates Tau in vitro and 
in vivo at primed epitopes (T231) as well as PHF-1 (S396, S404) and AT8 epitopes (S199, 
S202, T205).192 Overexpression of GSK3β in transgenic mice is directly linked to the high 
levels of Tau phosphorylation193 and enhanced by Aβ.194 Pyrazolopyrazines, 
pyrazolopyridines and aminothiazoles decreased Tau aggregation in P301L Tau transgenic 
mouse model by exhibiting high selectivity for GSK3β.179,195 Similar effects have been 
observed for lithium competing with magnesium GSK3-binding, and with valproate which 
entered AD clinical trials.196 
Protein phosphatase-2A (PP-2A) is responsible for the dephosphorylation of Tau 
protein and the decrease in its activity is directly related to hyperphosphorylation.197 Upon 
inhibition of PP-2A by okadaic acid, levels of hyperphosphorylated Tau increased in 
cultures isolated from rat brains.198 Once hippocampal cultures were treated with 
memantine, an antagonist for okadaic acid, the main function of PP-2A was recovered. 
Despite the fact that little is known about PP-2A regulation as a promising therapy, these 
findings are likely to encourage future investigation. 
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Since the mentioned kinases and phosphatases are involved in many cellular 
processes, the identification of inhibitors of high selectivity remains a challenging strategy. 
 
1.5.2 Tau Vaccination 
Even though the idea of incorporating Tau-directed immunotherapy as a potential 
approach for the clearance of extracellular PHFs seems convincing, the mechanisms by 
which Tau-directed antibodies amend the pathology are far from being resolved.199 
Furthermore, immuno-mediated approach encounters challenges in targeting intracellular 
tangles as this requires direct uptake of the antibody. Despite the fact that vaccination with 
full-length Tau triggered encephalitis200, active immunization involving the Tau phospho-
peptide PHF-1 epitope, on the other hand, reduced Tau phosphorylation and prohibited the 
pathology in a P301L transgenic mouse model (JNPL3)201 However, current vaccinations 
unveil diverse outcomes with doubts regarding effective penetration of antibodies into the 
neuronal cytoplasm and glial cells.202 Moreover, similar to Aβ immunization neuro-
inflammation is most likely to occur.203 With this in mind, the achievability of Tau 
vaccination remains unrevealed.  
 
1.5.3 Tau Clearance 
Yet another approach to prevent the gained neurotoxicity suggests the clearance of 
Tau aggregates from the cell and possibly its degradation. This would involve two major 
pathways responsible for protein degradation, autophagosome and proteasome.204 This 
strategy has been reported for oligomers and aggregates of huntingtin, αS, and Tau.205,206 
The autophagy scheme is simplified as such: the intracellular aggregates are first engulfed 
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with a double membrane which fuses to the lysosome. The content of the vesicle is then 
degraded by acidic hydrolases.207 Although Rapamycin-induced autophagy was successful 
in a Drosophila fruit fly model,202 however, increased levels of Aβ were observed.208  
Among the numerous studies on proteasomal degradation of Tau, molecular 
chaperones were reported to be the most prominent. Specifically, the family of Heat Shock 
Proteins (Hsp) has occupied considerable attention in protein folding and proteostatis. The 
inhibition of chaperones Hsp27 an Hsp90 were directly linked to the proteasomal 
degradation of highly phosphorylated Tau.115,209,210 The enhanced behavioral developed in 
a transgenic mouse model expressing human Tau with one of the FTDP-17 mutations 
confirmed the role of Hsp90 in the clearance of Tau aggregates.211 The interaction of Tau 
protein and members of the Hsp family will be discussed later in details (Part 1.9). Besides, 
preliminary studies on Tau degradation implicated the involvement of cytosolic proteases 
such as Puromycin-sensitive aminopeptidase (PSA), Caspase-3 and Calpain-1.212,213  
 
1.5.4 Isoform Approaches 
4R and 3R isoforms are expressed equally in mature healthy brains but their ratios 
divert dramatically during Tauopathies. Among the mutations associated to FTDP-17, the 
dominance of two-fold to six-fold excess of 4R over 3R becomes obvious.214 Additional 
diagnoses of brain tissues from PSP, CBD and temporal cortices of AD diseases reported 
the occurrence of higher ratios of 4R Tau aggregates.215,216 Kinesins and Tau compete for 
microtubule binding. Bearing in mind the higher affinities of 4R isoforms over 3R towards 
MT, any isoform imbalance in favor of 4R obstructs the kinesin-regulated cell 
trafficking.217 Therefore, targeting the imbalance in Tau isoform ratios by controlled 
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alternative splicing of exon 10 seems a promising therapeutic approach. Using Tau 
transfected cells, the modification of mRNA has been successfully demonstrated by a 
spliceosome-mediated RNA trans-splicing (SMarT) method.218 Briefly, the concept is to 
decrease the ratio of 4R in favor of 3R Tau by generating a trans-spliced Tau chimera using 
a pre-trans-splicing construct that incorporates exon 11, 12 and 13 together with a binding 
site for intron 9.217 However, the poor penetration of RNA into brain cells complicates the 
adaption of this method to animal models and possible solutions are being investigated.117 
 
1.5.5 Microtubule-Stabilizing Drugs 
The loss-of-function associated to hyperphosphorylated and aggregated Tau is 
compensated by MT-binding drugs. These molecules are expected to promote tubulin 
polymerization and stabilize MT assembly. Low doses of these agents are both sufficient 
and recommended to restore the expected physiological functions and dynamics. MT over-
stabilization is connected to side effects like peripheral neuropathy.219 MT-stabilizing 
agents exhibited protective responses against Tau-mediated neurotoxicity in cultured 
neurons.220,221 One candidate was found to be Paclitaxel, commercially known as Taxol 
and a natural compound with established chemotherapeutic properties. When transgenic 
mice lines with reduced MT density and motor impairments were treated with paclitaxel, 
the MT density increased and a substantial development in the axonal transport was 
observed.222 But since paclitaxel is not able to cross the BBB, the accompanied 
improvements were linked to the ligand absorption through the peripheral neuromuscular 
joints and successively transported to the spinal motor neurons223 
Another family of compounds is Epothilones. Epothilones A and B are commercial 
antifungal agents that bind β-tubulin and promote MT assembly better than paclitaxel as 
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was supported by NMR, crystallography and computational investigations.224 Further 
screenings identified Epothilone D, a stabilizing agent with advanced therapeutic 
properties and enhanced brain penetration abilities. Epitholine D has recently entered a 
phase 1b clinical trial for AD and related tauopathies.219 In addition, numerous natural 
products or synthetic compounds such as Discodermolide, Dictyostatin, Eleutherobin, and 
Cyclostreptin have been evaluated for enhanced MT-stabilization with the clear objective 
of preserving low levels of the drug and effective crossing of the BBB.219  
    
1.5.6 Anti-aggregation Strategies 
Current Tau-based treatment strategies have been directed towards identification of 
small organic compounds that are able to inhibit or disassemble amyloid aggregates. This 
approach mainly involves determining molecules that are able to dissociate existing 
oligomers and fibrils or prevent the formation of their precursors and derivatives. Insights 
into the mechanisms of action by which these compounds target the protein state (being 
monomeric, oligomeric or filamentous) reveal the pathological consequences.  
The drugability 225 of a potential inhibitor is evaluated based on: 
1. solubility upon oral absorption  
2. metabolic stability  
3. penetration of the blood brain barrier 
4. pharmacokinetic behavior 
5. low toxicity 
6. suitable half-lives 
7. effective excretion  
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Design strategies based on fibril –specific fluorescence (Thioflavin S, tryptophan), 
pelleting and filter assays, cell viability and microscopy (FRET, EM, AFM) have been 
implemented to identify drug candidates and report their pharmacological properties. For 
instance, potency defines the drug´s evoked response at low concentrations, affinity reflects 
its binding ability and efficacy relates the receptor occupancy to the drug´s response. 
Hence, the three terminologies are interconnected and are evaluated by the term half 
maximal effective concentration (EC50). Similarly, the half maximal inhibitory 
concentration (IC50) and disassembly concentration (DC50) respectively report the 
effective concentrations required to inhibit the assembly into aggregates or disassembly of 
preexisting aggregates. The equilibrium dissociation constant (Kd) of a compound is 
equally important and relates the concentration needed to reach half maximal saturation of 
the binding sites. Cytotoxicity is commonly monitored by lactate dehydrogenase (LDH) 
assay that reports on the leakiness of membranes in degenerating cells. 
The process of drug discovery consists of stages for identifying candidates that 
further undergo structural and functional optimization to improve their biological 
functions. Once the target system or protein is defined, selected chemical compounds and 
fragments are screened using primary assays. This lead generation step can adapt two 
approaches: high throughput screening (HTS)226 or fragment-based drug design 
(FBDD).227 While HTS screens a large library of compounds that bind their targets with 
medium affinity (Kd < 1 µM) but low ligand efficiency, FBDD targets a smaller number of 
molecules and fragments of higher ligand efficiency but weak affinity (µM-mM). Recently, 
cell-based high content screens (HCS) have been developed to assay the biological events 
in the presence of the candidates.228  
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The identified hits undergo further optimization to enhance their structure-activity 
relationships (SAR) and improve their selectivity, potency and pharmacokinetics. NMR is 
one of the most suited methods that provides structural information for rational lead design. 
Ligand-mediated screenings based on SAR by NMR have indeed augmented considerably 
the number of screened libraries and expanded the confidence in FBDD.229  
The final time-demanding and expensive stage is clinical trial. This covers the 
broader scope of drugability, patient’s safety and drug´s efficacy to the target. Drug 
discovery remains a challenging research field with more than 90% of the candidates 
entering clinical trials are bound to failure and very few drugs successfully accomplish the 
long journey from lab bench to bedside. Section 1.6 will present in more details the up-to-
date cutting edge research of aggregation inhibitors aimed at treatment of Tau aggregates.  
 
1.6 Aggregation Inhibitors 
Conceptually, the inhibition of Tau assembly is certainly an appealing approach for 
treatment of tauopathies where engineered compounds would selectively target Tau 
assemblies. However, this methodology encounters abundant practical challenges and is 
bound to high percentages of failure such as low penetration of the BBB, provoked toxicity, 
and overestimated selectivity. Nevertheless, the development of effective protocols to 
identify inhibitors through HTS is established by incorporating several biophysical 
techniques together with cell and animal models.  
Fibrillar Tau deposits are stained by dyes such as Thioflavin T and S (ThT, ThS) 
that exhibit enhanced fluorescence upon binding to cross β structures.230 This assay was 
combined with pelleting and filter experiments, cell viability and microscopy to identify 
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chemical compounds in primary screenings. Using ThS fluorescence assay, Sarkosyl 
insolubility and EM, 42 compounds from 9 chemical classes were screened for their 
plausible inhibition of in vitro heparin-induced full length Tau assembly. Phenothiazines, 
polyphenols and porphyrins were among the classes as potential inhibitors.231 In a larger-
scale screening of 200,000 compounds, similar assays were conducted with 3R and 4R Tau 
fragments (K19 and K18) to evaluate their inhibition for aggregation and their induced 
disassembly.232 From the primary screenings, 77 compounds of the identified hits were 
distributed among the organic families N-phenylamines, anthraquinones, 
phenylthiazolylhydrazides, and rhodanines. These classes were further analyzed by a 
handful of secondary assays including toxicity and activity in cells. Noteworthy, 
quinoxalines and pyrimidotriazines were among the newly identified classes in an HTS 
library of 51,000 compounds screened for inhibition of heparin-induced fibrils.233 
Numerous screenings of small organic molecules revealed common features of 
potential aggregation inhibitors. Most importantly was the action of inhibitors to redirect 
the amyloid fibril formation to off pathway nontoxic oligomers.234 On the other hand, the 
role of aromatic interaction was found to be equally important in driving amyloid assembly 
as well as a recognised inhibition mechanism.235 Self-aggregation is a common feature in 
many organic classes, which is influenced by concentration, pH, ionic strength, 
temperature, solvent polarity, and structure.236 For instance, the high concentration of a 
compound candidate and consequently its aggregates enhanced Tau fibrillization in one 
case156 but in another case, it inhibited amyloid fibril formation.237 The structural, physical 
and chemical properties of the most promising classes of organic compounds together with 
their biological applications are discussed in more details below (Table 3 and part 1.6.1-
1.6.10).   
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Table 3: Chemical Structures of Screened Classes. 
IC50 values obtained from 60,231,233,238-240.  
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Table 3: Chemical Structures of Screened Classes. (Continue) 
 




Phenothiazine is a hetero tricyclic molecule with a central thiazine ring and two 
outer benzene rings (Table 3). Derivatives of the parent compound are pharmaceutically 
significant and are characterized by the type of substituents attached at the peripheral rings. 
Many phenothiazines are commercial drugs with antipsychotic (Chlorpromazine), 
antihistaminic (Promethazine), antimalarial (Chloroquine), and cancer chemopreventive 
effects241-243 targeting dopaminergic and neuronal receptors of the central nervous system 
(α-adrenergic, serotonin, histamine).244-246 The amphiphilic character of phenothiazines 
and high degree of ring lipophilicity enable them to cross the BBB.247 Phenothiazines have 
been also reported for their inhibitory and anti-proliferative effects of calmodulin (CaM) 
and PKC activities.248  
The widespread use of a remarkable phenothiazinium salt in diverse medical 
applications has proved the clinical efficacy of this class in drug research. This compound 
is [3,7-bis(dimethylamino)phenothiazinium chloride],better known as Methylthionine 
hydrochloride or Methylene Blue (MB). MB was first synthesized in 1876 by the German 
chemist Heinrich Caro at BASF. Soon after, dye derivatives were applied in microscopy 
for staining biological tissues, with distinct chemical classes exhibiting different selectivity 
to cell types. In 1891, the German biologists Paul Guttmann and Paul Ehrlich suggested 
the physiological and clinical relevance of histological stains and discovered the treatment 
of Malaria with MB.249 Nowadays, MB is regarded as the therapeutic agent from which the 
chemical development of antimalarial drugs initiated. Part 1.8 is dedicated to the physical 
and chemical properties of MB along with its biological applications. 
 




Rhodanines are derivatives of thiazolidine with a central core regarded as a 
template for engineering biologically active molecules (Table 3). For instance, Epalrestat, 
is a well-known inhibitor of aldose reductase that delays the progression of diabetic 
neuropathy.250 The rhodanine-based derivative 2-thioxothiazolidin-4-one was identified 
during a high-throughput screen232 and secondary assays were then performed to 
characterize the assembly and disassembly of Tau aggregates based on IC50 and DC50 
values.238 Insights into the SAR was obtained by systematically replacing the rhodanine 
core and the branched substituents with different functional groups. The thioxo group of 
the rhodanine core maintained the highest potency due to its low electronegativity and high 
potential for hydrogen bonding. Moreover, esterification of the branched carboxylic acid 
reduced the disassembly, while increasing the linker with the core up to two carbons 
showed higher inhibitory effects. On the other hand, variations of the side chain on the 
furan heterocycle reduced the potency. Therefore, the relevance of the thioxo group of the 
core, the optimal chain length connecting the carboxylic acid and the role of the electron-
rich furan altogether establish the observed pharmacological properties. The screened 
compounds were further investigated in murine neuroblastoma N2a cells to characterize 
inhibition and cytotoxicity with ThS fluorescence and LDH assays. Rhodanines at sub-
concentration levels (100-600 nM) were found to inhibit Tau aggregation and PHF 
disassembly without exhibiting cytotoxicity or interference with the stability of MT.238 
However, rhodanines should be further investigated for their ability to cross the BBB. 
 




Phenylthiazolhydrazides (PTH) were predicted by in silico screenings251 and 49 
compounds were selected to verify the lead structure. The most active functional groups 
were optimized for SAR and the overall biological activity upon incubation with 4R K18 
fragment. BSc3094 was reported to be the most potent PTH as depicted by a generated 
pharmacophore model252 and saturation transfer difference (STD) NMR experiments.251 
The compound contains a hydrophobic region within the thiazole ring (Table 3), the 
carboxyl amide is a hydrogen-bond acceptor and of the two aromatic rings, the 
benzimidazole ring is more hydrophobic, favors π-stacking interactions and represents the 
binding epitope as accessed by STD NMR. Although the cell activities of rhodanines and 
PTH were comparable, The latter showed lower in vitro potency and higher cytotoxicity, 
suggesting a higher cell permeability.239   
 
1.6.4 N-Phenylamines 
N-phenylamines were also identified within the HTS approach232 and showed 
similar activities as rhodanines, but with lower in vitro pharmacological potency.253 EM 
micrographs of the treated K19 filaments revealed shortening and breaking morphologies 
in a dose-dependent fashion. The identified B4A1 and B4D3 (Table 3) were further tested 
for cell viability and toxicity using neuronal cell lines N2a and expressing four repeat 
domains of Tau (K18) in wild type and the pro-aggregation mutant K18ΔK280. The 
selected compounds inhibited and disassembled Tau aggregates in cells and reduced the 
LDH release. The drugs efficiencies for inhibition and disassembly were reported to be 60 
to 70% and 40 to 45%, respectively. Toxicity was relatively low at the used concentrations, 
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however, the determination of the effective cellular concentration was uncertain. The SAR 
of this class remains unclear and requires further investigation. 
 
1.6.5 Anthraquinones 
Anthraquinones incorporate a tricyclic aromatic ring system of an anthracene with 
two keto groups located on the central ring (Table 3). Hydrogen bonding is enhanced in 
the presence of one or more aryl hydroxyl groups. Several hydroxyanthraquinone 
derivatives, known as anthracenediones, are well-established medicines that include 
laxatives (emodin), antimalarial (rufigallol) and chemotherapeutic (mitoxantrone, 
daunorubicin and adriamycin) drugs. HTS for K19 PHF inhibition reported the 
hydroxyanthraquinones derivatives emodin, daunorubicin and adriamycin as potential 
candidates.232 The study also included two compounds identified as hydroxyanthraquinone 
PHF016, containing 4 hydroxyl groups, and the benzophenone derivative PHF005. The 
first three compounds showed dose-dependent inhibitory effects toward hTau23 and 
hTau24 PHF formation (50% at 0.1 µM and 90% at 60 µM) whereas PHF016 and PHF005 
had low significance. When incubated with 3R hTau23 PHFs, a similar trend was observed: 
emodin, daunorubicin and adriamycin were most potent with DC50 values of 7 to 13 µM. 
By contrast, PHF016 and PHF005 achieved better results than the others with DC50 values 
between 10 and 40 µM. The results of subsequent assays (ThS fluorescence, tryptophan 
fluorescence shift, EM and filter trap) have all emerged into one conclusion: the 
compounds are more efficient in inhibiting de novo formation of filaments rather than in 
depolymerizing them.232 However, extending incubation times up to 28 days revealed that 
the disassembly is time-dependent. Interestingly, these compounds do not interact with the 
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assembly of microtubules and are specific to the pathological aggregation. Of the 5 
compounds tested in N2a cell model expressing K18ΔK280, emodin was most effective by 
suppressing the aggregates in the treated cells.  
 
1.6.6 Polyphenols 
Polyphenols are natural and synthetic organic compounds that exhibit multiple 
phenol structural units. Polyphenols occur in plants and dietary supplements (red wine, 
green tea, olive oil) with established antibiotic and neuroprotective properties. The 
polyphenolic compound extracted from green tea, (-)epigallocatechin-3-gallate (EGCG), 
exhibits potent antioxidant, therapeutic and anti-carcinogenic effects. The chemical 
structure of EGCG incorporates pyrogallol (benzene-1,2,3-triol) and gallic acid (3,4,5-
trihydroxybenzoic acid) that are connected to a catechin-like subunit (Table 3). EGCG 
provokes essential bioactivities in cellular processes such as MAPK, Wnt signaling, and 
proteasome inhibition.254-256 More importantly, EGCG has been intensely investigated for 
its neuroprotective actions in neurodegenerative pathologies, specifically as a potent 
inhibitor for S, A, polyglutamine and Tau fibrillization pathways. EGCG redirects S 
amyloid formation to off pathway non–toxic stable oligomers254 that are impaired in the 
pore formation of planar lipid bilayers.257,258 It binds directly to monomeric αS and 
stimulates the assembly of spherical oligomers with average diameters of 20 nm.259 These 
off-pathway oligomers are incompetent of forming amyloidogenic β-sheet structures and 
are nontoxic to mammalian cells. Additionally, immunohistochemical analysis of coronal 
sections from transgenic mice has revealed that EGCG reduces Aβ40 and Aβ42 deposition
260 
and suppresses sarkosyl–soluble phosphorylated Tau isoforms.261 EGCG was also 
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investigated in Huntington´s disease whereupon its oral administration in drosophila flies, 
it acts as an antagonist for the polyglutamine-based huntingtin protein and interferes with 
toxic aggregation.262 SAR-based analyses have investigated the impact of EGCG 
derivatives. Both hydroxyl-containing moieties, pyrogallol and gallate, are indeed essential 
for inhibition since a gallate-free catechin proved to be inactive. 
Despite the fact that EGCG penetrates the BBB in mammals with no adverse 
effects,263 several contradicting results have questioned its candidacy for clinical trials. 
These studies have shown that EGCG exhibit a relatively poor bioavailability and is 
modified through biotransformation reactions such as methylation or glucoronidation.264 
The binding of EGCG to unfolded regions is nonspecific with consequences of interfering 
with any of the numerous signaling proteins that possess such regions.265    
 
1.6.7 Benzothiazoles 
Benzothiazoles are compounds with a stable electron-withdrawing aromatic system 
that provides hydrophobic interactions. ThT and ThS are examples of benzothiazole 
derivatives. Thiacarbocyanine is a class of compounds with two benzothiazole moieties, 
better known as cyanine dyes (Table 3). A library of screened classes of inhibitors has 
suggested compound 3,3´-bis(β-hydroxyethyl)-9-ethyl-5,5´-dimethoxythiacarbocyanine 
iodide, better known as N744, as a candidate that inhibits arachidonic acid-induced 
fibrillization of full-length Tau and causes disaggregation of pre-formed Tau filaments.266 
Despite the incubation of N744 with Aβ and αS at similar sub-stoichiometric 
concentrations, aggregation proceeded independently thus confirming the high selectivity 
to Tau. However, N744 was determined to have a biphasic activity. At low concentrations, 
the domination of monomeric and dimeric forms of N744 inhibit Tau aggregation with low 
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IC50 values (0.3 – 13 µM). At higher concentrations, N744 self-assembles in H-aggregates 
of columnar stacks and enhances Tau fibrillization.267 This suggested that once the 
concentration of the binding target is low, dimer formation of N744 is stabilized and seems 
to be the responsible species behind the inhibitory effect. On the other hand, the ligand´s 
higher order aggregates fail to inhibit Tau fibrillar formation or disaggregation. Thus, 
confirming that these concentrated aggregates are the driving force behind the protein 
fibrillization and is in line with the fact that proteins with extended β-sheets influence 
cyanine aggregation.268 Surprisingly, in other cases, it was the formation of compound 
aggregates that had the inhibitory role on amyloid fibril formation.237 In a complementary 
study, characterization of a cyclic bis-thiacarbocyanine containing two thiacarbocyanine 
moieties showed higher potency than thiacarbocyanine N744 suggesting that the mode of 
inhibition relies on the molecule´s multivalency rather than self-stacking.269 The 
identification of these inhibitors set the basic template for designing multivalent molecules. 
The necessity of prolonged aromatic systems and enhanced solubility while optimizing 
length, flexibility and hydrophobicity of the linkers all together provide higher potency.  
Recently, a study reported the synthesis of N,N’-alkylene bis-thiacarbocyanines 
with different chain lengths to examine their impact on potency and extension of the 
structure-activity relationship.270 The linker length of four methylene units preserved the 
open monomer conformation and resulted in the highest efficiency. Despite the progressive 
improvement in the synthesis and effects of these molecules, this class of inhibitors has not 








Aminothienopyridazines (ATPZ) are heterocyclic compounds containing a 
pyridazine-derived ring fused to a thiophene moiety (Table 3). This class of compounds 
was first identified in a quantitative HTS of 292,000 compounds for possible inhibition of 
K18 P301L aggregates.271 Secondary screenings of selected ATPZs derivatives showed 
that these compounds do not interfere with MT assembly and are selective for Tau but less 
effective towards Aβ42. In an extended study, ATPZs were evaluated for their in vitro and 
in vivo efficacy as well as SAR by designing derivatives that took into account plausible 
BBB permeation.272 Notably, the amino group on the thiophene ring is important for 
biological function, whereas alkylation were unfavorable on both rings. Recently, ATPZs 
were described as agents that facilitates oxidation of cysteines in Tau.273 This identified the 
mode of action by which ATPZ promote intermolecular and intramolecular disulfide bond 
formation in 3R and 4R isoforms, respectively. Although this retains 4R Tau in its 
monomeric form, however ATPZ enhances the dimeric assembly in 3R Tau which act as 
aggregation seeds. Since, these dimers are still capable of fibrillization, the application of 
ATPZ in treating AD does not seem appropriate. 
 
1.6.9 Quinoxalines 
Quinoxalines are heterocyclic compounds that comprise a benzene ring and a 
pyrazine ring in their core structures (Table 3). Quinoxalines such as Actinoleutin and 
Echinomycin are known for their pharmaceutical and antitumoral properties. In a large-
scale HTS library of 51,000 compounds, primary assays were conducted to evaluate the 
inhibition of heparin-induced Tau fibrils.233 The study reported several classes that were 
already nominated as potential inhibitors (phenothiazines, porphyrins, anthraquinones) in 
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addition to newly identified classes (quinoxalines and pyrimidotriazines). Of all remaining 
candidates, 2,3-di(furan-2-yl)-quinoxaline (113F08) exhibited IC50 values in the range of 
1 to 3 µM. Upon inspection of different quinoxaline derivatives for improved SAR, the 
potency of the candidate 113F08 was found to be highly dependent on the presence of the 




Porphyrins are aromatic heterocyclic macrocycles that belong to the cyclic 
tetrapyrrole family. The structural basis of a porphyrin incorporates four pyrrole subunits 
interconnected at their alpha carbon atoms via a methine bridge to include a total of 22 π 
electrons (Table 3). The four central nitrogen atoms provide the chromophore for a 
multitude of metal complexes including iron, magnesium, cobalt, nickel, copper and 
aluminum. The metal ion of these metalloporphyrins usually has a charge of 2+ or 3+. The 
iron-containing porphyrin Heme is a cofactor of the protein hemoglobin. Porphyrins have 
established applications that include dye industry, catalysts, sensitized solar cells, and 
photodynamic therapy. The metalloporphyrins Hemin and Hematin, structurally related to 
heme, have been reported to interfere with Aβ42 oligomerization with the most likely 
forming iron-histidines complexes via the π-electrons of the imidazole ring. 
Phthalocyanine (Pc) belongs to the family of cyclic tetrapyrroles where the 
hydrophobic central structure accommodates a porphyrin moiety except the imines replace 
the methines (Table 3). The resulting central 16-membered ring is hydrophobic, highly 
conjugated and contains a total of 8 nitrogen atoms, 4 of which can coordinate with metal 
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ions. In contrast to the unsubstituted pyrroles in porphyrins, Pc contains four isoindoles 
(benzo-fused pyrroles) that can carry various functional groups at the peripheral outer 
benzo substitution positions. In addition to the substitution of hydrogen atoms by halogens, 
hydroxyl, amino, alkyl, aryl, thiol and nitro functional groups, Pc exhibits a sulfonation 
degree from 0 up to 4, with Phthalocyanine tetrasulfonate (PcTS) accommodating four 
negatively charged sulfonate groups (Table 3). In addition to their wide employment in 
textile dyeing and organic pigments, Phthalocyanines have gained industrial applications 
as photoconducting agents in photocopying devices, chemical sensors, optical storage 
devices, and catalysts for numerous chemical reactions. Of most importance is their role in 
photodynamic therapy.274,275 This class of cyclic tetrapyrroles has stronger absorbance at 
longer wavelengths than porphyrins. The photodynamic properties of PcTS derivatives are 
currently under investigation for possible cancer treatment. Their preferential uptake in 
cancerous cells and their high fluorescence yields both display advantages for tumor 
detection using time-resolved imaging techniques. Of all PcTS-metal complexes, 
chloroaluminum Phthalocyanine Tetrasulfonate (AlPcTS) is most hydrophilic and 
possesses significant photodynamic effects. The administration of phthalocyanines to 
animals results in their localization in the plasma membranes and subcellular organelle 
membranes such as nuclei, mitochondria, lysosomes, and microsomes. It is therefore 
accepted that membranes are principal targets of phototoxic effects associated with Pc-
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1.7 Phthalocyanine Tetrasulfonate 
The term Phthalocyanine originates from Greek (naptha means rock oil and cyanine 
means dark blue) and was first used in 1933 by Sir Reginald Linstead to describe this class 
of macrocyclic compounds.276 Scottish Dyes Ltd. pioneered the application of this family 
and was granted the first patent of phthalocyanines. Years later, X-ray crystallography 
confirmed the structure of these compounds.  
 
1.7.1 Physical and Chemical Properties 
Phthalocyanines exhibit various photophysical and chemical properties based on 
the nature of peripheral substituents or axial ligands to the chelated central metal ion. 
During PcTS synthesis, sulfonation may occur on adjacent or opposite rings and hence 
preparations usually contain a mixture of regioisomers in undefined relative amounts 
between mono and tetrasulfonate.277 This possible ambiguity is overcome by use of the 
same preparation during spectral studies and cell cultures or by further batch purifications.  
Following the displacement of two hydrogen atoms from the central nitrogens in 
PcTS, the metal ion occupancy neutralizes one (Fe3+, Mn3+, Al3+) or both (Ni2+, Cu2+, Zn2+, 
V4+O) of the resulting negative charges. The metal type favors a preferred coordination 
stereochemistry. For instance, Ni2+ and Cu2+ form square planar complexes, with the metal 
atom being coplanar to the four nitrogens whereas Fe3+, Al3+, and V4+ establish square 
pyramidal structures, wherein the metal lies outside the plane of the nitrogens. Fe3+ can 
additionally bind two axial ligands, one on each side of the macrocycle and retain the 
coplanarity with the nitrogens. Although the nature of the metal does not seem to be a 
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critical determinant of the inhibitory activity, however, it influences the photophysical 
properties in terms of triplet quantum yield and lifetime.278 
Like several organic dyes, PcTS aggregates in solution due to the non-covalent 
attractive interactions between the aromatic rings that drive the coplanar association of 
PcTS monomer to dimers and further to higher order complexes. Physical effects such as 
metal ion occupancy, ionic strength, temperature, and concentration dependency may alter 
this molecular self–assembly. The peripheral hydrophilic sulfonate groups promote the 
solubility of the whole system in aqueous solutions, but also trigger coulomb repulsive 
forces due to the negative charges. The non-covalent π-π interaction is caused by 
intermolecular overlapping of p-orbitals in π conjugated systems, with large orbital 
dependent contribution to the dispersion component of Van der Waals forces. These 
abundant delocalized π electrons favor flat polycyclic aromatic systems to adopt stacked 
arrangements. Other stacking forces include hydrogen bonds, charge transfers and dipole-
dipole interactions. On the other hand, electrostatic forces might considerably weaken this 
effect in aromatics but does not entirely cancel it. This oligomerization phenomenon arises 
from the planarity of the system with π-π stacking associating the aggregates perpendicular 
to the axis of the plane. Depending on the geometry of the stacked arrangement and relative 
orientation, the resulting structures can adapt two assemblies, H- (hypsochromic) or J- 
(Jelley) aggregates.278 Although both forms define the linear stacking of coplanar 
molecular units with a distance of 3.3 Å, the angle between the long molecular axis and the 
stacking axis, known as the tilt angle α, distinguishes H-oligomeric (α = 900) from J-
polymeric (α < 100)  aggregates. 
Monomeric Pcs have characteristic absorption spectra with two absorption peaks, 
one appearing at approximately 350 nm (known as Soret peak) and another around 600 
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nm. Aggregation is spectroscopically detected and depending on the direction of the 
relative orientation, the absorption of the Soret region occurs at shorter (H- aggregates) or 
longer wavelengths (J- aggregates). Aggregation is also recognized by NMR spectroscopy. 
The concentration-dependent association of molecules in solution perturbates the 
diamagnetic shielding of their constituent nuclei. As a result of the coplanar stacking, ring 
currents reinforce the magnitude of the diamagnetic shielding and trigger upfield chemical 
shifts in resonances of nuclei located near the π electron macroring, mostly the peripheral 
aromatic protons (Figure 12). Aqueous media tend to promote PcTS self-stacking, whereas 
detergents, plasma proteins and organic solvents such as DMSO stabilize the monomeric 
species.279 
 
Figure 12: The Self-stacking of PcTS as Detected by NMR Spectroscopy. 
Structural elucidation of PcTS and evaluation of its concentration-dependent self-aggregation from 1D 1H 
NMR spectra. The coplanar stacking of PcTS in solution (in 50 mM phosphate buffer pH 6.8) perturbates the 
diamagnetic shielding and trigger upfield chemical shifts in resonances of the protons located near the π 
electron macroring, mostly the peripheral aromatic protons. At low concentrations of PcTS (50 µM, blue and 
100 µM, red), both calculated and evaluated concentrations (from NMR spectra) are in accordance. At higher 
concentrations, the coplanar stacking results in a significant deviation between calculated and evaluated (i.e. 
500 µM versus 176 µM, green; and 1500 µM versus 286 µM, pink). Measurements were conducted on 
BRUKER 400 MHz spectrometer at 278K. 
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1.7.2 Biological applications 
PcTS is known for its diverse applications in biological systems and its anti–
amyloidogenic effect has been investigated in several studies. TSEs are group of rare 
neurodegenerative diseases that infect sheep (Scrapies), cattle (Bovine spongiform 
encephalopathy BSE), deer (Chronic wasting disease CWD) and humans (Creutzfeldt-
Jakob disease CJD). These pathogeneses share a common event where the functional 
protease-sensitive prion protein (PrP-sen) switches conformation to a partially protease-
resistant form (PrP-res). From a number of screened porphyrins and Phthalocyanines in 
scrapie-infected mouse neuroblastoma cell cultures,280 PcTS exhibited in vivo prophylactic 
and therapeutic effects for its inhibition of PrP-res aggregates281 and substantially 
prolonged the lives of treated mice.282 A study was further carried to investigate whether 
the metal occupancy and the extent of sulfonation can strongly influence in vivo and in 
vitro potency of PrP-res inhibition.277 Although the compound´s solubility increases 
dramatically with the number of sulfonates, the extent of PcTS sulfonation had little effect 
on EC50. PcTS and Ni(II)PcTS showed significantly delayed disease incubation times and 
together with Fe(III)PcTS were among the most potent (lowest EC50) in murine cells. The 
proposed mechanism of the anti-TSE activity suggests that cyclic tetrapyrroles bind PrP 
aggregates or stack sequentially onto a bound monomer via π-π interactions of the aromatic 
system whereas electrostatic bonding interactions between negative SO3
3- and positive 
centers on target binding site contribute much less to the overall effect. A metal-sensitive 
property of cyclic tetrapyrroles may be relevant to inhibition and ability to oligomerize via 
various types of π stacking. More recently, the interaction of free and metal-based PcTS 
with hamster PrP (90-232) has been further characterized by a handful of complementary 
assays.283 The high and low binding affinities of PcTS and AlPcTS, respectively, 
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correspond to the high (PcTS) and low (AlPcTS) tendencies of self-stacking and are 
affected to a lower extent by the buffer ionic strength. It is, however, expected that changes 
in solvents and tissue microenvironments may well modify the equilibrium constants, 
kinetics of formation and dissociation of aggregates.28 Moreover, the binding is modulated 
by the aromatic residues with a stoichiometry of 4 to 5 PcTS moieties per PrP molecule. 
Indeed, this oligomerization process has been demonstrated to be essential for the 
inhibitory activity of PcTS on protein aggregation. Importantly, PcTS suppresses the 
formation of AS amyloid.284 Using NMR spectroscopy, it was shown that PcTS inhibits 
S filament assembly and induces the formation of non–toxic aggregates mediated by 
specific binding to aromatic residues at the N-terminus (Y39).285 This study provided 
crucial evidences that PcTS diminishes the amount of aggregated S in a dose dependent 
fashion and converts them into smaller amorphous nonfibrillar species that are non-toxic, 
have reduced β-sheet signature (CD spectroscopy), and are sensitive to dissolution by mild 
detergent Sarkosyl. Taking advantage of its chelating and molecular self–assembly 
properties, PcTS forms a complex with the redox–active metals that induce toxic A40 
oligomeric species and results in an amyloid fibrillar meshwork.235 Surprisingly, there are 
few studies on PcTS as a possible candidate in disassembling Tau protein filaments but 
with no further structural or mechanistic basis. Recently, we revealed the mechanism 
behind the interaction between PcTS and full-length human Tau protein.60 By combining 
NMR spectroscopy, electron paramagnetic resonance spectroscopy (EPR) and Small-
angle X-ray scattering (SAXS) together with other biophysical techniques, we 
demonstrated that PcTS targets tyrosine residues of monomeric hTau40 and converts the 
protein into soluble oligomers that contain a dynamic noncooperatively stabilized core. 
The experimental details and extensive discussion of results are presented in Chapter 2.  
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1.8 Methylene Blue 
MB has received considerable attention as a potential drug candidate for targeting 
AD; not only for its inhibition of Tau aggregation but also for its regulation of Aβ fibril 
formation. Non-neuroleptic MB penetrates the BBB and its dimethyl derivatives have 
enhanced properties for aggregation.286 Together with other beneficial pharmacokinetics, 
the determining factors for an optimal mode of action depends on the oxidation-reduction 
behaviour, planarity and aromaticity of the system. 
 
1.8.1 Physical, Chemical and Biochemical Properties 
As previously mentioned, MB is a derivative of the hetero tricyclic phenothiazine 
exhibiting a cationic thiazine ring and two dimethylamino functional groups (NMe2) on the 
outer benzene rings at positions R3 and R7 (Table 3). Molecules similar in structure and 
physical properties to the parent compound MB include Azure A (R3 = NMe2, R7 = NH2), 
Azure B (R3 = NMe2, R7 = NHMe), Azure C (R3 = NHMe, R7 = NH2) and Thionin (R3 = 
NH2, R7 = NH2). The cationic thiazine ring of MB and the azures establishes the planarity 
and aromaticity of the system and through oxidation-reduction reactions these compounds 
convert to the neutral nonaromatic Leuco forms (Figure 13). MB and its derivatives absorb 
around 670 nm and display photosensitizing properties, whereupon the presence of oxygen 
and light, they generate a singlet oxygen287 which is substantially vital in photodynamic 
therapy and production of organic peroxides.  
Similar to PcTS and other organic dyes, MB forms dimers and higher order 
aggregates in a concentration dependent manner. Importantly, the response of MB in most 
biological systems is characterized by a hormetic behavior. Hormesis defines a drug with 
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opposing effects in low and in high doses. In low µg ranges, MB is neuroprotective, acting 
as an electron donor and an antioxidant in mitochondria; while at higher doses it withdraws 
electrons away from the mitochondrial transport chain complexes and alters the activity of 
the associated enzyme, cytochrome oxidase.288 A study using rat brain homogenates 
proposed a mechanism by which the autoxidizable property of MB provokes the hormetic 
biological effects on cytochrome oxidase. The iron center of this enzyme increases its 
activity by oxidizing low concentrations of LMB to MB. At higher MB doses, the 
reversible equilibrium between both species (LMB and MB) is lost. The activity of the 
enzyme then decreases as excess MB withdraws electrons from the transport chain 
complexes. This hormetic dose-response has been also reported in the treatment of 
Methemoglobinemia. At a low concentration of MB, the targeted NADP-methemoglobin 
reductase converts methemoglobin to hemoglobin.289 However, at higher concentrations 
and stronger oxidizing capacity, the effect is reversed and MB causes itself 
methemoglobinemia.290 This proves that MB does not exhibit a pharmacological dose-
dependent profile but rather its effective concentration would determine its role as an 
electron donor or acceptor.  




Figure 13: Reduction-Oxidation Interplay of Phenothiazines. 
The reduction of MB yields leucoMB (1) and is regenerated in oxidizing conditions (2). Mono- and di-N-
demethylation yield azure B (3) and azure A (4), respectively. Adapted from 291.  
 
1.8.2 Biological applications 
During the international conference on Alzheimer´s Disease held in 2008, a major 
breakthrough in the treatment of AD was announced from clinical trials sponsored by 
TauRx Therapeutics.292 Based on the designed formulation, Rember™, containing an 
optimized form of MB, the report presented evidence that this drug dissolves the tangle 
filaments isolated from AD brains, and disrupts abnormal Tau aggregation in cell models. 
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Upon oral administration of MB to 321 participants in a phase II clinical trial over 84 
weeks, patients with mild to moderate cognitive impairment exhibited 81% reduction of 
cognitive decline rate at week 50.239 These findings triggered a wave of scientific supports 
and arguments; as well as a handful of strategic measurements over the years that followed. 
From extensive pharmacokinetic studies performed on rat models, MB distribution among 
organs was found to be dependent on the form of administration, but its permeation of the 
BBB was irrespective of the route.293 Along its biochemical pathways, MB undergoes an 
in vivo redox cycle where it is reduced by NADPH into the leucoMB (LMB). In the 
presence of molecular oxygen or Fe(III)–containing compounds, LMB is oxidized to 
regenerate MB (Figure 13). In parallel, the mono– and di–N–demethylation of MB 
respectively yield azure B and azure A; two metabolites with established pharmacological 
effects.294 Furthermore, the oxidized forms of MB derivatives exhibiting one or more 
amino hydrogens (NHMe or NH2) can potentially form a neutral quinoneimine upon 
deprotonation (Figure 14). This species readily diffuses through membranes in contrast to 
the charged MB.  
A large number of hypotheses were proposed to postulate the protective role of MB 
in neurodegeneration. One approach is based on cycling between the oxidized and reduced 
forms of MB.295 Other studies compare the potential inhibition of Tau aggregation by MB 
and azure B with a therapeutic superiority of the latter. A third suggestion involves the 
Hsp70 chaperone where the MB–driven inhibition of Hsp70 ATPase modulates the 
degradation of toxic polyglutamine protein and increases its accumulation in the cell.296 
With the same Hsp70 inhibition scheme, the level of Tau protein is selectively decreased 
and consequently provokes cell protection from toxic accumulations.297 Lining up the 
recently published failure of MB in zebra fish models of Tauopathy298 and its interpretation 
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with a biphasic dose–response relationship, it is still unclear whether the therapeutic 
behaviour of MB corresponds to its inhibitory action on Tau aggregation, its antioxidant 
activity by interaction with electron transport chain of mitochondria, or its binding and 
modulation of partner proteins. Nevertheless, MB has recently stepped into a phase III 
clinical trial.299  
The fundamental link between MB and azure B had to be further clarified to 
determine whether the monodemethylation favoured with several in vitro and in vivo 
conditions, confirms that MB is the prodrug of the active agent azure B. MB is one of the 
first compounds identified that blocked Tau-Tau interaction. To access additional insights 
on the efficacy of MB and the interplay of both azure A and azure B, we were interested in 
identifying their possible interactions with Tau protein at molecular levels.291 Our findings 
suggest that the mode of action of these phenothiazines lies behind the interplay in the 
reduction/oxidation potential of their thiazine ring and the native cysteine residues of Tau. 
Using NMR spectroscopy and other biophysical techniques, we demonstrated that these 
compounds specifically modify the cysteines and retain Tau in a monomeric disordered 
conformation. Chapter 3 presents the experimental details and an extensive discussion of 
the results. As previously mentioned (part 1.4.2), the oxidation of Tau at its cysteines 
(C291, C322) is a posttranslational modification that has an impact on aggregation driven 
by a disulfide bond. This will be comprehensively discussed furthermore in part 1.8.3. 
At the same time, MB has been widely investigated for its inhibition of aggregating 
proteins deposited in other neurodegenerative diseases. In TSEs, MB binding to 
hydrophobic and charged residues provoked a diminished rate of PrP-res oligomerization 
and limited fibrillar formation.300 On the other hand, MB targets Aβ42 differently by 
inhibiting monomeric conversion into oligomers but enhancing fibril formation; hence 
1.8 Methylene Blue 
 
 81 
suggesting that oligomerization and fibrillization of Aβ42 follow different pathways.
301 All 
in all, several modes for the protective role of MB in neurodegeneration have been 
postulated, and although the mechanisms differ widely but many of them are reinforced 




Figure 14: Conversion of Azure B to Quinoneimine. 




1.8.3 The Impact of MB on Cysteine Oxidation 
The nucleophilic sulfhydryl group of a cysteine amino acid is prone to chemical 
modification.302 The sulfur character undergoes several distinct redox pathways and 
facilitates regulatory roles in electron donation, hydride-transfer reactions, and free radical 
reactions.303 The most dominant chemical oxidation is the disulfide bridge formation where 
it enhances structural stability in some cases, and initiates protein aggregation in other 
cases. Sickle-cell hemoglobin, Aβ, and Tau were among the identified proteins that 
undergo fibrillization following a nucleus-driven mechanism, known as seeding or 
nucleation.304 Therefore, screening compounds that interfere with the disulfide bond 
formation is a possible therapeutic intervention for inhibiting Tau assemblies.  
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The two native cysteine residues of Tau (C291, C322) exist in the repeat regions 
R2 and R3, hence, 3R and 4R isoforms contain respectively one or two cysteines. 
Accordingly, 4R isoforms exhibit an intramolecular disulfide (S-S) bond between C291 
and C322, whereas the sole cysteine in 3R isoforms (C322) favors intermolecular disulfide 
bonding and consequently formation of dimers305 and higher aggregates.58,176 However, 4R 
isoforms are not completely resistant to aggregation but they indeed exhibit both intra and 
intermolecular S-S bonds and consequently a mixture of monomers, dimers and higher 
aggregates.306  
Lining up the suggested involvement of cysteine-induced dimers in the pathological 
cascade (Figure 10) and the potential of phenothiazines in disrupting Tau aggregates, we 
studied the oxidation-reduction behaviour of MB and its metabolites azure A and azure B 
for determining factors of Tau aggregation inhibition.291 Our study showed that these 
organic molecules inhibit aggregation of Tau via oxidation of the native cysteine residues 
to sulfenic, sulfinic and sulfonic acids. Cysteine-oxidation keeps monomeric Tau in an 
aggregation-incompetent disordered state avoiding the formation of toxic Tau aggregation 
intermediates. Moreover, our aggregation assays performed on the 3R construct, K19, 
demonstrated that disulfide bond formation is diminished in the presence of MB and 
aggregation of K19 is not promoted. We also showed that demethylation of MB provides 
new modes of interaction with Tau. Similar to MB, the metabolites azure A and azure B 
oxidize Tau’s cysteines, but also interacts with aromatic residues, indicating that in vivo 
where MB can be modified to azure A and azure B, additional modes of Tau aggregation 
modulation are possible. The experimental details and extensive discussion of the results 
are presented in Chapter 3. 
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1.8.4 MB and Protein Sulfenic Acids 
Despite the fact that disulfide bond formation is the most prevailing chemical 
modification of cysteines that occurs under different conditions, thiols undergo a wide 
range of oxidation states from +6 to -2. Peroxidation governs the formation of cysteine-
sulfenic acid (Cys-SOH), a species that play an essential role in redox control of many 
protein functions, such as enzymatic catalysis and cell signaling. Protein-SOHs are in the 
center of both regulatory and pathological events. The Cys-SOH is moderately stable but 
in the presence of a free thiol, it can form disulfide bonding, or progressively proceed to 
higher oxidation orders to yield cysteine-sulfinic acid (Cys-SO2H) and cysteine-sulfonic 
acid (Cys-SO3H).
307 The nature of these transient species and their high reactivity both 
increase the challenge in detecting, isolating and quantifying them. Nevertheless, the 
different forms of oxidized cysteines have been detected in several signal transduction 
cascades and regulatory proteins including protein tyrosine phosphatases,308 
peroxiredoxins,309 glyceraldehyde-3-phosphate dehydrogenase,310 cysteine protease 
papain,311 and human serum albumin.312  
Yet another significant involvement of MB-mediated oxidation was observed with 
the molecular chaperone family of heat shock proteins 70 (Hsp70).296 These proteins bind 
ATP through their N-terminal domain and trigger conformational changes in their C-
terminal domain. Consequently, this enhances the affinity to interact with their unfolded 
substrates and thereby protecting them against aggregation. (Part 1.9 will discuss the Hsp 
family in more details). Hsp70s were implicated in reducing Tau accumulation and have 
been linked to redox signaling based on the reactivity of the cysteine residues.313 The two 
proteins, Hsc70 and Hsp72, have similar sequences and exhibit four or five cysteine 
residues, respectively. The additional cysteine of Hsp72, Cys306, has been associated to 
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the ATPase activity. The MB-mediated oxidation of Cys306 contributed in the loss of ATP 
binding. Moreover, upon treatment of HeLaC3 cells with MB, the designed Hsp72/C306S 
mutant (resistant to MB oxidation) blocked the clearance of Tau whereas the Hsp72/C306D 
mutant (mimicking oxidation) reduced Tau levels in these cells. Of all cysteines, MB 
oxidized Hsp72 at Cys306 to Cys-SOH and had no effect on any of the cysteines of Hsc70. 
This modification blocked Hsp72 from binding ATP and hence compromised its function 
in regulating levels of Tau. Keeping in mind that Hsp72 is upregulated during stress, this 
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1.9 Heat Shock Protein 
The collection of Heat shock proteins (Hsp) include members of functionally 
related proteins that are highly expressed when exposed to high temperatures, pH 
alteration, or oxygen deprivation. These proteins are abundant in all living organisms and 
constitute essential factors for cell growth and viability. Hsps are molecular chaperones 
that are mostly involved in folding and refolding mechanisms of denaturated proteins.149 
They prevent protein aggregation by interacting to exposed hydrophobic surfaces of 
aggregation-prone polypeptides. Other functions include protein assembly, translocation 
and degradation of misfolded aggregates. Hsps are further classified into major families 
based on their related functions and molecular masses. These classes comprise Hsp70, 
Hsp40, Hsp60, Hsp90, Hsp100 and other small heat shock proteins, sHsps (Figure 15). 
Within a sophisticated molecular network, these proteins function cooperatively to 
maintain a stable cellular homeostasis.  
Proteins of the Hsp70 family consist of two conserved functional domains, 
nucleotide binding domain (NBD) and substrate binding domain (SBD) both connected by 
a flexible linker. This family mainly supports refolding of misfolded and aggregated 
proteins but also import unfolded species to major cellular compartments (mitochondria, 
endoplasmic reticulum) for folding or degradation purposes.  
 The specificity of Hsp70 interaction is determined by members of the Hsp40 
family (known as J-proteins). The four α-helical domains of Hsp40 stimulate the activity 
of ATPase314 and confiscate denaturated substrates by controlling their interaction with 
Hsp70.315 The SBD of the Hsp70 then regulates substrate binding via its helical regions. 
Selective nucleotide factors affect the replacement of ATP by ADP, and consequently the 
dissociation of the complex. Free Hsp70 reorganizes for repeating cycles to ensure proper 
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folding. Hence, the co-chaperones Hsp40-Hsp70 constitute the overall molecular 
chaperone machine that is responsible for early stages of protein folding and refolding. 
Following substrate binding of Hsp70, another class of proteins, Hsp90, has been 
reported for further interactions.316 But unlike other chaperones, Hsp90 proteins bind their 
targets at an advanced stage of folding. Hsp90 plays a major role in the folding scheme of 
essential client proteins like protein kinases and transcription factors. Both N- and C-
domains of Hsp90 interact with the substrate, however the N-terminus accommodates the 
ATP binding domain that recognizes co-chaperones and client proteins. The C-terminal 
residues of Hsp90 assembles the homodimer with the ATP-bound state adopting a circular 
structure. 
Other classes of the Hsp proteins are equally important. Hsp60 is a family of 
chaperonins that facilitates an ATP-mediated process responsible of folding multimeric 
proteins. Hsp100, on the other hand, solubilizes misfolded proteins and clears irreversible 
protein aggregates. After binding to ATP, Hsp100 accumulates into hexameric ring-shaped 
complexes that favor proteasomal degradation. One class of the Hsp family includes 
proteins with smaller molecular masses ranging between 12 and 43 kDa. These sHsp 
proteins adapt a conserved α-crystalline domain. Oligomeric species of sHsps assemble 
into large surface areas to accommodate the aggregates and transfer non-native proteins to 
other Hsp machinery for proper folding. 
Several Hsp molecular chaperones are prominent in proteasomal degradation of 
highly phosphorylated Tau.115,209,210.   
 




Figure 15: The Hierarchy of Heat Shock Proteins.  
Heat shock proteins are functionally related molecular chaperones that are involved in folding mechanisms 
of denaturated proteins. They classified into major families based on their related functions and molecular 
masses. These classes comprise Hsp70, Hsp40, Hsp60, Hsp90, Hsp100 and other small heat shock proteins. 
Adapted from 317.  
 
 
1.9.1 Molecular Chaperones and Tau Protein  
The major functions behind Hsp70 clearance of Tau aggregates are associated to 
ATP hydrolysis and peptide binding. The N-terminal ATPase domain triggers 
conformational changes of the NBD and SBD domains upon ATP binding. The hydrolysis 
of the ATP-bound form to the ADP-bound arrangement increases the affinity for substrate 
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binding. The SBD then switches from an open to a closed conformation and activates its 
binding pockets. Favored by a high affinity for neutral and hydrophobic residues, the C-
terminal SBD binds its target. In parallel, Hsp40 (J-proteins) catalyzes the conversion of 
ATP to ADP, stabilizes the substrate-bound form, and further recruits other substrates to 
close proximity of active Hsp70. Once proper folding occurs, selective nucleotide factors 
affect the replacement of ATP by ADP, hence remodeling the ATP-bound form. The SBD-
open conformation then releases the substrate and consequently dissociates the complex. 
Unbound Hsp70 undergoes multiple folding/re-folding cycles. The Hsp40-Hsp70 
chaperone machine ensures proper protein folding/refolding and prevention of misfolded 
species. Remarkably, Hsp70 inhibitory mode exhibits higher preferences to oligomeric Tau 
aggregates over fibrillar.318 The affinity towards 3 repeat isoforms was found to be 
higher.319  
On the other hand, the cooperative functioning of Hsp70 and Hsp90 have been 
widely reported.320 Hsp70 is monomeric and contains a single ATP-binding pocket that can 
be activated by Hsp40 whereas Hsp90 occurs as a homodimer accommodating four ATP-
binding pocket that are independent of Hsp40 activation.321 The levels of Hsp70 and Hsp90 
are crucial in determining clearance or preservation of Tau aggregates.322 The high ATP 
consumption of both proteins, specifically by Hsp90, triggered the concept of modulating 
their ATPase activities through pharmacological intervention and genetic manipulation.  
Among the Hsp70 family, protein Hsp72 and heat shock cognate 70 (Hsc70) 
protein were highly relevant in tau degradation.323 In mammalian systems, Hsc70 is 
constitutively expressed while Hsp72 expression is stress-induced. Although the two 
proteins exhibit more than 80% resemblance in their primary sequences with minor 
variances at the C-terminal, both proteins influence Tau conformation and clearance 
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kinetics differently. Constitutive Hsc70 slowed Tau clearance while inducible Hsp72 
accelerated it.324 In addition to these opposing effects, Hsp72 exhibited higher affinity for 
Tau than Hsc70 as accessed by NMR spectroscopy. These findings were directly associated 
to the minor sequence differences at the C-terminus of both proteins and supported 
therapeutic relevance in promoting Hsp72 and inhibiting Hsc70. Chapter 4 presents these 
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1.10 NMR Spectroscopy 
 NMR spectroscopy is an indispensable tool in structural elucidation of small 
organic molecules and large biomolecules. The classical NMR parameters such as 
chemical shifts, scalar couplings and nuclear Overhauser enhancement all provide valuable 
information about the environment of nuclear spins. Tremendous number of protein 
structures of challenging systems have been solved by the aid of advanced NMR 
approaches. NMR-directed studies of protein-ligand interactions have augmented 
considerably the understanding of wide range of biological processes from 
neurotransmitter and drug binding to enzyme-substrate interactions. NMR-based FBDD 
quantitatively improved SAR approaches and expanded the confidence and the number of 
screened libraries. 
 
Table 4: Common NMR Parameters. 
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Each type of nuclear proton is characterized by a magnetic moment 𝝁 relating the spin 
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When positioned in an external magnetic field B, the magnetic moment 𝝁 orients with the 
static field along the z-axis, B0, and the nuclear spins split into quantized energy levels. In 
the case of a nucleus with spin Î = 
𝟏
𝟐
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where ℏ = 
𝒉
𝟐
. Transitions between these energy levels can be induced upon irradiation with 
a radiofrequency ℎ𝝊 corresponding to the energy difference between two states: 
  
𝚫𝑬 = 𝜸. ℏ. 𝑩𝟎 = 𝒉𝝊  𝟏𝟎. 𝟒 
 
The Larmor frequency 𝝎0 of a nuclear spin only depends on the magnetic field and its 
gyromagnetic ratio:  
𝝎𝟎 = 𝜸. 𝑩𝟎  𝟏𝟎. 𝟓 
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1.10.1 NMR Chemical Shifts 
The observed nuclear larmor frequency depends on the local chemical environment 
and defines the chemical shift 𝜹 as the difference between this frequency and a reference 
frequency:  
 
𝜹(𝒑𝒑𝒎) = 𝟏𝟎𝟔. (
𝝊 − 𝝊𝟎
𝝊𝟎
) 𝟏𝟎. 𝟔 
 
In peptides and proteins, the backbone conformation and the associated chemical shifts 
1Hα, 
1HN and
 13Cα are directly correlated.
325 Ring currents of aromatic residues affect 𝜹Hα 
values whereas hydrogen bonding and dihedral angles mainly influence 𝜹HN values.326 
Moreover, the chemical shifts 1Hα, 
13Cα, 
13Cβ, and 
13CO are sensitive probes to secondary 
structure. The secondary chemical shift 𝚫𝜹𝑪 identifies these elements. Relative to random 
coil values,327 experimental 𝜹Cα and 𝜹CO shift upfield in β-sheets (𝚫𝜹𝑪 < 𝟎) and 
downfield in α-helices (𝚫𝜹𝑪 > 𝟎). 
 
𝚫𝜹𝑪 = 𝜹𝑪𝒆𝒙𝒑 − 𝜹𝑪𝒄𝒐𝒊𝒍 𝟏𝟎. 𝟕 
 
The secondary chemical shift 𝚫𝜹𝑪 identified local structural propensities in different IDPs 
such as prion,328 αS,329 βS,330 and Tau.86 
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1.10.2 Heteronuclear Single Quantum Coherence 
The standard 2D NMR measurement is the heteronuclear single quantum 
coherence (HSQC) experiment. This pulse sequence records one-bond correlation spectra 
between 1H and 13C or 15N. The sensitivity of NMR is governed by the natural abundance 
of the active nucleus and its gyromagnetic ratio. Since the proton satisfies both 
requirements, the transfer of magnetization from proton to other nuclei allows the 
measurement of heteronuclear NMR experiments with high sensitivity. The main scheme 
involves a proton (1H) excitation, then polarization transfer to the selected heteronucleus 
(13C or 15N) and finally a polarization back transfer for detection on protons. A common 
building block for this purpose is the Insensitive nuclei enhancement through polarization 
transfer (INEPT). The pulse sequence of a standard HSQC experiment combines two 
INEPT magnetization transfers, the first between periods A and B and the second between 
D and E (Figure 14). The first 900 pulse flips the spin 𝑰 from equilibrium (Î𝒛) to a 
transverse magnetization (Î𝒚). During period A (known as spin echo), the 180
0 pulse on 
both 𝑰 and 𝑺 spins refocuses the chemical shift modulation but allows coupling to evolve 
(2Î𝒙Ŝ𝒛). The two 900 pulses at period B transfer the coherence to the directly-attached 
heteronucleus (2Î𝒙Ŝ𝒛  2Î𝒛Ŝ𝒚) During period C, t1 evolution takes place but the central 
1800 pulse on spin 𝑰 refocuses the evolution of the heteronuclear coupling 𝑱𝑰𝑺 (2Î𝒛Ŝ𝒚). 
Simultaneous 900 pulses at period D transfer the anti-phase magnetization back to spin 𝑰 
(2Î𝒛Ŝ𝒚 − 2Î𝒚Ŝ𝒛). The second spin echo during period E transforms the anti-phase 
component back to the in-phase magnetization (−2Î𝒚Ŝ𝒛 Î𝒙). The signal is finally 
detected in the proton dimension. A modification to the standard pulse sequence is the 
constant time (ct) HSQC (Figure 14), in which an additional element is inserted between 
the two INEPT sequences so that the heteronuclear coherence evolves during  a constant 
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Figure 16: Pulse Sequences for Basic and Constant-time HSQC. 
(a) The pulse sequence of a standard HSQC experiment involves two INEPT magnetization transfers for 
proton excitation, polarization transfer to the selected heteronucleus, and back transfer for detection on 
protons. [900 pulse  (Î𝒚); 180
0 pulse  (2Î𝒙Ŝ𝒛); 90
0 pulses  (2Î𝒙Ŝ𝒛  2Î𝒛Ŝ𝒚); 180
0 pulse  (2Î𝒛Ŝ𝒚); 90
0 
pulses  (2Î𝒛Ŝ𝒚  − 2Î𝒚Ŝ𝒛) (−2Î𝒚Ŝ𝒛  Î𝒙)]. (b) The constant time (ct) HSQC incorporates an additional 
element for the evolution of the heteronuclear coherence during a constant time period T to avoid splitting of 
13C-13C couplings. Adapted from 331,332. 
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The successful use of 2D 1H-15N HSQC is based on the large dispersion of 
backbone 15N amide and 13C carbonyl chemical shifts and their dependency on the local 
environment. In a folded protein, residues on the surface are present in a hydrophilic 
surrounding in contrast to the ones buried in the hydrophobic core. Both groups have 
distinct environments, and hence their chemical shifts are very different. This leads to the 
obvious spreading of chemical shifts (Figure 15).  On the other hand, residues in an IDP 
share similar and averaged chemical environments where the resulting chemical shifts are 
primarily affected by their own side chain and their neighboring residues. Each residue 
type exhibits a corresponding random coil value, where 15N random coil values are better 
dispersed (100-135 ppm) than the 1H values (6.5-9.5 ppm).333 The chemical shifts of 












Figure 17: HSQC Spectra of Folded and Disordered Proteins. 
Comparison between the 2D 1H-15N HSQC spectra of 42-kDa Maltose Binding Protein (50 µM in 20 mM 
phosphate buffer, 50 mM NaCl, 20 mM β-cyclodextrine; pH 7.1) and 45-kDa hTau40 (50 µM in 50 mM 
phosphate buffer; pH 6.8). Spectra were measured at 310 K and 278 K, respectively on a BRUKER 700 MHz 
spectrometer equipped with a cryoprobe. 
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1.10.3 Chemical Shift Mapping of Binding Sites 
Titration by NMR is a powerful technique to evaluate protein-ligand and protein-
protein interactions. The sensitivity of the backbone amide chemical shifts towards changes 
in their local chemical environment allows a convenient mapping of the protein´s 
interacting sites with its partner. After recording a series of 2D 1H-15N HSQC spectra at 
increasing ligand concentration, the chemical shifts of the residues are monitored for 
possible perturbations. A partner pertubates the chemical shifts of the residues at the 
binding interface and may induce conformational changes (Figure 18). The mapping of 
the chemical shifts of both dimensions (𝜹HN and 𝜹N) for an amino acid residue is 










 𝟏𝟎. 𝟖 
 
where ∆𝜹𝑵 is the difference between bound ligand (𝜹𝑵𝒃𝒐𝒖𝒏𝒅) and free protein (𝜹𝑵𝒇𝒓𝒆𝒆)   
and ∆𝜹𝑯 is the difference between bound ligand (𝜹𝑯𝒃𝒐𝒖𝒏𝒅) and free protein (𝜹𝑯𝒇𝒓𝒆𝒆).  
 
Importantly, the evaluation of linewidths changes is a complementary approach to decipher 
chemical exchange processes such as ligand binding, protein folding and oligomerization. 
The rate of conformational exchange between bound and free states is estimated upon 
interaction of the ligand. An intensity ratio plot represents the ratios between the lineshape 
intensities of the bound state (𝑰𝒃𝒐𝒖𝒏𝒅) and  (𝑰𝒇𝒓𝒆𝒆) and the free state that are extrapolated 
from HSQC spectra (Figure 18). 




Figure 18: Mapping of Chemical Shifts and Linewidths Changes. 
(a) Selected region of 2D 1H-15N HSQC spectra of hTau40 (100 µM in 50 mM phosphate buffer; pH 6.8) in 
free form (green) and at increasing concentration of PcTS (50 µM, black and 100 µM, red). Spectra were 
measured at 278K on a BRUKER 800 MHz spectrometer equipped with a cryoprobe. At increasing ligand 
concentration, certain broadenings in NMR signals and deviations in chemical shifts (372Glu, 310Tyr, 
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1.10.4 Site-Directed Spin Labeling of Proteins 
The combination of site-directed spin labeling and NMR paramagnetic relaxation 
enhancement (PRE) measurements has proven to be a powerful approach for studying 
dynamic proteins. PRE experiments provide valuable structural constraints and 
quantitative interpretation of spin relaxations. Classical PRE studies often use site-directed 
mutagenesis to express the protein of interest with a single cysteine. Through established 
sulfur chemistry, a nitroxide spin label, typically S-(2,2,5,5-tetramethyl-2,5-dihydro-1H-
pyrrol-3-yl) methyl methanesulfonothioate (MTSL)334 or its derivatives, is tagged to 
sulfhydryl of the cysteine (Figure 19). The unpaired electron of the nitroxide induces 
paramagnetic dipolar transverse relaxation of nearby nuclear spins that are converted into 
effective distances between the paramagnetic center and the electron-proton interacting 
spin (usually the amide protons). This long-range interaction is detected up to 25 Å, a clear 
advantage over nuclear dipolar interactions that range up to 6 Å. Similar to what was 
previously discussed for nuclear proton (Part 1.10), an unpaired electron exhibits an 
electronic magnetic moment 𝝁𝒆 related to its angular momentum 𝑱: 
𝝁𝒆 = 𝒈. 𝝁𝑩.
𝑱
ℏ
 𝟏𝟎. 𝟗 
where 𝒈 is Landé factor and 𝝁𝑩 is Bohr magneton (equivalent to nuclear magneton 𝝁𝑵) 




 𝟏𝟎. 𝟏𝟎 
Where 𝒎𝒆 is the electron mass and 𝒆 is its charge. The gyromagnetic ratio of the unpaired 







 𝟏𝟎. 𝟏𝟏 
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The estimation of 𝝁𝒆 using the constant values of 𝝁𝑩, 𝒈, and ℏ, reveals that the electronic 
magnetic moment is more than 600 times larger than the nuclear magnetic moment.334 This 
enhances the longitudinal and transverse relaxation rates of the nuclear spins. More 
importantly, the high value of 𝜸𝒆 allows the measurement of long-range distance 
information. Both relaxation rates are indeed distance-dependent by a factor of 𝒓𝟔. 
However, internal correlation times, such as flexibility, cross relaxation and exchange 
processes contribute to the longitudinal relaxation rate 𝑹𝟏. The transverse relaxation rate 
𝑹𝟐, on the other hand, is more reliable.



























] 𝟏𝟎. 𝟏𝟐 
   
Taking into account the relation between peak intensity and relaxation rate,336 PREs of the 
amide cross peaks can be directly measured by recording two sets of 2D 1H-15N HSQC 















where 𝒕 is the INEPT delay in the HSQC pulse sequence. Practically, the paramagnetic 
spectrum contains broadened peaks corresponding to residues in the vicinity of the attached 
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MTSL spin label. After cleavage of the spin label by reducing agents, the NMR signals are 




Figure 19: Site-directed Spin Labeling for PRE Measurements.  
The reaction between the sulfhydryl group of the cysteine and the sulfonothioate group of the nitroxide spin 
label MTSL forms a disulfide bond. The unpaired electron of the nitroxide induces dipolar transverse 
relaxations of amide protons that report on distances up to 25 Å. The broadened peaks in the paramagnetic 
spectrum of hTau40/C291A/C322G/S352C (15 µM in 50 mM phosphate buffer; pH 6.8) correspond to 
residues in the vicinity of the MTSL spin label attached at position C352. The addition of 1 mM DTT cleaves 
the spin label and the NMR signals are recovered in the diamagnetic spectrum. Spectra were measured at 278 
K on a BRUKER 800 MHz spectrometer equipped with a cryoprobe. The backbone conformation of hTau40 
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1.10.5 Equilibrium Denaturation 
The process of amyloid fibrillar formation involves conformational changes of the 
soluble protein prior its polymerization into a common cross–β structure. Equilibrium 
denaturation has been intensely employed to reveal conformational properties associated 
with unfolding processes, high-order assemblies, or partner binding.337 Upon titration of a 
denaturant such as urea or guanidinium thiocyanate (GuSCN), the evolution of individual 
residues in the denaturated state can be monitored by 1H–15N HSQC experiments. The 
spectral intensities of protein residues at increasing denaturant concentrations can then be 
fitted to different profiles based on the following criteria: (1) percentage of the initial 
intensities in the absence of urea from the fully denaturated state, (2) concentration of urea 
at which denaturation is initiated, (3) midpoint of the transition, and (4) concentration of 
urea at which the resonance fulfils full denaturation. One interesting application was the 
equilibrium denaturation of PcTS-induced Tau oligomers (Chapter 2).60 This approach 
revealed the distinct behavior of the residues belonging to different domains (Figure 21). 
For instance, T71 was fully denaturated whereas A429 was more resistant up to 1M urea. 
On the other hand, NMR T17 and K143 were partially resistant but their NMR signals 
progressively increased in the presence of 0.75 M urea. It is worth noting that the broadened 
NMR signals of hTau40 in the oligomeric state (excess PcTS) were partially (8 M urea) or 
fully (3 M GuSCN) recovered (Figure 22). Nevertheless, several peaks remained resistant 
even at 8 M urea. Considering the fact that the ionic nature of GuSCN establishes a higher 
denaturation efficiency toward systems baring electrostatic interactions. Therefore, a 
careful comparative investigation of urea and GuSCN denaturation activities would reveal 
exquisite information.  




Figure 20: Urea Denaturation Profiles.  
Normalized intensities from 2D 1H-15N HSQC spectra of PcTS-hTau40 oligomers (1500 µM-100 µM in 50 
mM phosphate buffer; pH 6.8) are plotted at increasing urea concentrations. The data demonstrates distinct 
behavior of the residues between fully denaturated and partially resistant. Spectra were measured at 278K on 




Figure 21: Equilibrium Denaturation of PcTS-stabilized Oligomers.  
Selected regions of 2D 1H-15N HSQC spectra of hTau40 monomer, PcTS-hTau40 oligomers without and 
with the addition of 8 M urea or 3 M GuSCN. Adapted from 60. 
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1.10.6 Diffusion Ordered Spectroscopy 
The Brownian molecular motion describes the translational diffusion of a solute in 
solution. This phenomenon is represented by the coefficient of lateral diffusion 𝑫 that 
depends on sample temperature, solvent viscosity, molecular shape and molecular size. In 
practice, molecules in solution are non-spherical solvated systems that tumble with defined 
dynamics. Taking this into consideration, the apparent size of the hydrated particle is then 
characterized by its diffusional properties using the terminology of the hydrodynamic 
radius 𝑹𝑯.





 𝟏𝟎. 𝟏𝟑 
where 𝑲 is Boltzmann constant, 𝑻 is temperature, and 𝜼 is the viscosity of the solution. 
Unlike 𝑹𝑯, the well-defined parameter from crystallography, the radius of gyration 𝑹𝒈,  
does not include solvent effects (Figure 22) but only describes the equilibrium 
conformation of the total system where each atom is defined by its mass 𝒎𝒊 and 






 𝟏𝟎. 𝟏𝟒 
The lateral diffusion 𝑫 of small organic molecules and large biomolecules are 
conveniently measured using Pulsed Field Gradient (PFG) NMR techniques.339 Once a 
magnetic gradient pulse of magnitude 𝒈 is applied to the sample, the molecules are 
spatially encoded. After a diffusion time 𝚫, in which these particles freely move in 
solution, a second gradient pulse decodes their new coordinates. Affected by this diffusion, 
the intensity 𝑰 of detected NMR signal is then attenuated at a degree proportional to 𝚫 and 
𝒈:  
𝑰 = 𝑰𝟎 𝒆𝒙𝒑 [−𝑫. 𝜸
𝟐. 𝒈𝟐. 𝜹𝟐(𝚫 − 𝜹 𝟑⁄ )] 𝟏𝟎. 𝟏𝟓 
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where 𝜹 is the duration of the magnetic pulse. (Figure 22) The most dominant pulse 
sequences used in PFG-NMR diffusion measurements are derived from the stimulated echo 
(STE) pulse sequence that reduces artifacts in the diffusion spectra by employing bipolar 
pairs of gradient pulses and can readily incorporate a WATERGATE solvent 
suppression.340     
 
 
Figure 22: Diffusion Ordered Spectroscopy.  
Comparison of the hydrodynamic radius RH and radius of gyration Rg in a protein. Pseudo 2D 1H DOSY 
spectra of hTau40 measured by the PGSTE-WATERGATE sequence where g1, g2 and g3 are rectangular 
gradient pulses with different amplitudes, and the shaped rectangles represent “W5” binomial π pulses. The 
phase cycle for the pulse sequences is ϕ1 = x, −x; ϕ2 = y, y, −x, −x; ϕ3 = x, y, −x, −y; ϕ4 = x, y, −x, 
−y; ϕ5 = y; ϕr (receiver phase) = x, −x, −x, x. For ϕ2 = y (or ϕ5 = y), the phasing of the “W5” binomial pulse 
train is (x)5 − (−x)5; for ϕ2 = −x, the phasing is (y)5 − (−y)5. Spectra of hTau40 (40 µM in 50 mM phosphate 
buffer; pH 6.8, 10% D2O) were measured at 278 K on a BRUKER 600 MHz spectrometer equipped with a 
cryoprobe using the optimized acquisition parameters: 128 scans, 16K complex points, spectral width of 
8992 Hz, gradient strength from 2% to 95% of the maximum gradient strength (55.14 G/cm) in 30 steps with 
 = 180 ms and  = 6.5 ms. Pulse sequence adapted from 340.
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1.11 Complementary Biophysical Techniques 
 
1.11.1 Dynamic Light Scattering 
The fundamental concept of photon correlation spectroscopy, widely known as 
Dynamic light scattering (DLS) is explained by the semi-classical light scattering theory.341 
The electric field of a monochromatic light impinging on particles in solution prompts the 
electrons of these molecules to adapt an oscillating polarization. Depending on size 
distribution and particle shape, the polarized molecules scatter the incoming light and 
determine its frequency shifts (Doppler Shifts), polarization and intensity. DLS measures 
the Brownian translational diffusion. The measured diffusion coefficients are then fitted to 
an autocorrelation function adapted from statistical mechanics to reconstruct size 
distribution and describe the particle´s motion.    
 
1.11.2 Fourier Transform Infrared and Circular Dichroism  
Fourier Transform Infrared (FTIR) and Circular Dichroism (CD) are two 
vibrational spectroscopies that allow analysis of protein secondary structure. FTIR is a 
powerful technique that has been used to demonstrate characteristic differences in the 
molecular arrangement of β–sheets in amyloid fibrils and native proteins.342 In the spectral 
region, amide I and II vibrational bands are most sensitive to the secondary structural 
components of the protein backbone (Figure 23).343 The amide I band corresponds to C=O 
stretching vibrations of the peptide linkages, appears over the range 1700 to 1600 cm–1 and 
its characteristic frequency component correlates highly to each of the structural elements. 
In contrast, the amide II band derives mainly from in–plane NH bending and CN stretching 
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vibrations and displays much less sensitivity towards protein conformation. Depending on 
the nature of side chains and hydrogen bonding involved, the additional amide vibrational 
bands become very complex to interpret.  
CD spectroscopy is the most utilized technique for determination of the secondary 
structural composition and folding properties of peptides and proteins. Whether purified 
from biological tissues or recombinantly expressed, CD determines protein stability and 
conformational modifications. Each of the structural elements has a characteristic CD 
spectral signature reflecting the molar ellipticity (Figure 23).344 The spectrum of a typical 
α-helical protein displays two negative bands (222 and 208 nm) and one positive (193 nm). 
A protein with β- pleated sheets shows two bands, one negative (218 nm) and one positive 
(195 nm). On the other hand, a disordered protein exhibits a low ellipticity at 210 nm and 
a negative band at 195 nm. A triple helix protein has a typical extended helical 
conformation. The low overall ellipticity reflects a protein´s denaturated state.  




Figure 23: FTIR and CD Vibrational Spectroscopies.  
(a) The two vibrational bands in FTIR spectra (amide I from C=O stretching vibrations and amide II from 
in–plane NH bending and CN stretching vibrations) are most sensitive to the secondary structural components 
of the protein backbone. (b) CD spectroscopy determines the secondary structural composition with spectral 
signatures reflecting the molar ellipticities of α-helical, β- pleated sheets, disordered and extended helical 
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1.11.3 Small Angle X-ray Scattering 
Small angle X-ray scattering (SAXS) has emerged in the field of structural biology 
as a complementary method to characterize the overall size and shape of biomolecules in 
solution. The basic principle of SAXS involves illuminating the solution with a 
monochromatic x-ray source and measurement of the intensity at different scattering 
angles. The analysis of the angular-dependent scattered intensities will then reveal the 
structural information of the particle. Practically, from the so-called Guinier´s plot the 
average radius of gyration of the biomolecule is calculated. The Kratky plot reports whether 
the molecules are in a disordered state or a globular protein.345 Moreover, Fourier 
transformation of the scattering profile provides information about the distance distribution 
function p(r) associated to the maximum distance Dmax within the particle and offers a 
rough estimation of the particle shape. Recent improvements enabled the technique to study 
not only monodispersed samples but also oligomeric mixtures.346,347 
In case of folded proteins, the three dimensional structure can be refined by 
incorporating the scattering profile in a computational study. The overall shape is then 
calculated using either the ab initio method348 or the rigid body modeling.349 On the other 
hand, SAXS studies of IDP proteins combine other techniques such as the Ensemble 
optimization method (EOM)350 to generate a pool of random conformations within a 
defined landscape. This involves sampling a conformational space to select sub-ensembles 
that best fit to the experimental results. IDPs are characterized by large Rg and Dmax values 









Figure 24: Small Angle X-ray Scattering and Geometric Structures.  
Scattering intensities and distance distribution functions p(r) calculated for typical geometric shapes are 
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Anti-aggregation drugs play an important role in therapeutic approaches for 
Alzheimer´s disease. Although, a large number of small molecules that inhibit the 
aggregation of the Tau protein have been identified, little is known about their mode of 
action. Here we reveal the mechanism and the nature of Tau species that are generated by 
interaction of Tau with the organic compound Phthalocyanine tetrasulfonate (PcTS). We 
demonstrate that PcTS interferes with Tau filament formation by targeting the protein into 
soluble oligomers. A combination of NMR spectroscopy, electron paramagnetic resonance 
and small-angle X-ray scattering reveals that the soluble Tau oligomers contain a dynamic, 
non-cooperatively stabilized core with a diameter of 30 to 40 nm that is distinct from the 
core of Tau filaments. Our results suggest that specific modulation of the conformation of 




Neurodegenerative diseases share related pathological processes characterized by 
the generation of proteinaceous deposits exhibiting excessive -sheet structures.1 Growing 
evidence has implicated the aggregates in the onset, progression and clinical symptoms of 
these disorders.2 The most widespread dementia syndrome is Alzheimer´s Disease (AD), 
which is characterized by the progressive accumulation of extracellular senile plaques 
consisting of –amyloid polypeptide and intracellular neurofibrillary tangles consisting of 
Tau protein.3,4  
Tau protein belongs to the class of "natively unfolded" or intrinsically disordered 
proteins.5,6 It is abundant in neuronal axons and interacts with tubulin to stabilize and 
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promote microtubule assembly for the transport of vesicles and organelles.7 In solution, 
Tau is highly dynamic with an intricate domain structure.8 During the course of AD 
progression, Tau becomes excessively phosphorylated, loses its function and aggregates 
into neurofibrillary tangles.4 The accumulation of Tau aggregates is a multistep process 
that involves the formation of various transient species. Increasing evidence suggests that 
small oligomeric species contribute to Tau-mediated neurotoxicity.9 
So far only symptomatic treatment is available for AD and other protein misfolding 
diseases and new therapeutic concepts range from Tau vaccinations 10 and 
antiphosphorylation strategies11 to microtubule–stabilizing 12 and anti–aggregation 
drugs.13-22 One important class of aggregation inhibitors are porphyrins such as 
Phthalocyanine tetrasulfonate (PcTS).16,22,23 PcTS has been widely investigated for its in 
vivo prophylactic and therapeutic effects in scrapie disease and inhibits the formation of 
protease–resistant prion protein aggregates.23,24 In addition, PcTS can interfere with Tau 
aggregation and is able to disassemble Tau filaments.16 Taking advantage of its chelating 
and molecular self–assembly properties, PcTS was also employed to remove the redox–
active metals that induce toxic A40 oligomeric species and to convert the aggregates into 
an amyloid fibrillar meshwork.25  
Despite the wealth of potential inhibitors of Tau aggregation little is known about 
the mechanisms of inhibition and the nature of the generated Tau species. Here we study 
the interaction of PcTS with 441-residue human Tau protein (Figure S1). Using a 
combination of NMR spectroscopy, electron paramagnetic resonance (EPR) and small-
angle X-ray scattering (SAXS) we reveal detailed insights into the mechanisms of Tau 
aggregation inhibition and the structure and dynamics of soluble Tau oligomers.  
 




Proteins and Reagents. Unlabeled and labeled wild-type and mutated human Tau 
protein isoforms and constructs (htau40, htau24, htau23, K18) were expressed and purified 
as described previously.26 Briefly, proteins were expressed in the vector pNG2 (a derivative 
of pET-3a; Merck) in Escherichia coli strain BL21 (DE3). The expressed proteins were 
purified from bacterial extracts by making use of the heat stability of the protein and by 
FPLC SP-Sepharose chromatography (GE Healthcare). To label uniformly the Tau 
proteins with 15N and 13C isotopes, E.coli bacteria were grown in minimal medium 
containing 1g/ liter of 15NH4Cl and 4g/ liter of D-Glucose (
13C-6), or 1g/ liter of 15NH4Cl 
alone. The cell pellets were resuspended in extraction buffer (50 mM MES, 500 mM NaCl, 
1 mM MgCl2, 1 mM EGTA, 5 mM DTT, pH 6.8) complemented with protease inhibitor 
mix, disrupted with a French press and boiled for 20 min. The soluble extract was isolated 
by centrifugation, and the supernatant was dialyzed against buffer A (20 mM MES, 50 mM 
NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM DTT, 0,1 mM PMSF, pH 6.8) and loaded on an 
FPLC SP –Sepharose column. The proteins were eluted by a gel filtration column by a 
linear gradient of buffer B (20 mM MES, 1 M NaCl, 1 mM EGTA, 1 mM MgCl2, 2 mM 
DTT, 0.1 mM PMSF, pH 6.8). The Tau isoforms were separated from breakdown products 
by a gel filtration column Superdex G-200 (GE Healthcare).  
PcTS was purchased from MP Biomedicals (MP Biomedicals S.A. Heidelberg, 
Germany). ThS, urea and GuSCN were purschased from Sigma (Sigma–Aldrich Chemie 
GmbH, Schnelldorf, Germany). Spin-labeling of Tau was performed as described 
previously.8  
Aggregation assay. 50 µM monomeric htau40 was incubated with 12.5 µM 
heparin in 20 mM BES–buffer, pH 7.4 and 1mM DTT for 10 minutes at 950C to destroy 
2. Inhibition of Tau Filament Formation by Conformational Modulation 
 
 139 
the intra-molecular disulfide bridges of compact monomers. After cooling down the 
reaction mixture to 37°C the sample was replenished with 1 mM DTT again and a protease 
inhibitor-mix (1 mM PMSF, 1 mM EDTA, 1 mM EGTA, 1µg/mL leupeptin, 1 µg/mL 
aprotinin, and 1 µg/ml pepstatin) was added. The resulting solution was separated into 
different vials. PcTS was added to the vials in concentrations ranging from 200 pM to 200 
µM and incubated for 10 days at 37 0C. 1 mM DTT was added daily to avoid its depletion. 
Before each fluorescence measurement the samples were equilibrated 30 minutes at room 
temperature and diluted 6-fold with BES buffer followed by the addition of 20 µM ThS. 
Fluorescence was measured on a Safire (TECAN) fluorimeter with excitation and emission 
wavelengths of 440 nm and 521 nm, respectively. In addition, a 200 µM PcTS solution was 
prepared in the same buffer conditions to examine the absorption properties in the range of 
250 to 700 nm and to exclude possible interference with ThS fluorescence.  
SDS-page analysis. For SDS-page analysis 50 M monomeric htau40 samples 
containing 1 mM DTT were prepared in 50 mM PBS buffer, pH 7.4, and heated for 20 
minutes at 95 0C. After cooling down in a water bath, the samples were incubated with 750 
M PcTS for 1 or 24 hours at 4 or 37 0C. Reference (Ferritin 440 kDa and protein marker) 
and control samples (htau40 in PBS buffers) were prepared and all samples were run on 10 
% SDS–PAGE gels. Two additional htau40 samples were prepared in PBS and incubated 
for 3 days at 37 0C in the presence or absence of PcTS before running them on a 10 % 
SDS–PAGE gel. 
Spin Labeling of Tau. We constructed and labeled with (1-oxy-2,2,5,5-
tetramethyl-D-pyrroline-3-methyl)–methanethiosulfonate (MTSL) the double cysteines of 
the wild type (C291 and C322) as well as the mutants containing a single cysteine (C291A 
and C291A/C322G at different sites A15C, A72C, A125C, A178C, A239C, S352C, 
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A384C, and S416C) using the following protocol: DTT was first removed from the buffer 
prior labeling using size exclusion chromatography (PD–10 columns, GE Healthcare, 
Freiburg, Germany); then the monomeric protein was equilibrated in phosphate buffer 
saline (PBS) buffer pH 7.4. MTSL (5–fold molar excess in ethyl acetate) was allowed to 
react with the free sulfhydryl group(s) of the cysteine(s) at 21 0C for 2.5 hours. The 
unreacted spin label was removed by PD–10 columns equilibrated in 50 mM Na phosphate 
buffer pH 6.8 and the resulting spin–labeled protein was concentrated by using Amicon 
Ultra–15 (molecular weight cutoff 3000, Millipore, Cork, Ireland).  
NMR spectroscopy. NMR experiments were recorded at 5 0C on Bruker Avance 
700 MHz or 800 MHz spectrometers equipped with cryogenic probes. NMR samples 
contained 15N/13C double labeled or 15N single labeled protein in 50 mM phosphate buffer 
pH 6.8. 1 mM DTT and 10 % (v/v) D2O. Different concentrations of PcTS were prepared 
in the same phosphate buffer and the dilution factors were corrected whenever needed. For 
each measurement (except when time dependence was investigated) PcTS was freshly 
added to a sample of monomeric Tau protein and the measurement was started within less 
than 15 minutes. In case of PcTS titrations, increasing concentrations of PcTS were 
subsequently added to the same Tau sample with a delay of less than 10 minutes between 
individual HSQC measurements. In order to probe the time dependence on NMR signal 
intensities the samples were kept at room temperature for the specified time periods (3 days 
and 7 days, Figure S3c; 2 weeks, Figure S3d).  
Interaction of PcTS with 100 M Tau was investigated using two-dimensional 1H–
15N HSQC spectra recorded with 600 complex points and 32 scans per increment with 
spectral widths of 8389 Hz and 1844 Hz in the 1H and 15N dimensions, respectively. The 
total measurement time for each 1H–15N HSQC was six hours. In case of the control 
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titration with 10 M htau40 (Figure S6), the recording time for a single 1H–15N HSQC was 
increased to 20 hours. NMR intensity ratio plots were reported with a 3-residues averaging 
window. Two dimensional 1H-13C HSQC spectra were acquired using 1024 complex points 
and 12 scans per increment with spectral widths of 7003 Hz and 12330 Hz (aliphatic 
region) or 5282 Hz (aromatic region) in the 1H and 13C dimensions, respectively, resulting 
in a total measurement time of five hours. Spectra were processed with NMRPipe27 and 
analyzed using the software Sparky3.  
For equilibrium denaturation experiments a solution of PcTS and 15N-labeled 
htau40 (200 M) in a ratio of 15 to 1 was prepared in 50 mM phosphate buffer pH 6.8, 
containing 1.8 mM DTT and 10 % (v/v) D2O. A 2D 
1H–15N HSQC spectrum was measured 
for three hours. Then the denaturant concentration was increased and at each denaturant 
concentration a 2D 1H–15N HSQC spectrum (measurement time: three hours) was 
recorded. Denaturants solutions were prepared immediately before use and concentrations 
ranged from 0 to 8 M for urea and 0 to 3 M for GuSCN. NMR signal intensities were fitted 
to sigmoid, Hill, or exponential curve functions using Igor Pro 6.22A. 
PRE broadening was investigated using 15N-labeled htau40 at a concentration of 15 
μM. PRE effects were measured from the peak intensity ratios between two 2D 1H–15N 
HSQC NMR spectra acquired in the presence of the nitroxide radical and after addition of 
4 mM DTT (heated to 45 °C for 10 min before measurement) to the same sample. Addition 
of DTT will cleave the MTSL tag from the cysteine residue, such that the spin label is no 
longer attached to the protein and the protein is in the diamagnetic state. The measurement 
time for each 2D 1H–15N HSQC NMR was 17 hours. 
NMR diffusion experiments were recorded on Bruker Avance 600 MHz 
spectrometer equipped with cryogenic probe for htau40 protein (40 M with or without 
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15–folded excess PcTS) using a stimulated–echo based pulsed gradient spin–echo 
sequence incorporating the WATERGATE solvent suppression.28 The diffusion time and 
the length of the gradient pulses were optimized for each sample. The gradient strength 
was linearly increased from 2 % to 95 % of the maximum gradient strength in 30 steps, 
where the 100 % gradient strength corresponds to 55.14 G/cm. Each 1H spectrum was 
recorded with 128 scans and 16K complex over a spectral width of 8992 Hz, resulting in a 
total experimental time of two hours for a complete NMR diffusion experiment. Several 
peaks in the aliphatic region of htau40 were selected and the intensities of their diffusion–
based spin–echo attenuation were extracted to determine an average diffusion coefficient. 
Note that the NMR-based characterization of the Tau oligomers occurs via their flexible 
N- and C-terminal tails (Figure 2) From the apparent diffusion coefficients of htau40 and 
a range of protein standards (cytochrome C 12.4KDa, 17.8 Å; lysozyme 14.3 KDa, 20.5 Å; 
myoglobin 18 KDa, 21.2 Å; and ovalbumin 45 KDa, 30.5 Å) the Stokes radii were 
calculated.29 
EPR spectroscopy.  Selected single–labeled htau40 (20 M in phosphate buffer 
pH 6.8) samples were freshly prepared in absence or presence of 15-fold excess PcTS and 
transferred in 1–mm inner diameter capillary prior each measurement. Continuous wave–
EPR spectra were recorded at room temperature at X–band on a Bruker Elexys 500 
spectrometer equipped with an ER 4122SHQE resonator. The incident power used was at 
2.0 mW over a field range of 100 G and 1024 spectral points, and a modulation amplitude 
of 0.8 G. The line broadening of the central peak of each spin-labeled htau40 was quantified 
using the width of the peak-to-peak separation. Integration of the EPR spectra in the 
absence and presence of PcTS resulted in similar double integral values, indicating that the 
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same amount of Tau protein contributes to the visible EPR signal in the absence and 
presence of PcTS. 
Fourier transform–infrared spectroscopy. FTIR spectra of 50 M K18 and 100 
M htau40 (with and without 1.5 mM PcTS) in 50 mM phosphate buffer were collected at 
room temperature using the Bruker Confocheck FT–IR spectrometer. The delay time 
between preparation of the Tau-PcTS sample and start of the FT-IR measurements was 
about 10 minutes. The FT-IR setup consists of the AquaSpec transmission cell designed 
for measurements of aqueous solutions and equipped with a cryogenic MCT detector 
cooled with liquid nitrogen. Reported spectra represent averages of 5 scans recorded 
between 3000 cm–1 and 1000 cm–1 where each scan was acquired with a spectral resolution 
of 4 cm–1 and measurement time of 100 seconds. The same measurement was repeated 
three times using freshly prepared samples to confirm the reproducibility of the results. 
Dynamic Light Scattering.  DLS measurements were performed at 5 0C using a 
DynaPro Titan temperature controlled microsampler (Wyatt Technologies Corporation). 
Samples (40 µM of htau40 in 50 mM phosphate buffer, pH 6.8 and 1 mM DTT inserted 
in 50 µl flow cells in absence or presence of 15-fold excess of PcTS) were illuminated by 
a 25 mW, 780 nm solid–state laser, and the intensity of 900 angle scattered light was 
measured at 4 μs intervals by a solid–state avalanche photodiode. Measurements were 
performed using freshly prepared samples, each experiment lasted 20 minutes and was 
repeated 6 times to confirm the reproducibility of the results (i.e. total of 2 hours). The 
average values with their standard deviations were analyzed using the software 
package Dynamics 6.7.7.9.  
Circular Dichroism.  CD spectra of 30 M K18 and 10 M htau40 in 50 mM 
phosphate buffer were acquired at room temperature using a Chirascan CD spectrometer 
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(Applied Photophysics Limited) in the absence or presence of 15-fold excess of PcTS. 
Spectra were acquired with 350 l in a cuvette with 1–mm path cell over the range covering 
190 to 250 nm using a 1 nm band width and a scanning speed of 20 nm/min. Five scans 
(measurement time for a single scan was 10 minutes) were averaged for each dataset and 
the subsequent spectra of the buffer constituents were substracted from the protein samples. 
The same measurement was repeated at three times using freshly prepared samples to 
confirm the reproducibility of the results. Data are expressed in terms of the mean residual 
ellipticity (θ) in deg cm2 dmol–1. 
Electron microscopy. The sample with the highest PcTS concentration 
(PcTS:htau40, 200 M to 50 M) from the aggregation assays was diluted 1:7.5 with 20 
mM BES buffer, pH 7.4 and 5 l were placed on copper 600mesh grids covered with carbon–
film. The sample was stained with 2 % uranyl acetate after immunostaining with gold–
labeled anti–tau antibody K9JA–gold10nm and examined on a CM12 tranmission electron 
microscope.  
Fluorescence–activated cell sorting. The assay was performed with inducible N2a 
cells expressing the four–repeat–domain construct with a single deletion at position 280 
(K18K280). Three wells contained 1 ml cell suspension and 0.0005 % Thioflavin S. 
Negative controls were not treated further. Positive controls were treated with 1 g/ml 
doxycyclin. Samples were treated by addition of 50 M PcTS and the same amount of 
doxycyclin. After incubation for 4 days at 37 0C, the floating and adherent cells were 
combined, pelleted for 5 minutes (at 295 g) and washed once with PBS buffer. Cells were 
counted in a BD FACS Canto TMII flow cytometry system. The cell distribution was 
determined by accessing the cell size from the forward scatter FSC and the cell granularity 
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from the side scatter SSC. Cells with ThS–positive aggregates were measured by the 
fluorescent signal intensity in the FTIC channel (λexcitation = 495nm, λemission = 519nm). 
Small Angle X-ray Scattering Data. Data were collected at X33 at the European 
Molecular Biology Laboratory on DORIS III (DESY) at a wavelength of 1.5 Å at 25 °C 
using a Pilatus 1M photon counting detector. Samples were freshly prepared immediately 
prior to the SAXS measurements and contained Tau concentrations from 2.5 mg/ml to 10 
mg/ml and 1.8 mM DTT in 50 mM phosphate buffer pH 6.8. At 15-fold excess of PcTS, 
data were measured before and after filtering using centrifugal filter with 0.2 µm cutoff 
(Millipore, Carrigtwohill, Ireland). Each sample was exposed to 8 frames of 15 seconds 
each, with consistency checks between frames. Data analysis was performed in ATSAS 
2.3 30. The average molecular masses of solutes were estimated from the intensity 
extrapolated to zero angle. The maximum diameter was estimated by indirect fourier 
transform using ATSAS 2.3 30. The amount of monomeric htau40 at intermediate PcTS 
concentrations was estimated using NMR spectroscopy (as described in Supporting 
Information). Estimation of the average number of Tau molecules in soluble oligomers at 
intermediate PcTS:Tau ratios using a combination of NMR and SAXS. At 10-fold and 15-
fold excess of PcTS residues G120-S400 were broadened beyond detection, demonstrating 
that Tau has been completely converted into soluble oligomers. Thus, the SAXS signal for 
these samples can exclusively be attributed to Tau oligomers. In contrast, at intermediate 
PcTS concentrations both monomeric and oligomeric Tau species were present (according 
to NMR and SDS-PAGE) complicating the SAXS analysis. Nevertheless to allow a 
detailed analysis of the oligomeric Tau species at these PcTS concentrations, we took 
advantage of NMR spectroscopy. Assuming that a similar region of Tau is part of the 
oligomers formed at high and intermediate PcTS concentrations, an assumption that is 
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supported by a comparison of the NMR broadening profiles at 5-fold and 15-fold excess 
of PcTS (Figure 2a), the NMR signal intensity ratios of the residues in this region were 
averaged and used as estimate for the amount of residual monomeric Tau. The average 
oligomeric numbernof the remaining fraction was then computed from the nominal 
concentration of Tau, the percentage r of remaining monomer in solution (as estimated by 
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where 𝑒𝑟 is the error for the monomer ratio (two times the standard deviation of 
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Proteins PcTS Inhibits Tau Filament Formation. The aggregation of the Tau 
protein in vitro is promoted by polyanions such as heparin.31 Using this approach, we tested 
the ability of PcTS (Figure 1a) to suppress fibrillization of htau40. Porphyrins do not 
interfere with the binding of Tau to heparin excluding a competitive effect.16 PcTS 
decreased the amount of fibrillized Tau as quantified by thioflavinS (ThS) in a dose–
dependent manner (Figure 1b). From the assay, we determined an IC50 value of 1.25 M. 
For the 412-residue isoform htau34 an IC50 value of 67 M was previously determined 
suggesting isoform-specific differences.16 Using electron microscopy we then investigated 
the morphology of htau40 that was incubated for 10 days at 37 0C in the absence and 
presence of a 4–fold molar excess of PcTS. In the absence of PcTS, we observed formation 
of Tau filaments with the characteristic twisted appearance (Figure 1c). In contrast, 
globular particles and other amorphous aggregates were detected in the presence of PcTS 
(Figure 1d and Figure S2). Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) revealed predominantly two high molecular weight Tau species with 
approximate molecular weights of 300 and 450 kDa (Figure 1e and Figure S3). In addition, 
time-dependent changes in the distribution of high molecular weight species showed that 
the 450 kDa species becomes predominant with increasing incubation time (Figure S3a). 
 





Figure 1: PcTS inhibits Tau filament formation by induction of oligomers.  
(a) Chemical structure of PcTS. (b) ThS fluorescence after incubation of 50 M htau40 wild-type with 12.5 
M heparin for 10 min at 95 0C and subsequent incubation for 10 days at 37 0C in the presence of increasing 
concentrations (200 pM–200 M) of PcTS. Electron micrographs of (c) heparin–induced htau40 aggregates 
showing PHF–like structures (scale bar, 100 nm) and (d) the sample treated with 4–fold molar excess of 
PcTS (scale bar, 40 nm). The black dots represent the gold–labeled antibody K9JA–gold10nm used for 
immunostaining. (e) SDS-PAGE analysis of PcTS–stimulated htau40 oligomers.  
 
 
The Interaction with PcTS is Mediated by Aromatic Rings. To obtain insight 
into the mechanism of PcTS-induced oligomerization of Tau, we probed the PcTS:Tau 
interaction using NMR spectroscopy. Upon addition of PcTS, the intensities of several 
peaks in 2D 1H-15N heteronuclear single quantum coherence (HSQC) spectra of htau40 
decreased in a concentration–dependent manner (Figure 2a). The broadening is caused by 
an exchange of Tau molecules between the free and the PcTS-bound state. At equimolar 
concentration of PcTS, the aromatic residues Y310, F346 and F378, which are located in 
the repeats R3-R4 and the C-terminal region, were most strongly affected (Figures 2a, 2b). 
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In addition, Y197 in the proline-rich region P2 and Y394 bound to PcTS. Only weak 
changes in NMR signal position and intensity were observed for the other three aromatic 
residues of htau40 (F8, Y18, Y29) at the Tau N-terminus. The importance of aromatic 
residues was further supported by interaction studies performed for the Tau mutant 
htau40/Y310N: 306VQIVNK311 showed reduced chemical shift and intensity changes upon 
addition of PcTS (Figure 2c). Instead, stronger changes were observed for Y197, F346 and 
F378 indicative of an enhanced interaction. At 5:1 and 15:1 PcTS:htau40/Y310N 
additional binding to the aromatic residues at the N-terminus of Tau occurred. We conclude 
that π–π attractive forces between the PcTS aromatic ring and the aromatic residues of Tau 













Figure 2: PcTS binds to aromatic rings of Tau.  
(a) NMR signal broadening of 100 M htau40 at increasing PcTS concentrations (PcTS:Tau 1:2 blue, 1:1 
yellow, 5:1 green, 15:1 red) as a function of residue number. Aromatic residues of htau40 are marked. (b) 1D 
1H NMR spectra of htau40 in the absence (black) and presence of the corresponding ratios of PcTS. (c) NMR 
signal broadening of the htau40/Y310N variant at increasing PcTS concentrations. (d) Decrease of the 
concentration of monomeric Tau at increasing PcTS concentrations. The residual monomer concentration 
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PcTS Stimulates Assembly of Soluble Tau Oligomers. With increasing PcTS 
concentrations we observed an overall decrease in NMR signal intensity for G120-S400 
(Figures 2a, 2d). At 15-fold excess of PcTS, all signals in the central part of Tau were 
broadened beyond detection indicating that residues in this region are too immobile to be 
detected by liquid-state NMR. This is in line with the PcTS-driven assembly of Tau 
oligomers as evidenced by SDS-PAGE and electron microscopy (Figures 1d, 1e), and is 
supported by the disappearance of signals in 1H-13C HSQC spectra of htau24 and K18 
(Figures S4, S5). Importantly, highly similar NMR broadening profiles were observed at a 
10-fold lower concentration of PcTS but keeping the same PcTS:Tau molar ratio (Figure 
S6). As the self-stacking ability of PcTS is concentration dependent,32 the data show that 
the signal broadening is not due to monomeric Tau binding to large PcTS aggregates, but 
because of stimulation of Tau oligomer assembly by PcTS. Moreover, the NMR data reveal 
that not all regions in Tau are immobilized in the Tau oligomers, as residues M1-A119 and 
G401-L441 remained visible (Figure 2a). 





Figure 3: Secondary structure analysis of Tau oligomers.  
(a) FT–IR spectra of htau40 in the absence (black) and presence of a 15-fold excess of PcTS (red). (b) Far 
UV–CD spectra of htau40 in the absence (black) and presence of a 15 – fold excess of PcTS (red).   
Remodeling of Tau Oligomers. Biochemical analysis had revealed an increase in 
the concentration of SDS-resistant Tau oligomers with increasing incubation time and 
temperature (Figure S3). At the same time, NMR spectroscopy showed that PcTS rapidly 
converts Tau from the monomeric state to oligomers – the total time from preparation of 
the Tau-PcTS sample to completion of the 2D 1H-15N HSQC was 6 hours (Figure 2a). Thus, 
PcTS rapidly stimulates formation of oligomers that are mostly not resistant to SDS, but 
become more stable during incubation. In addition, time-dependent changes in the 
distribution of high molecular weight species – the ~450 kDa species becomes more 
pronounced – observed in SDS-PAGE point to a change in the structural properties of the 
PcTS-stimulated oligomers of Tau with increasing incubation time (Figure S3a). 
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Consistent with the finding, we observed time-dependent changes in the NMR spectra of 
Tau in the presence of 15-fold excess of PcTS. Two weeks after addition of PcTS, NMR 
signal intensities in the C-terminal tail of htau40 were decreased by an additional ~50 % 
(Figure S3d). The reduced signal intensities can be caused by a lower mobility of the tail, 
a stronger interaction with the core of the oligomer (see below) or the formation of an 
increased amount of oligomers, in which the C-terminal tail is rigidified and therefore not 
visible to NMR spectroscopy in solution. 
Tau Oligomers have a Dynamic Core. Paired helical filaments (PHFs) represent 
fibrous assemblies of Tau with an amyloid-like core of rigid cross-β structure.33 The 
formation of cross-β structure during in vitro heparin-induced aggregation of Tau was 
observed by ThS in the absence of PcTS (Figure 1b). In the presence of PcTS, cross-β 
structure was not formed, judging by the absence of the ThS signal (Figure 1b).  
To obtain further insight into the secondary structure of PcTS oligomers, we 
performed CD spectroscopy and fourier transform infrared (FTIR) spectroscopy. The FTIR 
amide I (1655 cm–1) and II (1541 cm–1) bands are the vibrational bands that are most 
sensitive to protein secondary structure. However, no changes in their frequencies, and 
only minor changes in the other bands, were observed in the Tau oligomers when compared 
to monomeric Tau (Figure 3a). This is also supported by CD spectroscopy of htau40 
(Figure 3b) and the repeat domain construct K18 (Figure S7). We conclude that Tau 
oligomers stimulated by PcTS do not contain detectable elements of α-helix or β-structure. 
To obtain information about the dynamics within Tau oligomers, we applied EPR 
spectroscopy to htau40 variants tagged with the paramagnetic nitroxide radical MTSL. In 
agreement with previous reports,34 monomeric Tau gave rise to EPR spectra with three 
sharp lines characteristic for a highly flexible protein backbone (Figure 4a). The EPR 
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spectra of the PcTS-induced Tau oligomer were more similar to that of monomeric Tau 
with three clearly distinguishable lines. Indeed for positions 15, 72 and 416 no difference 
with respect to monomeric Tau was observed pointing to comparable mobility. However, 
for spin-label positions 125, 178, 239, 322, 352 and 384 EPR lines were broadened (Figures 
4a, 4b), in particular for the sites 352 and 384 that are close to the aromatic residues F346, 
F378 and Y394 (Figures 2a, 4b). The line-broadening is in line with the burial of these sites 
in the Tau oligomer. At the same time, the EPR spectra of the Tau oligomers are very 
different from those of PHFs, which had strongly reduced amplitude and lost the outer two 
hyperfine lines.34 The EPR data thus demonstrate that the core of PcTS-stimulated Tau 
oligomers remains dynamic. 





Figure 4: (a) EPR spectra of MTSL–cysteine tagged htau40 at several positions in the absence (black, 
monomeric Tau) and presence of PcTS (red, oligomeric Tau). (b) Comparison of the EPR linewidth of the 
central line in the absence (black, monomeric Tau) and presence of PcTS (red, oligomeric Tau).   
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Global Folding within Tau Oligomers. Next, we probed the long-range structure 
in the Tau oligomers using paramagnetic relaxation enhancement (PRE) of NMR signals35 
(Figure 5). In addition, to the single cysteine mutants employed for EPR, we labeled the 
two native cysteines, C291 and C322, with MTSL. The paramagnetic nitroxide label results 
in broadening of amide resonances, which can be quantified through the NMR intensity 
ratios in the paramagnetic and diamagnetic states. The PRE effect scales as the inverse 
sixth power of the distance between the unpaired electron of the nitroxide unit and the 
NMR spin, providing a powerful probe of distances. Although residues in the microtubule-
binding domain were too immobile to be detected, i.e. are hidden in the oligomer, the 
flexible tails provided sensitive probes. When spin labels were attached to the native 
cysteines in wild-type Tau, an approximately 10 % enhancement of the NMR broadening 
was observed at the N-terminus when compared to monomeric Tau (Figure 5d). A more 
severe broadening was induced at the C-terminus with PRE intensity ratios of ~0.6 (Figure 
5d). The strong broadening at the C-terminus demonstrates a transient interaction of the 
flexible tails with the NMR-invisible core of the Tau oligomers. In contrast, little 
paramagnetic broadening was induced with a spin-label at position 239 (Figure 5c). When 
compared to the network of transient long-range interactions in monomeric (Figure 5 and 
8) and PHF Tau36, the interaction of the N-terminal tail with the microtubule-binding 
domain is weakened, while that with the C-terminus is tightened in PcTS-stimulated Tau 
oligomers. 





Figure 5: Changes in transient long-range interactions in Tau upon incorporation into oligomers. 
 Paramagnetic relaxation enhancement of backbone amide protons of MTSL spin–labeled htau40 at selected 
positions (a–g) in the absence (black) and presence of a 15-fold excess of PcTS (red). The plots show the 
intensity ratios between 2D 1H–15N HSQC spectra with the nitroxide in its paramagnetic and diamagnetic 
state. 
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PcTS-stimulated Tau Oligomers Have a Compact Core. At large excess of 
PcTS, Tau is completely converted into soluble oligomers (Figure 2d). Pulsed-field 
gradient NMR and dynamic light scattering showed an effective hydrodynamic radius of 
~68 Å (Figure 6). We then performed a SAXS analysis of Tau at different protein and PcTS 
concentrations (Figure 7 and Figure S8). The observed SAXS profile for monomeric Tau 
is in line with its intrinsically disordered nature.37 However, with increasing PcTS 
concentrations the Kratky plot drastically changed (Figure 7b). At 15-fold excess of PcTS 
the Kratky plot revealed a sharp peak that is characteristic for the presence of highly 
compact Tau species with an average radius of gyration of 98 ± 15 Å. The average radius 
of gyration exceeds the hydrodynamic radius by a factor of ~1.4 in line with the flexible 
disordered tails of the Tau oligomers detected by NMR spectroscopy (Figure 2a). In 
addition to the changes in the Kratky plot, the scattering intensities strongly increased at 
higher PcTS-Tau ratios. Noteworthy PcTS alone scattered much weaker and therefore does 
not contribute substantially (Figure S8a). The scattering intensities – corrected for the 
concentration of monomeric protein as determined by NMR spectroscopy (see materials 
and methods) – showed that already at an equimolar concentration oligomeric species 
containing approximately 5-11 Tau molecules were formed, and only slightly increased to 
7-14 at 5-fold excess of PcTS (Figure 7c and Figures S7b, c). In contrast, at the higher 
PcTS:Tau ratios of 10:1 and 15:1 the oligomeric species shifted to an average of ~24 Tau 
molecules. The maximum diameter, Dmax, of the two oligomeric species was calculated 
as 393 ± 10 Å and 348 ± 27 Å, respectively (Figure 7d). The slightly smaller Dmax value 
at higher PcTS is supported by the sharpening of the peak in the Kratky plot (Figure 7b). 
Consistent with these observations, SDS-page analysis revealed two predominant PcTS-
induced Tau species with approximate molecular weights of 300 and 450 kDa (Figure 1e). 





Figure 6: Hydrodynamic radius of monomeric and PcTS–stimulated oligomeric htau40 determined by 





Figure 7: Low-resolution SAXS models of Tau oligomers.  
(a) Experimental SAXS spectra and (b) Kratky plots of 10 mg/ml hau40 (black) alone and in the presence of 
increasing concentrations of PcTS (color coded panel). Note that the PcTS signal does not contribute 
significantly to the total scattering intensity (Figure S8). (c) Estimation of the number of Tau molecules in 
PcTS-stimulated oligomers at different PcTS:htau40 ratios (with htau40 at 2.5 mg/ml). The dark red bar 
shows the data for the 15:1 sample after filtering. Error bars were estimated from the standard error of I0 
variations between different concentrations of htau40 but at the same ratio of PcTS and accounting for errors 
in the NMR-based estimation of the concentration of monomeric htau40 (see Supporting Information). (d) 
The P(r) of Tau oligomers at 5-fold (green) and 15-fold (red) excess of PcTS. 
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Tau Oligomers are Stabilized Non-cooperatively. To obtain a detailed 
description of the conformational stability of different regions in the Tau oligomers, we 
performed equilibrium denaturation experiments.38 A comparison of NMR spectra 
obtained in 8 M urea and 3 M GuSCN revealed a distinct sensitivity of the Tau oligomers 
to the two denaturants (Figures 8a-c and Figure S9). All observable residues were classified 
into one of four groups depending on their urea denaturation profile (Figures 8d-e). The 
denaturation profiles differed between the groups, but within a group residues displayed 
cooperative behaviour (Figure 8e). Surprisingly, residues G120-T205 belonging to group 
III, which are broadened beyond detection in the Tau oligomers, were very sensitive to low 
concentrations of urea. In contrast, residues in the second proline–rich region and the 
repeats were not detected even at 8 M urea demonstrating that they form the core of PcTS-
stimulated oligomers of Tau. The resistance to urea denaturation is in line with π–π stacking 
as a key factor for oligomer stability.  
Residues belonging to group I and II from the urea denaturation roughly coincide 
with residues having a common denaturation profile in GuSCN (GuSCN group I) (Figures 
8f-g). Strikingly, in the repeat region signals were detected already at 0.1 mM GuSCN, 
demonstrating a very low stability of the Tau oligomers in ionic denaturants. In addition, 
signal intensities in 3 M GuSCN were highly similar to those observed in monomeric Tau 
(Figure S10). The different denaturation profiles for individual residues indicate that the 
PcTS-stimulated Tau oligomers are noncooperatively stabilized. 
PcTS Inhibits Tau Aggregation in Cells. To investigate the impact of PcTS-
induced oligomer formation on Tau aggregation in cells, we used the Neuroblastoma N2a 
cell model.39 After 4 days of incubation at 37 0C, the fluorescence signal intensity of the 
ThS–positive aggregates was measured. The amount of ThS–positive cells in the untreated 
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positive control was set to 100 %. From this cell–based assay, we observe that PcTS leads 
to a 97 % reduction in the fluorescence of ThS–positive cells relative to the untreated 
positive control (Figure 9), demonstrating that PcTS is a highly effective inhibitor of Tau-





Figure 8: Stability of Tau oligomers.  
(a) Selected region of 2D 1H–15N HSQC spectra of htau40 in the presence of a 15-fold excess of PcTS, and 
after addition of 8 M urea (b) and 3 M GuSCN (C). Resonances of residues that were rigidified in the Tau 
oligomers were partially (b) or fully (c) recovered. (d) Ratios of NMR signal intensities in 2D 1H–15N HSQC 
spectra of htau40 with 15-fold excess of PcTS at increasing urea concentrations (Iurea) when compared to 
values in the absence of urea (IPcTS-Tau). Increasing signal intensities indicate a residue-specific destabilization 
of the Tau oligomers. (e) Urea denaturation profiles of PcTS-stimulated Tau oligomers. All observable 
residues were classified into one of four groups based on their initial intensities, their sensitivity to urea 
concentration and their intensities in 3 M urea. The denaturation profiles differed between the groups, but 
within a group residues displayed cooperative behaviour. (f) Residue-specific analysis of NMR signal 
intensities of PcTS:htau40 (15:1) at increasing concentrations of GuSCN. Only non-overlapping peaks were 
included. Groups of residues (I-VI) that show a common profile of denaturation are marked above and their 
denaturation profiles are shown in (g). 
 






Figure 9: Percentage of ThS-positive cells determined by a FACS analysis of inducible N2a cells 
expressing the four–repeat domain pro–aggregation K18∆K280 construct.  
Cell suspensions containing either ThS alone (negative control) or ThS and doxycyclin without (positive 
control) or with 50 M PcTS (treated cell culture) were incubated for 4 days at 37 0C. The fluorescence signal 
intensity of ThS–positive aggregates was measured and the amount of cells in the untreated positive control 




Our study demonstrates that the organic compound Phthalocyanine tetrasulfonate 
binds to specific aromatic residues of Tau and inhibits Tau filament formation by targeting 
Tau into soluble oligomers. Using a combination of NMR spectroscopy, EPR spectroscopy 
and SAXS two predominant oligomeric species were revealed comprising ~7-14 and 24 
Tau molecules, respectively. The core of the soluble Tau oligomers is highly compact with 
a maximum diameter of 30-40 nm (Figure 7), but is non-cooperatively stabilized (Figure 
8). Biochemical experiments and analyses in Tau animal models suggested that Tau 
oligomers and not PHFs might represent the acutely toxic species.9,40 Tau oligomers 
prepared in vitro, which impair memory and cause synaptic dysfunction in mice,41 were 
largely SDS – stable apparent trimers, displayed a spherical morphology and contained β-
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sheet structure.42 In contrast, Tau oligomers stimulated by PcTS are only partially SDS-
stable, are not spherical and do not contain β-structure (Figures 1-7), pointing to distinct 
structural properties of toxic Tau oligomers. 
Despite the highly compact core of PcTS-stimulated Tau oligomers significant 
heterogeneity is likely to remain both with respect to the species being present and the 
number of Tau molecules in the oligomeric species. EPR spectroscopy demonstrated that 
even the compact core of Tau oligomers remains highly dynamic (Figure 4). The dynamic 
nature of the oligomer is in clear contrast to the pronounced rigidity of  the β-sheet rich 
core of Tau amyloid fibrils 34. In addition, the EPR line-broadening observed for the spin-
labels at position 352 and 384 (Figure 4) - in comparison to spin-label positions in the C-
terminal domain - suggest that this region is more rigid or compact in Tau oligomers. This 
region also contains the three aromatic residues F346, F378 and Y394 that comprise the 
primary binding sites for PcTS (Figure 2a). In contrast, the β-sheet rich core of PHFs is 
located more to the N-terminal part of the repeat region extending at most to residue 
~355.43-45 Thus, the location of the compact core of PcTS-stimulated Tau oligomers and 
Tau filaments is partially distinct in line with the finding that PcTS-stimulated Tau 












PcTS belongs to the family of cyclic tetrapyrroles, is planar with a hydrophobic 
central aromatic macrocyclic structure, and carries four negatively charged sulfonate 
groups at its peripheral outer benzo substitution positions. Previously, we showed that 
PcTS binds to the aromatic residues of -synuclein in the monomeric protein.22,46,47 Here 
we demonstrate that PcTS inhibits formation of Tau filaments in vitro and in cells (Figures 
1, 9) by selectively interacting with residues Y197, Y310, F346, F378 and Y394 in the 
central domain of Tau and converting the Tau protein into soluble oligomers. The specific 
interaction with aromatic residues in the central domain of Tau - and not with aromatic 
residues at the N-terminus - is distinct from a non-selective sequestration of protein 
molecules due to self-association of anti-amyloid agents.48 It is also distinct from the non-
selective mechanism that involves the covalent linkage via lysine residues into high-
molecular weight oligomers as suggested for the polyphenol oleocanthal.19,49 
Site-directed mutagenesis indicated that the different PcTS-binding sites in Tau are 
independent (Figure 2c). In addition, the observation that soluble Tau oligomers are formed 
in the absence of a single residue, Y310, supports a key role of PcTS-stimulated oligomer 
formation for the inhibition of Tau aggregation. While Y310 is buried in the fibrillar core 
of PHFs,36,43 Y197 and Y394 remain accessible for interaction with PcTS providing a 
mechanism for the previously demonstrated dissolvation of Tau filaments by PcTS.16 
In summary, we revealed detailed insights into the mechanism of Tau aggregation 
inhibition and the structure and dynamics of soluble Tau oligomers. Our study 
demonstrates that the structure of off-pathway oligomers of Tau is distinct from the 
structure of toxic Tau oligomers. 
 





Supporting Information. Overview over Tau isoforms; changes in chemical shifts 
of Tau induced by PcTS; time-dependent changes in NMR intensity profiles; interaction of 
PcTS with the Tau fragment K18 and Tau isoform htau24; influence of PcTS concentration 











We thank Marina Bennati and Eva-Maria Mandelkow for stimulating discussion and Ilka 
Lindner for sample preparation. This work was funded through the Cluster of Excellence 
and DFG Research Center "Nanoscale Microscopy and Molecular Physiology of the 
Brain", the MPG consortium Toxic Protein Conformation, the Metlife foundation, the 










AD, Alzheimer´s Disease; htau40; 441-residue Tau protein; PHFs, paired helical filaments; 
PcTS, Phthalocyanine tetrasulfonate; NMR, nuclear magnetic resonance; HSQC, 
heteronuclear single quantum coherence; EPR, electron paramagnetic resonance; SAXS, 
small-angle X-ray scattering; ThS, thioflavinS; SDS-Page, sodium dodecyl sulfate 





(1) Ross, C. A.; Poirier, M. A. Nat Med 2004, 10 Suppl, S10. 
(2) Forman, M. S.; Lee, V. M.; Trojanowski, J. Q. J Chem Neuroanat 2000, 20, 225. 
(3) Hardy, J.; Selkoe, D. J. Science 2002, 297, 353. 
(4) Goedert, M.; Spillantini, M. G. Science 2006, 314, 777. 
(5) Cleveland, D. W.; Hwo, S. Y.; Kirschner, M. W. J Mol Biol 1977, 116, 227. 
(6) Schweers, O.; Schonbrunn-Hanebeck, E.; Marx, A.; Mandelkow, E. J. Biol. Chem. 
1994, 269, 24290. 
(7) Drubin, D.; Kirschner, M. J. Cell Biol. 1986, 103, 2739. 
(8) Mukrasch, M. D.; Bibow, S.; Korukottu, J.; Jeganathan, S.; Biernat, J.; Griesinger, C.; 
Mandelkow, E.; Zweckstetter, M. PLoS Biol 2009, 7, e34. 
(9) Lasagna-Reeves, C. A.; Castillo-Carranza, D. L.; Jackson, G. R.; Kayed, R. Curr 
Alzheimer Res 2011, 8, 659. 
(10) Pul, R.; Dodel, R.; Stangel, M. Expert Opin Biol Ther 2011, 11, 343. 
(11) Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; 
Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; 
Lewis, J.; Dickson, D.; Duff, K. Proc Natl Acad Sci U S A 2005, 102, 6990. 
2. Inhibition of Tau Filament Formation by Conformational Modulation 
 
 167 
(12) Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E. 
B.; Xie, S. X.; Joyce, S.; Li, C.; Toleikis, P. M.; Lee, V. M.; Trojanowski, J. Q. Proc Natl 
Acad Sci U S A 2005, 102, 227. 
(13) Wischik, C. M.; Edwards, P. C.; Lai, R. Y.; Roth, M.; Harrington, C. R. Proc Natl 
Acad Sci U S A 1996, 93, 11213. 
(14) Pickhardt, M.; von Bergen, M.; Gazova, Z.; Hascher, A.; Biernat, J.; Mandelkow, E. 
M.; Mandelkow, E. Curr Alzheimer Res 2005, 2, 219. 
(15) Crowe, A.; Ballatore, C.; Hyde, E.; Trojanowski, J. Q.; Lee, V. M. Biochem Biophys 
Res Commun 2007, 358, 1. 
(16) Taniguchi, S.; Suzuki, N.; Masuda, M.; Hisanaga, S.; Iwatsubo, T.; Goedert, M.; 
Hasegawa, M. J. Biol. Chem. 2005, 280, 7614. 
(17) Bulic, B.; Pickhardt, M.; Schmidt, B.; Mandelkow, E. M.; Waldmann, H.; 
Mandelkow, E. Angew Chem Int Ed Engl 2009, 48, 1740. 
(18) Chirita, C.; Necula, M.; Kuret, J. Biochemistry 2004, 43, 2879. 
(19) Li, W.; Sperry, J. B.; Crowe, A.; Trojanowski, J. Q.; Smith, A. B., 3rd; Lee, V. M. J 
Neurochem 2009, 110, 1339. 
(20) Ehrnhoefer, D. E.; Bieschke, J.; Boeddrich, A.; Herbst, M.; Masino, L.; Lurz, R.; 
Engemann, S.; Pastore, A.; Wanker, E. E. Nat Struct Mol Biol 2008, 15, 558. 
(21) Woods, L. A.; Platt, G. W.; Hellewell, A. L.; Hewitt, E. W.; Homans, S. W.; Ashcroft, 
A. E.; Radford, S. E. Nat Chem Biol 2011, 7, 730. 
(22) Lamberto, G. R.; Binolfi, A.; Orcellet, M. L.; Bertoncini, C. W.; Zweckstetter, M.; 
Griesinger, C.; Fernandez, C. O. Proc Natl Acad Sci U S A 2009, 106, 21057. 
(23) Caughey, W. S.; Raymond, L. D.; Horiuchi, M.; Caughey, B. Proc Natl Acad Sci U S 
A 1998, 95, 12117. 
(24) Priola, S. A.; Raines, A.; Caughey, W. S. Science 2000, 287, 1503. 
(25) Park, J. W.; Ahn, J. S.; Lee, J. H.; Bhak, G.; Jung, S.; Paik, S. R. Chembiochem 2008, 
9, 2602. 
2. Inhibition of Tau Filament Formation by Conformational Modulation 
 
 168 
(26) Mukrasch, M. D.; Biernat, J.; von Bergen, M.; Griesinger, C.; Mandelkow, E.; 
Zweckstetter, M. J Biol Chem 2005, 280, 24978. 
(27) Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. J. Biomol. 
NMR. 1995, 6, 277. 
(28) Zheng, G.; Stait-Gardner, T.; Anil Kumar, P. G.; Torres, A. M.; Price, W. S. J Magn 
Reson 2008, 191, 159. 
(29) Jones, J. A.; Wilkins, D. K.; Smith, L. J.; Dobson, C. M. J. Biomol. NMR. 1997, 10, 
199. 
(30) Konarev, P. V.; Petoukhov, M. V.; Volkov, V. V.; Svergun, D. I. J. Appl. Cryst. 2006, 
39, 277. 
(31) Goedert, M.; Jakes, R.; Spillantini, M. G.; Hasegawa, M.; Smith, M. J.; Crowther, R. 
A. Nature 1996, 383, 550. 
(32) Boyle, R. W.; Dolphin, D. Photochem Photobiol 1996, 64, 469. 
(33) Berriman, J.; Serpell, L. C.; Oberg, K. A.; Fink, A. L.; Goedert, M.; Crowther, R. A. 
Proc Natl Acad Sci U S A 2003, 100, 9034. 
(34) Margittai, M.; Langen, R. Proc Natl Acad Sci U S A 2004, 101, 10278. 
(35) Gillespie, J. R.; Shortle, D. J Mol Biol 1997, 268, 170. 
(36) Bibow, S.; Mukrasch, M. D.; Chinnathambi, S.; Biernat, J.; Griesinger, C.; 
Mandelkow, E.; Zweckstetter, M. Angew Chem Int Ed Engl 2011, 50, 11520. 
(37) Mylonas, E.; Hascher, A.; Bernado, P.; Blackledge, M.; Mandelkow, E.; Svergun, D. 
I. Biochemistry 2008, 47, 10345. 
(38) Schulman, B. A.; Kim, P. S.; Dobson, C. M.; Redfield, C. Nat Struct Biol 1997, 4, 
630. 
(39) Pickhardt, M.; Biernat, J.; Khlistunova, I.; Wang, Y. P.; Gazova, Z.; Mandelkow, E. 
M.; Mandelkow, E. Curr Alzheimer Res 2007, 4, 397. 
(40) Brunden, K. R.; Trojanowski, J. Q.; Lee, V. M. J Alzheimers Dis 2008, 14, 393. 
(41) Lasagna-Reeves, C. A.; Castillo-Carranza, D. L.; Sengupta, U.; Clos, A. L.; Jackson, 
G. R.; Kayed, R. Mol Neurodegener 2011, 6, 39. 
2. Inhibition of Tau Filament Formation by Conformational Modulation 
 
 169 
(42) Lasagna-Reeves, C. A.; Castillo-Carranza, D. L.; Guerrero-Muoz, M. J.; Jackson, G. 
R.; Kayed, R. Biochemistry 2010, 49, 10039. 
(43) Andronesi, O. C.; von Bergen, M.; Biernat, J.; Seidel, K.; Griesinger, C.; Mandelkow, 
E.; Baldus, M. J Am Chem Soc 2008, 130, 5922. 
(44) Daebel, V.; Chinnathambi, S.; Biernat, J.; Schwalbe, M.; Habenstein, B.; Loquet, A.; 
Akoury, E.; Tepper, K.; Muller, H.; Baldus, M.; Griesinger, C.; Zweckstetter, M.; 
Mandelkow, E.; Vijayan, V.; Lange, A. J Am Chem Soc 2012, 134, 13982. 
(45) von Bergen, M.; Barghorn, S.; Muller, S. A.; Pickhardt, M.; Biernat, J.; Mandelkow, 
E. M.; Davies, P.; Aebi, U.; Mandelkow, E. Biochemistry 2006, 45, 6446. 
(46) Rao, J. N.; Dua, V.; Ulmer, T. S. Biochemistry 2008, 47, 4651. 
(47) Lamberto, G. R.; Torres-Monserrat, V.; Bertoncini, C. W.; Salvatella, X.; 
Zweckstetter, M.; Griesinger, C.; Fernandez, C. O. J. Biol. Chem. 2011, 286, 32036. 
(48) McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. J Med Chem 2002, 45, 
1712. 

























Figure S1: Isoforms of human Tau protein.  
Six isoforms of Tau protein exist in the human central nervous system and are generated by alternative 
splicing of the MAPT gene. The number of the insert regions in the projection domain (0, 1 or 2) and the 
presence or absence of the second repeat region in the microtubule–binding domain distinguish them. N or 
C = N or C–terminus, I = insert, P = proline–rich region, and R = repeat region.   






Figure S2: (a) Chemical shift deviations (Δδ1H/15Ntit−Δδ1H/15Nref) observed in 2D 1H–15N HSQC NMR spectra 
of htau40wt at increasing PcTS concentrations. Averaged, normalized chemical shift deviations were 
calculated according to ΔδAV=[0.5(δHtit−δHwt)2+0.02(δNtit−δNwt)2]½. Dotted black lines correspond to 
thresholds of chemical shift perturbations of 0.005 ppm for PcTS. (b) Absorption profile of PcTS 
demonstrating that the absorption properties of PcTS do not interfere with ThS fluorescence in the working 
range (excitation and emission wavelengths of 440 nm and 521 nm, respectively). (c) Electron micrographs 
of PcTS–htau40 oligomers. Scale bars, 40 nm (upper panels) and 70 nm (lower panels). The black dots 
represent the gold–labelled antibody K9JA–gold10nm used for immunostaining. 





Figure S3: Time-dependent remodeling of the PcTS-stimulated Tau oligomers.  
(a) PcTS–induced oligomers visualized by SDS–PAGE. 50 M monomeric htau40 samples containing 1 mM 
DTT were prepared in PBS buffer (pH 7.4) and heated for 20 minutes at 95 0C. After incubation with 750 
M PcTS for 1 or 24 hours at 4 or 37 0C, all samples were run on SDS–PAGE gels together with reference 
(Ferritin 440 kDa and protein marker) and control samples (monomeric htau40 in PBS buffers). The samples 
incubated for 1 hour at 4 and 37 °C show a protein band of higher molecular weight (gel a line 3 and 4). 
Further 23 hours of incubation, resulted in an intensity increase and the appearance of additional protein 
bands with a considerable decrease of the monomeric htau40 signal (comparison of gel a line 4 with gel b 
line 4). (b) Superposition of 2D 1H–15N HSQC spectra of 100 M htau40 in the absence (blue) and presence 
(yellow) of an equimolar ratio of PcTS. (c,d) Time-dependence of NMR signal intensity ratios of htau40 for 
(c) 1:1 PcTS-htau40 and (d) 15:1 PcTS–htau40. 





Figure S4: Interaction of PcTS with the shorter Tau isoform htau24.  
(a) Ratios of NMR signal intensities observed in 2D 1H–15N HSQC of 100 M htau24 (in 50 mM phosphate 
buffer pH 6.8) in the absence and presence of 100 M (green) and 1500 M (blue) PcTS. Residue numbers 
correspond to the sequence of htau40. The location of aromatic residues is indicated. Htau24 lacks the two 
negatively charged inserts (see domain organization on the top). (b) Overlay of the aliphatic regions from 2D 
1H–13C HSQC spectra of htau24 in the absence (red) and presence of a 1–fold (green) and 15–fold (blue) 
excess of PcTS. The aliphatic and aromatic (c and d) regions of the spectra show a strong decrease in the 
NMR signal intensities of the aromatic residues upon compound addition and their disappearance at large 
excess of compound. 





Figure S5: Interaction of PcTS with the Tau fragment K18 that comprises only the repeat domain of 
htau40.  
(a) Domain organization of K18. The two hexapeptides at the N-terminal ends of repeats R2 and R3 are 
highlighted. (b) Superposition of 2D 1H–13C HSQC spectra of 100 M K18 without (red) and with 15–fold 
(blue) excess of PcTS. The signals of all residues disappeared except for the highlighted resonances (green) 
that correspond to the flexible N– (A246, K257, K259, I260, and T263) and C– (N368 and E372) termini.  






Figure S6: (a) 1D 1H NMR of PcTS alone (green) and in the presence of htau40 at a PcTS:htau40 molar 
ratio of 15:1 (red). The concentration of PcTS and the experimental parameters were identical in the two 
measurements. The reduction of the PcTS signal in the presence of htau40 suggests that about 40% of PcTS 
is incorporated into the Tau oligomers and therefore no longer visible in the 1D 1H NMR spectrum. (b) NMR 
broadening profiles observed at a 10-fold lower concentration of htau40 (10 M) with the same PcTS:Tau 
molar ratio (1:1, yellow, 5:1 green, 15:1 red). The domain organization of htau40 is shown above.  





Figure S7: (a) FT–IR spectra of K18 in the absence (black) and presence of a 15-fold excess of PcTS (red). 
(b) Far UV–CD spectra of K18 in the absence (black) and presence of a 15-fold excess of PcTS (red).   
 
 






Figure S8: SAXS of PcTS-stimulated Tau oligomers.  
(a) SAXS profile of PcTS alone (green) and PcTS–htau40 profiles (1:1 orange and 15:1 red). The three 
profiles have been scaled based on the PcTS concentration, i.e. such that the PcTS concentration is effectively 
the same for the three profiles. Note that the scattering intensity for PcTS alone is much smaller and does not 
substantially contribute to the scattering of the Tau oligomers. (b,c) Estimation of the number of Tau 
molecules incorporated into the oligomers at different PcTS:htau40 ratios containing 5 (b) or 10 mg/ml (c) 
htau40. Samples with a PcTS:htau40 ratio of 15:1 were filtered (using a centrifugal filter with 0.2 µm cutoff) 
prior to the SAXS measurements. Error bars were estimated from the standard error of I0 variations between 
different concentrations of htau40 but the same ratio of PcTS and accounting for the concentration of residual 
monomeric protein as determined by NMR (see Experimental Section for further information).  









Figure S10: NMR signal intensities in 2D 1H-15N HSQC spectra of monomeric htau40 (black) and of htau40 
in the presence of a 15-fold excess of PcTS and 3 M GuSCN (green). Intensities for all peaks are shown, both 
isolated and overlapped with other peaks and without 3-residue averaging. Signal intensities in the two 
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Aggregation of the Tau protein is a key event in Alzheimer’s disease and Tau 
aggregation inhibitors are important as potential drugs. Phenothiazines, such as methylene 
blue and its derivatives, have a unique mechanism, specifically modifying the Tau cysteine 
residues. The modification keeps Tau in a monomeric disordered conformation preventing 




Alzheimer´s disease (AD) is the most widespread dementia syndrome showing 
progressive presence of abundant deposits of extracellular senile –amyloid polypeptide 
(A) plaques and intracellular neurofibrillary tangles (NFTs) consisting of Tau protein.[1, 
2] Tau protein is an intrinsically disordered protein that is abundant in neuronal axons where 
it promotes and stabilizes microtubule assembly.[3] With progression of AD, Tau 
aggregates and accumulates into NFTs.[2] As there is still no causative treatment or cure 
for AD and other tauopathies, Tau-based research aims to reveal the pathological 
consequences of amyloid formation and to implement new therapeutic strategies. In this 
effort, identification of inhibitors of tau aggregation as potential disease-modifying drugs 
and investigation of their mode of action play an important role.[4] 
Methylene Blue (MB), a tricyclic phenothiazine also known as methylthionine 
hydrochloride,[5] has a history of diverse medical applications stretching back over 100 
years, including use for distinctive cellular targets.[6] MB has been shown to prevent Tau 
aggregation in vitro [6-8] and to reduce the amount of Tau aggregates in a C. elegans model 
of Tau pathology.[9] This treatment has relieved Tau-induced toxicity of treated worms.[9] 
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Moreover, MB progressed to phase 2 clinical trials in human AD patients with promising 
results [10] and was recently announced to enter a phase 3 clinical trials.[11] Despite these 
positive effects, care must be exercised because MB and its derivatives azure A and B have 
toxic side effects at elevated concentrations.[12] In model systems (e.g. Tau-expressing 
neuronal cells, C. elegans expressing Tau-V337M [9] and zebra fish expressing Tau-P301S 
[13]) there are no detectable toxic effects at the concentrations used to inhibit Tau 
aggregation. Besides inhibition of Tau aggregation other modes of action for MB in 
Alzheimer's disease were proposed such as its antioxidant activity.[6] Moreover, MB 
inhibits oligomerization of amyloid- peptide by promoting fibrillization and interferes 
with aggregation of prion protein.[14, 15] Mono– and di–N–demethylation of MB yield azure 
B and azure A, respectively (Scheme 1), which also have anti-aggregation and 
pharmacological effects.[8, 12] Herein we reveal a distinct mechanism of action of MB and 
its metabolites azure A and azure B in the inhibition of Tau aggregation. We show that the 
mechanism of Tau aggregation inhibition is based on the interplay of reduction/oxidation 
of the native cysteine residues of Tau. MB and its metabolites prevent the formation of 
filaments and their toxic precursors by retaining Tau in a monomeric disordered 
conformation. 
The IC50 values reported for inhibition of Tau-aggregation by MB varies from 
approximately 2 μM for four-repeat Tau to around 30 μM for three-repeat Tau.[6, 8, 16] To 
identify the residues of Tau that are essential for the interaction with MB, we used NMR 
spectroscopy. For increasing MB concentrations, changes in NMR signal position and 
intensity in two-dimensional 1H-15N heteronuclear single quantum coherence (HSQC) 
spectra of the 441-residue full-length Tau protein, htau40, were observed (Figure 1a and 
Figure S1 in the Supporting Information). 






Scheme 1: The reduction of MB yields leucoMB (1) and is regenerated in oxidizing conditions (2). Mono- 
and di-N-demethylation yield azure B (3) and azure A (4), respectively. 
 
Chemical shift changes were found in repeats R2 and R3 in the microtubule-binding 
domain and included the second hexapeptide 306VQIVYK311 that is essential for 
aggregation of Tau. In addition, NMR signal perturbation was detected at the N-terminus 
in proximity to the aromatic residues Y18 and Y29. Most apparent, however, was the strong 
broadening of residues in proximity to the two native cysteines of htau40, C291 and C322 
(Figure 1a). Substitution of the two cysteines by alanine and glycine, respectively, 
abolished the NMR line-broadening in the repeat region (Figure 1b), and MB lost its 
inhibitory effect on Tau aggregation (Figure 2a,b, Figure S2). 
 





Figure 1: The Interaction of Methylene Blue with Tau. NMR intensity ratios I/I0 (I = intensity of Tau 
resonances in presence of compound; I0 = peak intensities of free Tau) from 2D 1H–15N HSQC spectra of 
htau40 (a-d). Signal broadening (I/I0 < 1.0) is due to exchange of Tau between the free Tau conformations 
and those in the presence of the compound. (a) and (b) show the NMR broadening profile of wild-type and 
the cysteine-free variant of htau40 at increasing concentrations of MB (see color–coded panel for 
ligand:protein ratios). The same titration analysis with wild-type htau40 was conducted with azure A (c) and 
azure B (d). The domain organization of htau40 is shown above (I = insert, P = proline–rich region, and R = 
pseudo-repeat). e) NMR signal broadening in 1H–15N HSQC spectra of htau23 (lacking I1, I2 and R2) in the 
presence of azure B. All NMR experiments contained 100 M protein and 1 mM DTT prepared in 50 mM 
phosphate buffer, pH 6.8.  





Figure 2: a, b) Filter assay and immunological detection of htau40/C291A/C322A (see also Figure S2) with 
azure B (a) and MB (b). Note, that azure B and MB interfere with ThS fluorescence precluding the use of 
ThS fluorescence for detection of filament formation. c) Aggregation of the three-repeat Tau construct K19 
in the presence of different concentrations of DTT and MB measured by a filter assay (see also Figure S5). 
Details on sample preparations are available as Supporting Information. The intensity refers to the amount 
of aggregated Tau.  





Figure 3: a, b) ESI–MS spectra of the free amino acid cysteine in the absence (a) and presence of MB (b). 
The color–coded fragments correspond to different oxidation states of the sulfhydryl group as represented by 
their chemical structures shown in (c).  
 
To obtain insight into the importance of the oxidation/reduction state of the cysteine 
residues of Tau, we added excess dithiothreitol (DTT) to the Tau-MB sample. Addition of 
DTT strongly decreased NMR signal broadening (see Figure S3), pointing towards MB-
induced oxidation of the native cysteine residues of Tau. NMR and mass spectrometry 
demonstrated that MB modifies cysteines to sulfenic, sulfinic and sulfonic acids (Figures 
3a-c and Figure S4). In addition, MB and its derivatives contain a central thiazine ring 
and are thus able to undergo oxidation-reduction reactions.  
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Although at neutral pH values the auto-oxidation rate of the reduced form of MB, 
leucoMB, is very fast and leucoMB is not stable, dithiol compounds are able to produce 
leucoMB under quasiphysiological conditions (Figure S4).[17] As we used 1 mM DTT to 
keep the native cysteine residues of Tau in a reduced state, an increasing fraction of MB 
was in the oxidized state when its concentration was increased during the titration.  
NMR spectroscopy revealed a diminished binding capacity of MB to Tau in the 
presence of DTT (Figure S3). To answer the question if MB shows an inhibitory effect on 
Tau aggregation under reducing conditions, we performed a filter assay with the three- 
repeat Tau construct K19 (containing only one cysteine) in the presence of different DTT 
and MB concentrations. 10 µM of K19 protein with 2.5 µM heparin3000 were incubated 
over 168 h with 0, 0.5, 1 and 5 mM DTT. The aggregation status of the MB-free sample 
was monitored via a Thioflavin S (ThS) assay (Figure S5). We observed diminished Tau 
aggregation in the presence of DTT. The ThS signal dropped to 36% of the DTT-free 
control. This is in line with a decrease of K19 dimer seeds by destruction of intermolecular 
disulfide bridges by DTT.  
We tested the aggregation ability of K19 under different reducing conditions. MB 
was used in the range from 0 to 1 mM, aggregation was allowed to proceed for 168 h, and 
the aggregation status was monitored with a filter assay (Figures 2c and S5). In the DTT-
free control MB lowered the aggregation efficiency of K19 by about 70%. With increasing 
amounts of DTT the inhibition of Tau aggregation was diminished. At 0.5 mM and 1 mM 
DTT the value dropped to approximately 30%, and with 5 mM DTT to 25%. The 
experiments show that MB is able to inhibit the aggregation of three-repeat Tau under 
reducing conditions up to 5 mM DTT. In living cells the reducing function is provided by 
gluthatione (GSH), an antioxidant preventing damage to important cell components.   
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For the proper function in the cell cytosol, GSH often reaches low millimolar 
levels.[18] This situation suggests that the 5 mM concentration of DTT chosen in our in vitro 
experiment was comparable to a relatively high cellular GSH concentration. It is known 
that the concentration of GSH declines with age and age-related neurodegenerative 
diseases.[19] As a consequence the reducing potential in the cytosol will become weaker. 
Thus the lowering of the GSH concentration will favor the aggregation of Tau. Another 
factor favoring aggregation of Tau is oxidative stress that is elevated in neurons affected 
in neurodegenerative diseases and leads to a shift in the redox balance of GSH to less 
antioxidative values and thus lower antioxidative properties.[20] 
As demethylation of MB is favoured with several in vitro and in vivo conditions,[5] 
we probed the interaction of the didemethylated and monodemethylated derivatives of MB, 
azure A and azure B (Scheme 1), with htau40. At low concentrations, azure A and B led 
to NMR signal broadening next to the two htau40 cysteines (Figure 1 c,d) which 
corresponds to their oxidation. However, at higher compound concentrations and in 
striking contrast to MB, azure A and azure B also showed strong signal broadening in 
regions containing aromatic residues such as the N-terminal tail and residues 360-400 
(16GTYG19, 27GGYT30, 114LEDEAAGHVT123, 362HVPGGG367,  371IETH374 and 
386TDHGAEIVYKS396). A similar effect was observed for the three-repeat isoform of Tau, 
htau23, that contains only the single cysteine C322 and for which strong signal broadening 
was observed for C322 as well as 362HVPGGG367 and  371IETH374 (Figure 1e). The reason 
for binding of azure A and azure B and not MB to the aromatic residues of Tau, lies in the 
hydrophilic nature of the MB molecule, which has been suggested to be responsible for the 
finding that MB is not an efficient stain for normal blood cells in contrast to azure B.[5] 
Thus, upon demethylation of MB new modes of interaction and aggregation inhibition are 
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possible in line with the finding that azure A and B are 30-fold more potent than MB in 
inhibition of Tau aggregation.[7] 
The 1H-15N HSQC of htau40 in the presence of MB, azure A and azure B retained 
its low dispersion and chemical shifts characteristic of a disordered protein. To obtain 
further insight into the Tau species that are stimulated by MB we performed circular 
dichroism (CD) and small angle X-ray scattering (SAXS) measurements. CD spectroscopy 
demonstrated that azure B did not induce detectable amounts of regular secondary structure 
in Tau (Figure 4a). SAXS showed that even at large excess of azure B, Tau is a highly 
disordered protein (Figures 4b, c). The SAXS-derived radius of gyration, Rg of 6.7±0.3 
nm (at five-fold excess of azure B), was comparable to that of monomeric Tau,[21] 
demonstrating that the MB-Tau interaction does not result in the formation of Tau 
aggregates. Indeed, determination of the hydrodynamic radius by pulsed-field gradient 
NMR[22] and dynamic light scattering (DLS) pointed to a slight compaction of the ensemble 
of Tau conformers that was released in the presence of excess DTT (Figure 4d). We 
conclude that MB and its derivatives azure A and B retain Tau in a monomeric aggregation 
incompetent state. 




Figure 4: MB and its Metabolites Retain Tau in a Monomeric Disordered State. a) Far UV CD spectra of 
htau40 in the absence (black) and presence of azure B (20:1, red). b) SAXS profiles and c) Kratky plots of 
htau40 alone (black) and together with azure B (brown) at increasing ligand-protein ratios (color-coded 
panel). Curves are translated arbitrarily for viewing purposes. d) Hydrodynamic radius of htau40 in the 
absence and presence of a 20-fold excess of azure B as determined by NMR and DLS, and after addition of 
8 mM DTT (right). Details on sample preparation are available as Supporting information.   
 
An important aspect of aggregation inhibition is that it can potentially interfere with 
the physiological function of the protein. As Tau is a microtubule-associated protein,[23] 
interference of phenothiazines with the ability of Tau to promote microtubule assembly 
might be detrimental in cells. However, azure A does not interfere with Tau-tubulin 
interaction when introduced at a 1000-fold excess with respect to Tau,[7] and MB did not 
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influence Tau-promoted microtubule assembly.[8, 24] Thus, the aggregation incompetent 
monomeric conformation of Tau induced by MB and its derivatives is able to efficiently 
interact with microtubules. 
Our data demonstrate that MB and its N-demethylated derivatives azure A and 
azure B modify the two native cysteine residues of Tau to sulfenic, sulfinic and sulfonic 
acid. The modification of protein cysteine residues through reversible oxidation of cysteine 
sulfhydryl groups and the formation of sulfenic acids are a crucial regulatory event in 
biological systems.[25] The nucleophilic character of the sulfhydryl group results in several 
distinct redox pathways and facilitates roles in electron donation, hydride-transfer 
reactions, and free radical reactions. Along these pathways, disulfide bridge formation is 
the most dominant chemical oxidation as it enhances structural stability. In case of Tau it 
was shown that intramolecular cross-linking of C291 and C322 in four-repeat isoforms of 
Tau (such as htau40) strongly inhibits PHF formation, while formation of intermolecular 
disulfide bond formation in three-repeat isoforms of Tau, e.g. htau23, promotes 
aggregation.[26] In striking contrast, we demonstrate that modification of the cysteines to 
sulfenic, sulfinic and sulfonic acid converts both four-repeat and three-repeat Tau to an 
aggregation incompetent, monomeric state (Figures 3, 4): MB inhibits aggregation of both 
four-repeat Tau and three-repeat Tau with IC50 values of approximately 2 μM 
[8, 16] and 30 
μM,[6] respectively. The lower IC50 value for three-repeat Tau is in line with the presence 
of a single cysteine residue, C322, that is, a single modification site, in comparison to the 
two cysteine residues of htau40. The specific modification of the cysteine residues is 
critical for aggregation inhibition as substitution of the cysteine residues by alanine did not 
interfere with filament formation (Figure S2), whereas it abolished the inhibitory effect of 
MB on Tau aggregation (Figures 2a, b).  
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In summary we have provided mechanistic insights into the inhibition of Tau 
aggregation by phenothiazines. Specific modification of the native cysteine residues retains 
Tau in a monomeric conformation preventing the formation of filaments and their toxic 
precursors. Demethylation of methylene blue establishes new interactions with Tau and 




Unlabelled and labeled wild-type and mutated human Tau proteins were expressed 
and purified as described in the literature.[27] MB, azure A and B were purchased from MP 
Biomedicals (MP Biomedicals S.A. Heidelberg, Germany). NMR experiments were 
recorded at 5 0C on Bruker Avance 700 MHz or Avance III 800 MHz spectrometers. NMR 
samples contained 15N-labeled Tau (100 M) in phosphate buffer (50 mM pH 6.8), DTT 
(1 mM), and 10 % (v/v) D2O. SAXS data were collected at X33 at the European Molecular 
Biology Laboratory on DORIS III (DESY) at a wavelength of 1.5 Å at 25 °C using a Pilatus 
1M photon counting detector. Samples were prepared in phosphate buffer (50 mM) and 
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Impact of removal of the two cysteines on Tau aggregation. Full-length Tau has 
a very low tendency to aggregate, consistent with its hydrophilic nature and high solubility. 
The influence of cysteines can be illustrated by the following experiments: The aggregation 
of wild-type htau40 is observed under non-reducing conditions (i.e. omission of DTT). The 
reaction was monitored with Thioflavin S (Figure S2a, blue line). In the course of 8 days 
there is no increase of the fluorescence signal, indicating little or no aggregation. Analysis 
of the endpoint sample by electron microscopy revealed some occasional short filaments 
(Figure S2b). By contrast, when the cysteine-less htau40-mutant was monitored over the 
same time period, it formed abundant amounts of bundled filaments (Figures S2a, red line 
and S2c).  This can be rationalized in the following way[1]: htau40 contains two cysteines 
(Cys291 and Cys322) which - in oxidative conditions - can form intra-molecular disulfide 
bridges that prevent dimerization and full-scale aggregation. But when the cysteine 
residues are replaced by alanine, aggregation can occur because the molecules are free to 
dimerize without the intra-molecular blocking conformation. 
Next, we monitored the kinetics of aggregation of wild-type htau40 under non-
reducing conditions in the presence of increasing amounts of MB by the filter assay 
(Figures S2d). [Note: MB interferes with the ThS fluorescence, which precludes the use of 
ThS fluorescence for filament detection.] The analysis showed small amounts of randomly 
aggregated material over the whole range of MB concentrations. 
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In the case of aggregation of wild-type htau40 under non-reducing conditions an 
inhibitory effect of MB cannot be detected because of the absence of free -SH groups (there 
is only minimal aggregation because of intra-molecular S-S bridges in the compact 
monomer conformation, see[1]). The result of the comparable experiment with the cysteine-
less htau40-mutant also does not show any inhibitory effect of MB because of the lack of 
-SH groups. The noticeable aggregation of the htau40-mutant can be explained by the fact 
that this protein is able to dimerize and to form -sheet stacking via hexapeptide motifs. In 
other words, intra-molecular disulfide bridges prevent aggregation (because they lock the 
molecule in a non-polymerizable state), inter-molecular disulfide bridges accelerate 




Proteins and Reagents. Unlabelled and 15N-labelled wild-type and mutant human 
Tau proteins were expressed and purified as described previously.[2] Methylene Blue (MB), 
azure A and azure B were purchased from MP Biomedicals (MP Biomedicals S.A. 
Heidelberg, Germany). Dithiothreitol DTT and Thioflavin S were purschased from Sigma 
(Sigma–Aldrich Chemie GmbH, Schnelldorf, Germany). 13C/15N double-labelled cysteine 
was purschased from Cambridge Isotope Laboratories (Cambridge Isotope Laboratories, 
Andover, United States). 
Quantification of aggregated Tau protein via filter-assay. 10 M of cysteine-
free Tau protein (htau40/C291A/C322A) was incubated in the presence of BES buffer (20 
mM, pH 7.4), 25 mM NaCl, 2.5 M heparin3000, protease-inhibitor mix (10 g/ml 
leupeptin, 1 g/ml aprotinin, 1 g/ml pepstatin, and 1 mM benzamidin). Methylene Blue 
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or Azure B were added in a concentration range from 0 to 1 mM and the samples were 
incubated for 8 days at 370C. Tau aggregation was monitored in the compound free sample 
by Thioflavin S assay and electron microscopy. After incubation, 2 % of the sample were 
filtered through an equilibrated nitrocellulose membrane (ø 0.45 m; Biorad, Schleicher 
and Schüll Bioscience GmbH, Dassel, Germany) and washed two times with 40-fold PBS 
buffer volume (137 mM NaCl, 2.7 mM KCl, 12 mM Na2HPO4/KH2PO4, pH 7.4). the 
membrane was shaken for 15 minutes in PBS to remove air bubbles ouf of the 
nitrocellulose matrix. The amount of remaining aggregated Tau was quantified via 
immunological detection with the pan-Tau antibody K9JA (anti-rabbit-goat HRP). The 
secondary antibody is labeled with HRP and the measurement was performed via 
ImageQuant LAS4000 mini (GE Healthcare), detection via ECL system (GE Healthcare), 
and quantification via Aida Image Analyzer software. 
Electrospray Ionization Mass Spectrometry. Samples of free (100 M) and MB–
containing (equimolar) 13C/15N double-labelled cysteine amino acid (Cambridge Isotope 
Laboratories, Andover, United States) were dissolved in 20 % acetonitrile / 0.2 % formic 
acid–aqueous solutions and directly infused into a Thermofisher LTQ instrument via a 
syringe pump at 3 ml/min. Spectra were acquired in the positive mode in the range of 60 
to 600 m/z, under the following source conditions: voltage 3.8 kV, capillary temperature 
275 0C; and processed with XCalibur.  
NMR Spectroscopy. All NMR experiments were recorded at 5 0C on Bruker 
Avance 700 MHz or Avance III 800 MHz spectrometers equipped with cryogenic probes. 
NMR samples contained 100 M 15N-labelled protein in 50 mM phosphate buffer pH 6.8, 
1 mM DTT and 10 % (v/v) D2O unless noted differently. 2D 
1H–15N HSQC experiments 
were acquired using 600 complex points and 32 scans per increment with spectral widths 
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of 8389 Hz and 1844 Hz in the 1H and 15N dimensions, respectively. Intensity ratio plots 
are reported with a 3–residues averaging window.  
1D 1H and 2D 1H–13C NMR spectra of the amino acid cysteine (100 M in the 
absence or presence of a 20-folded excess of MB prepared in 50 mM phosphate buffer, pH 
6.8 and 10 % (v/v) D2O, were acquired at 5 
0C on a Bruker 400 MHz spectrometer using 
16k points, 1k scans with spectral widths of 4006 Hz (in case of 1D 1H NMR spectra) and 
144 complex points, 16 scans per increment with spectral widths of 4006 Hz and 4024 Hz 
in the 1H and 13C dimensions, respectively  (in case of 2D 1H–13C NMR spectra). 
NMR diffusion experiments were recorded on a Bruker Avance 600 MHz 
spectrometer equipped with a cryogenic probe using a stimulated–echo based pulsed 
gradient spin–echo sequence incorporating the WATERGATE solvent suppression [3] with 
optimized diffusion time and gradient pulses lengths. The gradient strength was linearly 
increased from 2 % to 95 % of the maximum gradient strength in 30 steps, where the 100 
% gradient strength corresponds to 55.14 G/cm. Each 1H spectrum was recorded with 128 
scans and 16K complex over a spectral width of 8992 Hz. Several peaks in the aliphatic 
region of htau40 were selected and the intensities of their diffusion–based spin–echo 
attenuation were extracted to determine an average diffusion coefficient. Stokes radii were 
calculated from the apparent diffusion coefficients of htau40 referenced to a selection of 
protein standards (cytochrome C 12.4KDa, 17.8 Å; lysozyme 14.3 KDa, 20.5 Å; 
myoglobin 18 KDa, 21.2 Å; and ovalbumin 45 KDa, 30.5 Å; all prepared at concentrations 
of 100 M in 50 mM phosphate buffer containing 1 mM DTT and 10 % (v/v) D2O). 
Dynamic Light Scattering. DLS measurements were performed at 5 0C using a 
DynaPro Titan/temperature controlled microsampler (Wyatt Technologies Corporation). 
Samples (40 M of htau40 in 50 mM phosphate buffer, pH 6.8 and 1 mM DTT inserted in 
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50 μl flow cells) were illuminated by a 25 mW, 780 nm solid–state laser, and the intensity 
of 900 angle scattered light was measured at 4 μs intervals by a solid–state avalanche 
photodiode. Measurements were repeated three times using freshly prepared samples to 
confirm the reproducibility of the results, and the average values with their standard 
deviations were analyzed and reported by the Dynamics 6.7.7.9 software package. 
Circular Dichroism. Samples contained 10 M htau40 in 50 mM phosphate buffer 
pH 6.8 and 1 mM DTT. CD spectra were acquired at room temperature using a 1–mm path 
cell cuvette, on a Chirascan CD spectrometer (Applied Photophysics Limited) over the 
range covering 190 to 250 nm and a 1 nm band width and a scanning speed of 20 nm/min. 
Spectra were averaged over five scans. The measurements were repeated three times with 
freshly prepared samples to confirm the reproducibility of the results. Data are expressed 
in terms of the mean residual ellipticity (θ) in deg cm2 dmol–1. 
Small Angle X-ray Scattering. SAXS Data were collected at X33 at the European 
Molecular Biology Laboratory on DORIS III (DESY) at a wavelength of 1.5 Å at 25 °C 
using a Pilatus 1M photon counting detector. Each sample contained 87 M (4 mg/m) of 
htau40 in 50 mM phosphate buffer, pH 6.8 and 1 mM DTT, and was exposed to 8 frames 
of 15 seconds. Data were analyzed by ATSAS 2.3.[4] The maximum diameter was 
estimated by indirect fourier transformation. 
 
  





Figure S1. Chemical shift deviations (Δδ1H/15Ntit−Δδ1H/15Nref) observed in 2D 1H–15N HSQC NMR spectra of 
htau40 wild-type and mutants at increasing compound concentrations: a, b) MB, c) azure A, and d) azure B. 
Averaged, normalized chemical shift deviations were calculated according to 
ΔδAV=[0.5(δHtit−δHwt)2+0.02(δNtit−δNwt)2]½. Dotted black lines correspond to thresholds of chemical shift 
perturbations of 0.0025 ppm. e) Selected regions of 2D 1H–15N HSQC of htau40 at increasing concentrations 
of MB, and after further addition of 4 mM DTT (light blue).  





Figure S2. Impact of removal of the two native cysteines on Tau aggregation. a) Aggregation curve of wild-
type htau40 (blue line) compared with the cysteine-less mutant htau40/C291A/C322A (red line) under non-
reducing conditions without MB treatment monitored by a Thioflavin S assay. b, c) Endpoint samples (after 
168h for wild-type htau40, blue circle and after 192h for htau40/C291A/C322A, red circle) were monitored 
by electron microscopy to show the amount and shape of aggregated Tau protein. d) Filter assay of aggregated 
wild-type htau40 in the presence of increasing amounts of MB (0 to 1 mM) (see Supporting Text for 
additional information). 





Figure S3. Interplay between oxidized and reduced forms of MB and azure B. a) 1D 1H NMR spectra of 
MB, azure B and azure A. b) NMR signal intensity ratios in 2D 1H–15N HSQC of htau40 for MB–htau40 
20:1 in the presence of 1 mM (red) and of 4 mM DTT (light blue). c) NMR signal intensity ratios in 2D 1H–
15N HSQC of htau40 for azureB–htau40 20:1 in presence of 1 mM (red), 4 mM (green), 8 mM (brown) and 
50 mM DTT (purple).  




Figure S4. Reversible modification of cysteine by MB. a) 1D 1H NMR spectra of selected samples to 
highlight the redox reaction. The oxidized form of MB is reduced in the presence of excess DTT. Upon 
increasing the concentration of deuterated DTT from 1 to 4 mM in the MB-htau40 sample, the concentration 
of oxidized MB is decreased. Note that this was also clearly visible by the change in color of the NMR 
sample. The sample color changed from blue (oxidized MB) to transparent (leucoMB). b) 1D 1H NMR 
spectra of the free amino acid cysteine in absence (red) and presence of MB (blue) showing the displacement 
of H and H chemical shifts further downfield upon oxidation together with their recovery in presence of 
deuterated DTT (green). c) Superposition of 2D 1H-13C NMR spectra of the amino acid cysteine in the 
absence (red) and presence of MB (blue) showing the (C,H) and (C,H) chemical shifts in their reduced 
and oxidized forms.  





Figure S5. MB-driven inhibition of Tau aggregation under reducing conditions. a) Aggregation of the three-
repeat Tau construct K19 under reducing conditions in the presence of increasing DTT concentrations but 
without MB as monitored by a Thioflavin S assay. b) Aggregation of K19 in the presence of different DTT 
and MB concentrations measured by the filter assay (see also Figure 2h and Methods in Supporting 
Information for further details). 
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Dysfunctional tau accumulation is a major contributing factor in tauopathies, and 
the heat shock protein 70 (Hsp70) seems to play an important role in this accumulation. 
Several reports suggest that Hsp70 proteins can cause tau degradation to be accelerated or 
slowed, but how these opposing activities are controlled is unclear. Here we demonstrate 
that highly homologous variants in the Hsp70 family can have opposing effects on tau 
clearance kinetics. When over-expressed in a tetracycline-based protein chase model, 
constitutive Hsc70 and inducible Hsp72 slowed or accelerated tau clearance, respectively. 
Tau synergized with Hsc70, but not Hsp72, to promote microtubule assembly at nearly 
twice the rate of either Hsp70 homolog in reconstituted, ATP-regenerating Xenopus 
extracts supplemented with rhodamine-labeled tubulin and human recombinant Hsp72 and 
Hsc70. Nuclear magnetic resonance spectroscopy with human recombinant protein 
revealed that Hsp72 had greater affinity for tau than Hsc70 (I/I0 ratio difference of 0.3), but 
Hsc70 was thirty times more abundant than Hsp72 in human and mouse brain tissue. This 
indicates that the predominant Hsp70 variant in the brain is Hsc70, suggesting that the brain 
environment primarily supports slower tau clearance. Despite its capacity to clear tau, 
Hsp72 was not induced in the Alzheimer’s brain, suggesting a mechanism for age-
associated onset of the disease. Through the use of chimeras that blended the domains of 
Hsp72 and Hsc70, we determined that the reason for these differences between Hsc70 and 
Hsp72 with regard to tau clearance kinetics lies within their C-terminal domains, which are 
essential for their interactions with substrates and co-chaperones. Hsp72 but not Hsc70 in 
the presence of tau was able to recruit the co-chaperone ubiquitin ligase CHIP, which is 
known to facilitate the ubiquitination of tau, describing a possible mechanism of how the 
C-termini of these homologous Hsp70 variants can differentially regulate tau triage. Thus, 
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The microtubule-associated protein tau, when disengaged from microtubules, 
becomes deleterious in tauopathies (1-4). Part of this pathogenesis involves structural 
changes that promote its aggregation. Chaperone machinery, and in particular members of 
the heat shock protein 70 (Hsp70) family, are engaged with tau during these pathogenic 
events, and these proteins dramatically affect tau stability and function at this critical 
juncture (5-7). In mammalian systems, there are approximately 13 homologous Hsp70 
genes, including the primary cytosolic variants Hsc70 (HSPA8) and Hsp72 (HSPA1A). 
Though these two variants share nearly 80% sequence identity, some functional differences 
have been reported (8, 9). Hsc70 is constitutively expressed (10), while Hsp72 is expressed 
in response to stress (11). Moreover, the C-termini of these chaperones, known to interact 
with key co-chaperone effectors containing a tetratricopeptide (TPR) repeat motif, is where 
their sequences differ the most (12). Despite these observations, the term Hsp70 is often 
used to generically refer to both Hsc70 and Hsp72. 
We and others have shown that the collective Hsp70 chaperone network, and in 
particular Hsp72 and Hsc70, influences tau conformation, degradation, and aggregation 
kinetics. But how these fates are chosen for tau have been challenging to define. For 
example, some studies strongly suggest that over-expression of an unspecified Hsp70 
variant can facilitate tau clearance (5), whereas others suggest that both Hsp72 and Hsc70 
restore tau’s binding to microtubules (1, 7). Though differences in the cellular environment, 
such as stress (12) and client abundance (13) may contribute to this discrepancy, it has yet 
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to be definitely shown how these different fates for tau are chosen by the Hsp70 machinery. 
We show here that tau fate is critically linked to both Hsc70 and Hsp72.  
 
MATERIALS AND METHODS 
Materials. Hsc70 and Hsp72 antibodies were purchased from Stressgen, 
Famingdale, NY, USA  and specificity was validated as previously described (8). Total tau 
H150 antibody was purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA. 
Actin - and GAPDH antibodies were from Sigma, St. Louis, MO, USA and Biodesign 
International, Memphis, TN, USA, respectively. Myc and Flag antibodies were from 
Roche, Indianapolis, IN, USA and Sigma, respectively. CHIP antibody was provided by 
Cell Signaling, Danvers, MA, USA. Phosphatase inhibitor cocktails (1 & 3), albendazole 
and celastrol were purchased from Sigma. Cell lysis buffer- M-PER was purchased from 
Fisher Scientific, Pittsburgh, PA, USA. Secondary antibodies horse-radish peroxidase 
linked were purchased from Southern Biotech Inc., Birmingham, AL, USA. Lipofectamine 
2000 and secondary antibodies conjugated to flourophore were purchased from Invitrogen, 
Grand Island, NY, USA. Plasmids for wild type human Hsc70, Hsp72 and chimera were 
generated in the pCMV6 vector (Origene, Rockville, MD, USA) which was then 
engineered to contain an N-terminal Flag tag. Mutant constructs were generated using the 
Site directed mutagenesis kit from Stratagene, Santa Clara, CA, USA. All other clones 
were in pCDNA3.1 plasmid.  Human brain tissue was provided from the University of 
California at Irvine MIND.   
Cell Culture, Immunoblotting, Dot blot, immunostaining and 
Immunoprecipitation. Human neuroblastoma IMR-32, HEK and HeLa cells were 
maintained in the OptiMEM media supplemented with 10 % heat inactivated FBS and 1% 
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penicillin/streptomycin antibiotic solution. All the transfections, immunoblotting and 
immunoprecipitation experiments were performed as described previously (14). Dot blots 
were performed using the Whatman Minifold I apparatus on nitrocellulose (Whatman, 
Piscataway, NJ, USA). All values were normalized to Ponceau S. Recombinant Hsp72 and 
Hsc70 were applied at indicated molar concentrations in PBS. Lysates from human AD 
brain tissue and control brain tissue were spotted at 20µg total protein. Quantification of 
Western blot and dot blot data was performed using replicate values from ScionImage or 
Image J densitometric software suites. Dot blot calculations were performed using a semi-
log linear regression analysis. Immunostaining of mouse brain tissue was performed as 
previously described (15, 16).  
Tetracycline-Based Protein Chase HEK Cell Model Inducible HEK cell line was 
generated by the insertion of human wild type Tau 4R0N DNA into a pCDNA 4/TO 
plasmid vector carrying Zeocin selection (Invitrogen).  The Tau/TO plasmid construct was 
transfected into the Tetracycline-Regulated Expression (T-REx™; Invitrogen) HEK cell 
lines stably expressing tetracycline (Tet) repressor under the selection of Blasticidin. After 
24 hours of DNA transfection, Zeocin (400 µg/ml) and Blasticidin (5µg/ml) were added to 
the media (DMEM containing 10%FBS, 2mM L-glutamine, 1% Pen-Strep).  Every 3-4 
days later media was replaced with fresh media containing Zeocin and Blastidin. After 3 
weeks, double stable cell colonies were picked-up and transferred into 6 well plates. These 
colonies were induced by tetracycline (1µg/ml) and tested for tau expression by western 
blot. Tau expressing double stable HEK cells were maintained under the selection of 
Zeocin and Blasticidin and used for the experimentation. Following transfection with 
Hsp72 or Hsc70 clones, tetracycline-containing media was removed and replaced with 
normal media. Tau levels were reduced over time to near basal levels.   
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Live Cell Imaging. HEK-293 cells were plated onto a 6-well plate and maintained 
in DMEM plus 10% fetal bovine serum and 1% of 200mM L-glutamine. Plasmid 
transfections were done utilizing Lipofectamine 2000 (Invitrogen). HEK 293 cells were 
transfected with 2μg of Hsc70 DNA, 1μg of Tubulin-GFP DNA and 1μg of Tau-RFP DNA. 
The cells were incubated overnight with the Lipofectamine/plasmid mixture in Opti-MEM 
medium, and replaced with fresh complete media for an additional 36h. An Olympus 
FV1000 MPE multiphoton laser scanning microscope was used to capture images. Image 
analysis was completed with the Olympus FV10-ASW software, and significance was 
assessed by Pearson’s correlation coefficient. Cells were then lysed and analyzed by 
Western blot to confirm over-expression of Hsp72 and Hsc70. 
Recombinant Protein Production. The coding regions for WT 4R0N Tau, Hsp72, 
and Hsc70 were separately PCR amplified and subcloned into pET28A vectors with N-
terminal His6-tags.  Resulting plasmids were transformed into E. coli OneShot BL21 Star 
(DE3) cells (Invitrogen) and 10mL starter cultures were grown overnight in Luria Bertani 
(LB) media with 30µg/ml kanamycin. Cells were then inoculated into 1.0L LB media, 
grown at 37°C to A600 ~ 0.7-0.8, and induced with 1mM isopropyl β-D-1-
thiogalactopyranoside (IPTG).  After 3 hours of continued growth at 37°C, cells were 
harvested by centrifugation and resuspended in lysis buffer (500mM NaCl, 20mM Tris-
HCl, 5mM imidazole, 1x protease inhibitor cocktail III (Calbiochem, Billerica, MA, USA), 
1mM PMSF, pH 8.0).  The cells were then lysed by sonication, centrifuged (18200g, 
30min, 4°C), and supernatant was loaded onto 5mL of charged Ni-NTA agarose beads 
(Qiagen, Valencia, CA, USA).  Protein was eluted in lysis buffer containing 250mM 
imidazole.  Eluent was concentrated to 2mL and loaded onto a HiLoad 16/60 Superdex 200 
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pg size exclusion column. Purified fractions were dialyzed in 2 steps into 10mM phosphate 
buffer (pH 7.5) and concentrations were determined by BCA. 
In vitro microtubule assembly assay. These assays were performed as previously 
described (1, 14). Briefly, S-phase Xenopus egg extracts were prepared according to a 
standard protocol(17) and supplemented with 5% DMSO to stimulate microtubule 
polymerization as described(18).  Purified recombinant wt tau, Hsp72, and Hsc70 proteins 
were added at the final concentrations of 40, 80, and 80 ng/μl.  The extracts were incubated 
30 min at room temperature and obtained microtubule structures were visualized by 
fluorescence of incorporated Rhodamine-labelled tubulin.  
NMR.  15N labeled human Tau protein was expressed and purified as described 
previously (19).  NMR experiments were recorded at 5 0C on a Bruker Avance 800 MHz 
spectrometer equipped with a cryogenic probe. NMR samples contained 50 µM 15N single 
labeled Tau protein in 50 mM phosphate buffer and 10 mM NaCl, pH 6.8, 1 mM DTT and 
10 % (v/v) D2O. Unlabeled Hsp72 and Hsc70 samples were prepared in the same buffer. 
Two-dimensional 1H–15N heteronuclear single quantum coherence (HSQC) spectra were 
acquired using 600 complex points and 128 scans per increment with spectral widths of 
8012 Hz and 1944 Hz in the 1H and 15N dimensions, respectively. Spectra were processed 
with NMRPipe (20) and analyzed using CcpNMR Analysis(21). NMR intensity ratio plots 
were reported with a 3–residues averaging window.  
Immunostaining Mouse brains were processed for immunohistochemical analysis 
as described previously (16, 22).  Briefly, mice brain sections were immersed in 3% H2O2 
solution for 15 min at RT. After washing with PBS sections, were permeabilized by 
immersing in the 4% donkey serum blocking buffer (supplemented with 1.83% lysine, and 
2% Triton X-100) for 30 min at RT. Sections were treated with Anti-HSC70 (1:20000) and 
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anti-Hsp72 (1:300) primary antibodies for overnight at 4°C. After washing with PBS, 
sections were incubated with biotinylated anti-rat (1:1000) and anti-mouse (1:3000) 
secondary antibodies (southern biotech) for two hours and then with streptavidin-
peroxidase. The peroxidase reactions consisted of 1.4 mM diaminobenzidine with 0.03% 
hydrogen peroxide in PBS for 5 min. Finally, stained sections were mounted on glass 
slides, dehydrated, cleaned using histoclean and cover slipped. Imaging was performed 
with the Zeiss Mirax slide scanning microscope.  
Fluorescent polarization (FP) assay FP assays were carried out essentially as 
previously described (23). The peptide FITC-HLA (RENLRIARLY) was synthesized on 
Wang resin using microwave-assisted DIC/HOBt solid-phase peptide synthesis. It was 
capped with two β-alanine residues and labeled on resin via the N-terminus with 
fluorescein-5-isothiocyanate (Anaspec). The final product was obtained in > 90% purity. 
FP assays were carried out in 384-well plates (20 μL final volume) with a 30 minute 
incubation. Conditions: Hsp72 (2 µM) or Hsc70 (4 µM), 25 nM FITC-HLA probe, 100 
mM Tris buffer, 20 mM KCl, 6 mM MgCl2, pH 7.4.  
Sequence Alignment. Global sequence alignment of H. sapiens Hsp72 (HspA1A/ 
A29160) and Hsc70 (HspA8/A27077) using PRALINE (http://www.ibi.vu.nl/programs/ 
pralinewww/) with manual adjustment. Figure is drawn to scale and the degree of residue 










Hsp70 proteins have the capacity to both reduce and preserve tau in cells in addition 
to regulating its association with microtubules (1, 5, 7). The reasons for these functional 
differences are unclear. We speculated that one possible reason could be the unique effects 
of distinct Hsp70 variants. Since tau is a cytosolic protein, we investigated the relationship 
of tau with the two major cytosolic Hsp70 variants: Hsp72, which is induced by stress (11), 
and Hsc70, which is constitutively expressed (10). The effects of Hsp72 and Hsc70 over-
expression on tau stability were initially tested using a tetracycline-based protein chase 
model in HEK cells (TauTO/6TR). As shown in Figure 1A, tau levels are undetectable 
prior to tetracycline treatment and maximally induced 72 hours after tetracycline treatment. 
Once the tetracycline is removed, tau levels are depleted by natural turnover processes over 
the course of 72 hours (Fig 1B). Using this model, we demonstrated that Hsc70 slowed 
while Hsp72 accelerated tau clearance (Figs. 1C & D). This indicated that these two highly 
similar proteins were distinctly affecting tau turnover. We then confirmed that endogenous 
tau could interact with endogenous Hsc70 and Hsp72 using co-immunoprecipitation assays 
in neuronal IMR-32 cell lysates analyzed by immunoblot. The neuronal cells were first 
treated for 24 hours with celastrol, a compound that is known to enhance the expression of 
heat shock proteins including Hsp72 (24) and destabilize microtubules (25). This was done 
to determine whether inducing Hsp72 expression might facilitate the interaction of Hsp72 
with tau. Then, 30 minutes prior to harvest, these cells were also treated with the 
microtubule destabilizer albendazole to release tau from microtubules, a process that was 
previously found to enhance the tau/Hsc70 interaction (1). As previously reported, Hsc70 
bound more tau when microtubules were destabilized, but celastrol treatment had no impact 
on Hsc70 binding to tau (Figs 1E). Conversely, for endogenous Hsp72 to bind tau in a 
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similar manner, Hsp72 levels had to be induced by celastrol treatment for it to bind tau in 
a manner similar to Hsc70 (Figs. 1E).  These data suggested that relative levels of these 
two proteins could play a critical part in deciding whether tau was to be preserved or 
degraded. Our data suggested that Hsp72 was accelerating tau clearance while Hsc70 was 
slowing it. Therefore, we speculated that increasing the levels of Hsp72 could overcome 
any preservative effects of Hsc70 on tau. Cells over-expressing tau were transfected with 
equivalent amounts of Hsc70 along with increasing amounts of Hsp72. Analysis of these 
lysates by immunoblot revealed that the enhanced steady-state levels of tau by Hsc70 could 
indeed be negated by Hsp72 over-expression (Figs 1F & G). 
 




Figure 1: Hsp72 and Hsc70 have opposing effects on tau.  
(A) Western blot of lysates from HEK cells transiently transfected with tau driven by the minimal CMV 
promoter controlled by the tetracycline response element (TauTO) or empty vector, and transiently 
transfected with the tetracycline repressor protein (6TR). Cells were then treated with tetracycline and 
harvested at indicated time points. (B) HEK cells stably transfected with TauTO and the 6TR were treated 
with indicated concentration of tetracycline (Tet) for 24 hours. After 24 hours, Tet containing media was 
replaced with media either containing Tet (on) or without Tet (on/off) and these cells were incubated for an 
additional 72 hours (96 hours total). Lysates were analyzed by Western blot. (C) TauTO/6TR stably 
transfected cells were treated with tetracycline for 24 h. Cells were then transfected with Hsc70 or Hsp72 for 
24 h and tetracycline was removed. Cells were harvested at indicated times following tetracycline removal. 
(B) Quantification of tau levels in C shown as a percentage of empty vector transfected cells (Ctrl) ± standard 
deviation (SD) after GAPDH normalization (n=3). Open bars, blue bars and red bars indicate vector, Hsc70- 
and Hsp72-transfected cells, respectively. (C) Co-immunoprecipitation of tau from IMR-32 cell lysates 
treated with DMSO alone and albendazole with DMSO, or celastrol alone and albendazole with celastrol. 3 
μM Celastrol was applied 24 hours, followed by 20 μM Albendazole treatment for 30 minutes. Levels of 
Hsp72 and Hsc70 bound to tau were assessed. Inputs indicates whole lysates. (F) Western blot of tau in 
lysates of HEK cells co-transfected with Hsc70 and increasing amounts of Hsp72. (G) Quantification of tau 
levels in F shown as a percentage of Vector transfected cells ± standard deviation (SD) after GAPDH 
normalization. 
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Previous work suggested that Hsp70 proteins could promote the association of tau 
with microtubules (7); however  and based on our results, we speculated that Hsc70 would 
affect this more potently than Hsp72. Using co-localization analyses of GFP-tagged tubulin 
and RFP-tagged tau in live cells, we found a slight increase in tau-tubulin associations 
induced by Hsc70 (Figs. 2A-C). However, Hsp72 over-expression significantly decreased 
the association of tau with tubulin, further suggesting that Hsp72 promoted tau degradation 
(Figs. 2A-C). Western blot confirmed over-expression of both Hsp72 and Hsc70 (Fig 2D). 
While these studies supported opposing roles for these two Hsp70 variants on tau function, 
it still was not clear whether Hsp72 and Hsc70 had direct effects on the ability of tau to 
regulate microtubule formation. To better evaluate this, we utilized microscopy of in vitro 
cell-free Xenopus egg extracts supplemented with fluorescently-labeled tubulin and 
combinations of either recombinant 4R0N tau, Hsp72, or Hsc70 alone; or 4R0N tau 
combined with Hsp72 or Hsc70. Hsc70, Hsp72, and tau were all able to promote 
microtubule assembly alone relative to control, but Hsc70 and tau together appeared to 
dramatically synergize this process, producing densely-packed microtubule filaments (Figs 
3A & B). Conversely, Hsp72 did not appear to synergize with tau: In fact, there was a slight 
reduction in microtubule network formation when Hsp72 alone was added with tau.  
These findings suggested that despite their sequence similarity, Hsp72 and Hsc70 
caused distinct and even opposing effects on tau’s function and stability. To determine 
whether this was caused by differing binding locations on tau, nuclear magnetic resonance 
(NMR) spectroscopy was used to identify tau residues essential for Hsp72 and Hsc70 
interactions. Changes in NMR signal position and intensity in two–dimensional 1H–15N 
heteronuclear single quantum coherence (HSQC) spectra of the 441–residue full length tau 
protein were observed for both Hsp70 variants in a concentration–dependent manner (Fig 
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4A). The observed changes were caused by an exchange of tau between the free and the 
Hsp72/Hsc70–bound state. Strong signal broadening was particularly evident in the second 
and third repeats of tau comprising the two hexapeptides 275VQIINK280 and 306VQIVYK311 
essential for aggregation of tau into paired helical filaments (Fig 4B & C). This data was 
consistent with previous studies belying the importance of these motifs in chaperone 
mediated autophagy (26) and interaction with Hsc70 proteins (27). Strikingly, much more 
pronounced changes in repeats 2 and 3 were observed for Hsp72 than Hsc70 (Fig 4B), 
indicating differences in the interaction between Hsp72 and Hsc70 with Tau (Fig 4C). In 
addition, weaker interactions were observed with the residue stretches 346FKDRVQSK353 
and 375KLTFRE380. 





Figure 2: Hsc70, but not Hsp72, enhances the co-localization of tau with tubulin in cells.  
(A) Representative two-photon fluorescent images of live HEK cells co-transfected with tubulin-GFP and 
tau-RFP fusion constructs. Cells transfected with vector (Ctrl) or Hsc70 showed significant co-localization 
between tau and tubulin as compared to cells transfected with Hsp72.  (B) Higher magnification imaging of 
areas boxed in red in panel A. (C) Graph demonstrating the Pearson’s co-localization coefficient derived 
from 12 different images ± standard deviation (SD). * indicates p<0.05. (D) Western blot of cell lysates 
confirming over-expression of Flag-tagged Hsp72 and Hsc70.  
 
 





Figure 3: Hsc70, but not Hsp72, synergizes with tau to promote microtubule assembly.  
(A) Representative fluorescent images of Xenopus extracts supplemented with rhodamine-labelled tubulin 
and indicated combinations of recombinant tau, Hsp72 and Hsc70 (n=10). (B) Graph demonstrating that tau, 
Hsp72 and Hsc70 alone could promote microtubule assembly, but only Hsc70 combined with tau to 
dramatically influence microtubule formation.  * indicates p<0.05, *** indicates p<0.001. 





Figure 4: Hsp72 binds Tau with higher affinity than Hsc70.  
(A) Superposition of 2D 1H–15N HSQC spectra of Tau protein (50µM) in the absence (black) and presence 
of an equimolar (green) and 2–fold excess ratios of Hsp72 (orange). The inset highlights the resonances of 
the two hexapeptides and their attenuation in a concentration dependent manner. (B and C) NMR intensity 
ratios I/I0 (I = intensity of Tau resonances in presence of Hsp72 or Hsc70; I0 = peak intensities of free Tau) 
from HSQC spectra. Signal broadening (I/ I0 < 1.0) is due to exchange of Tau between the free conformations 
and those in the presence of Hsp72 or Hsc70. NMR signal broadening of Tau at increasing concentrations of 
(B) Hsp72 and (C) Hsc70 (1:1 green, 2:1 orange). The domain organization of Tau is shown above (I = insert, 
P = proline–rich region, and R = pseudo–repeat). The asterisk corresponds to the residues stretch 
346FKDRVQSK353. 
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We sought to better understand the mechanism responsible for these distinct direct 
effects of Hsp72 and Hsc70 on tau, and why in particular Hsp72 could out-compete Hsc70 
for tau binding. We performed fluorescence polarization assays in which recombinant 
Hsp72 and Hsc70 were incubated with both a labeled peptide known to interact with their 
substrate binding domains and increasing concentrations of recombinant tau. Tau was able 
to compete with the fluorescent mock-substrate peptide in a dose dependent manner, 
suggesting that tau was interacting with the substrate binding domains of Hsp72 and Hsc70 
(Fig 5A). While these data showed where tau interacted with Hsp72 and Hsc70, it did not 
explain why these two proteins were causing differential effects on tau biology in cells. 
Using the Praline algorithms, we found that while these two proteins shared >80% 
similarity in their complete protein sequence, their C-terminal regions had the highest 
sequence variation (30%; Fig. 5B & C). Therefore, chimeras were constructed to blend the 
nucleotide binding domains (NBD), substrate binding domains (SBD), and the most 
variable C-terminal domains (CTD) from Hsp72 and Hsc70 (Fig. 5D) to determine which 
region was most essential for the distinct tau effects. Over-expression of these chimeras in 
cells revealed that constructs possessing the CTD of Hsc70 preserved tau, while those 
containing the CTD of Hsp72 facilitated tau clearance (Fig. 5E & F). The NBD and SBD 
of both proteins appeared to be interchangeable. 
This C-terminal interaction suggested an important role for co-factors/co-
chaperones of Hsp72 and Hsc70 that bind to this same region in regulating tau stability. To 
test this, cells over-expressing tau and either Hsp72 or Hsc70 were transfected with siRNA 
targeting CHIP, a ubiquitin ligase co-chaperone known to regulate tau turnover (5, 6, 28). 
Western blot of these lysates showed that knocking down CHIP preserved tau despite over-
expression of Hsp72 or Hsc70 (Figs. 6A & B). This suggested that CHIP expression was 
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important for the effects of Hsp72 and Hsc70 on tau in cells. To assess whether CHIP 
binding to Hsp72 and Hsc70 was different, we performed co-immunoprecipitation using 
anti-Flag antibody in cells over-expressing myc-tagged CHIP, tau, and either Flag-tagged 
Hsc70 or Flag-tagged Hsp72. In cells over-expressing tau, the number of CHIP/Hsp72 
complexes was significantly greater than the number of CHIP/Hsc70 complexes (Fig. 6C), 
but surprisingly, in cells not over-expressing tau, the binding of CHIP to Hsc70 and Hsp72 
was equivalent (Fig. 6D). In this way, Hsp72, but not Hsc70, in the presence of tau and 
other co-factors in the cell would favor CHIP binding to tau. 





Figure 5: The C-terminal domains from Hsc70 and Hsp72 are essential for tau triage.  
(A) Fluorescence polarization (FP) assays with recombinant Hsp72 or Hsc70 in the presence of 1mM ADP, 
the FITC-HLA (RENLRIARLY) peptide and increasing amounts of recombinant tau were carried out in 384-
well plates (20 μL final volume) with a 30 minute incubation. Results are the average of experiments 
performed in triplicate.and error bars represent standard error of the mean. (B and C)  Sequence alignment 
showing 29% sequence variability in the C-termini of Hsp72 and Hsc70. (D) Schematic of Hsc70/Hsp72 
chimera design. (E) Western blot of lysates from HeLa cells stably expressing tau and transfected with Flag-
tagged Hsc70/Hsp72 chimeras. (F) Quantification of tau levels in D shown as a percentage of Vector 
transfected cells (Ctrl) ± standard deviation (SD) after GAPDH normalization (n=3). 





Figure 6: Tau influences the composition of Hsp70/CHIP complexes, affecting its own triage.  
(A) Western blots of HeLa cells that were transfected with Hsp72, Hsc70, and siRNA for CHIP. (B) 
Quantification of tau levels in A shown as a ratio to Actin ± standard deviation (SD) derived from 3 repeated 
experiments. Western blot of samples co-immunoprecipitated with anti-Flag antibody with (C) or without 
(D) tau over-expression shows that tau selectively increases the association of Hsp72 with CHIP. 
 
To better understand the physiological relevance of these physical differences, we 
investigated the protein levels of Hsc70 and Hsp72 in brain homogenates from normal and 
Alzheimer’s disease (AD) brains. Using a dot blot, we generated a standard curve for 
antibodies targeting Hsc70 and Hsp72 to account for differences in antibody affinity (Figs. 
7A-C). We then spotted 20 µg of total protein from AD and control brains onto dot blot 
membranes, probed with Hsp72 or Hsc70 antibodies, and plotted the resulting intensities 
along the standard curves generated with recombinant proteins (Figs. 7A-C). Relative 
quantitation of these proteins revealed that levels of Hsc70 were 30 times greater than 
Hsp72, with no difference between normal and AD brains (Fig 7D). Staining of mouse 
brain tissue produced similar results, revealing an excess of Hsc70 relative to Hsp72 (Fig. 
7E).  






Figure 7: Hsc70 levels are much higher than Hsp72 in human brain.  
Recombinant Hsc70 (A) and Hsp72 (B) were spotted onto nitrocellulose at indicated concentrations 
alongside 20µg of total protein from normal and AD brain lysates.  Ponceau S was performed, followed by 
blocking and immunoblot with anti-Hsc70 or anti-Hsp72 antibodies. (C) Semi-log linear regression analysis 
was performed using the values of the recombinant protein to normalize for difference in antibody affinity. 
(D) Abundance of Hsc70 (blue bars) and Hsp72 (red bars) immunoreactivity in lysates from normal and 
Alzheimer’s human brain (n=3/group) normalized to the standard curve composed of recombinant Hsc70 
and Hsp72, respectively in panels A and B. SD indicates standard deviation. (E) Representative images of 
immunostaining of mouse brain (n=4) with Hsc70 and Hsp72 antibodies. 
 




We have found that Hsc70 and Hsp72 have opposing effects on tau that are driven 
by their relative expression levels, affinities for tau, and their C-terminal interaction 
domains. The data presented here suggest that the C-terminal dynamics of Hsc70 and 
Hsp72 are essential for whether tau degradation is accelerated or slowed. Because the C-
terminal domains of these proteins form the lid of the substrate binding pocket and host 
interactions with co-chaperones that contain the TPR motif (29, 30), we predicted that 
levels of co-chaperones known to interact with the C-terminal portions of Hsp72 and Hsc70 
could also have a major influence on tau triage decisions. One such TPR-containing 
protein, the carboxyl terminus of Hsc70-interacting protein (CHIP), has been extensively 
linked by our lab and others to both Hsp70 proteins and tau (5, 6, 31, 32). This protein has 
ubiquitin ligase activity and has been shown to facilitate tau clearance. Here we discovered 
that CHIP is able to bind to Hsc70 and Hsp72 differently when tau is present. This suggests 
that there are unique structural changes to both Hsp70 variants brought on by tau and other 
co-chaperones that can dictate CHIP association. Future studies will determine what these 
structures are and what components are needed; however these cellular findings point to 
this phenomenon as an important component for tau triage. Perhaps this represents a 
mechanism for tau to maintain its own proteostasis; as tau levels become over-abundant 
and exceed the capacity of the microtubule network, tau interacts more with Hsp72 and 
recruits a distinct sub-set of co-chaperones including CHIP to promote its self-destruction. 
This would prevent its accumulation inside neurons. However, this same recruitment of 
CHIP did not occur when tau interacted with Hsc70, suggesting that restoring or boosting 
the levels of Hsp72 may supplant Hsc70 and promote tau clearance. 
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Interestingly, we also found that Hsp72 levels were not induced in Alzheimer's 
disease, despite the chronic stress conditions that must occur during the disease course. It 
is unclear why tau accumulation failed to promote more robust expression of Hsp72 in 
contrast to what has been reported for other neurodegenerative diseases brought on by 
protein misfolding and accumulation (11, 33). It is possible that Hsp72 levels are elevated 
early in the disease process, but then attenuate over time back to baseline levels due to the 
chronic proteotoxic stress. We would predict that even a small increase in Hsp72 could 
counter-balance tau burden by subverting the preservative effects of Hsc70 due to the 
enhanced affinity of Hsp72 for Hsc70, but not even slight increases were observed in 
human Alzheimer’s or tau transgenic mouse brain tissue. This could be indicative of the 
failing heat shock response that occurs in general with age (34, 35). Thus, selective 
enhancement of Hsp72 levels with small molecules or gene therapies could favor an 
environment that removes excess tau. 
Using NMR spectroscopy, we identified the binding motifs for a chaperone on tau. 
As expected, both Hsc70 and Hsp72 shared binding sites within the microtubule binding 
domains of tau. In particular, consistent with previous studies using traditional 
mutagenesis, the 275VQIINK280 and 306VQIVYK311 hexapeptide motifs were found to be 
critical for binding these chaperones to tau, (26, 27). These motifs are particularly 
important for tau in that they are necessary for tau aggregation (36, 37) and triage towards 
an inefficient chaperone mediated autophagy (CMA) pathway (26). These pro-amyloid 
motifs reside in most proteins (38) and may serve as beacons for chaperones (39, 40). Thus, 
as tau disengages from microtubules, these motifs are exposed, recruiting available 
chaperones. It is at this point that the balance between Hsp72 and Hsc70 may be most 
critical. Hsc70 is necessary for CMA in that it facilitates the triage of certain proteins 
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toward Lamp2a, a lysosomal membrane protein for CMA substrates (41); however Hsp72 
does not have a similar function. While facilitating CMA would at first seem beneficial in 
promoting tau clearance, tau actually is anchored to the lysosomal membrane following its 
triage to Lamp2a, whereby it is then proteolytically cleaved and primed for aggregation 
(26). Using NMR, we were also able to identify some additional consensus sites 
346FKDRVQSK353 and 375KLTFRE380 that were previously unidentified. Most intriguingly, 
the lysine at 353 is part of the known KXGS consensus sequence for the microtubule 
affinity regulating kinase 2 (MARK2). We previously demonstrated that CHIP is less prone 
to interact with tau when it is phosphorylated at MARK2 consensus sites (42-44). MARK2 
promotes the release of tau from microtubules (45) while also altering tau sorting within 
neurons (46). Since tau phosphorylated at these sites is protected from CHIP interaction, it 
suggests that this is a strategy adopted by the neuron to preserve tau during plasticity to 
conserve energy. We speculate that to promote plasticity, tau must detach from 
microtubules – but without a post-translational modification of some sort, a CHIP/Hsp72 
complex would quickly bind and promote tau clearance, a step that would require new tau 
protein to be synthesized after every axonal plastic event. By promoting phosphorylation 
of tau near the CHIP/Hsp72 binding sites, the neuron can preserve tau and conserve energy 
by allowing tau recycling: But this comes with a price; phosphorylation of tau destabilizes 
the axonal diffusion barrier that prevents tau localization to the soma and dendrites (46), 
the sub-cellular location where tau pathology is typically found in Alzheimer’s disease and 
other tauopathies. Therefore, while preventing CHIP/Hsp72 binding through MARK2 
phosphorylation may be energetically favorable for the neuron, it allows tau to move into 
the somatodendritic compartment where it is known to accumulate and become toxic. A 
delicate balance is required to meet energy demands while also preventing proteotoxicity. 
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Expression levels of Hsp70 variants, tau phosphorylation, microtubule integrity, and 
neuronal trafficking all must be managed to prevent tau from accumulating to the point of 
being neurotoxic. If any of these processes are altered, the toxic sequelae of tau can be 
accelerated. Thus, interventions aimed at any of these pathways could be effective 
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Calibration of PFG-Diffusion NMR 
(a) Representative table of standard proteins with their reported and measured 
hydrodynamic radii. The proteins were used to establish a (b) calibration curve for the 
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